Ganglioneuroblastoma

MONDO:0005035 Pathograph 14 Show in embeddings browser neuroblastic tumor

Ganglioneuroblastoma is a peripheral neuroblastic tumor of childhood, of sympathoadrenal (neural crest) lineage, composed of neoplastic neuroblasts, ganglion cells and Schwannian stroma and intermediate in differentiation between neuroblastoma and ganglioneuroma. The International Neuroblastoma Pathology Classification (INPC) divides peripheral neuroblastic tumors into four categories, two of which are ganglioneuroblastoma. Intermixed ganglioneuroblastoma is Schwannian stroma-rich and always of favorable histology. Nodular ganglioneuroblastoma is composite: one or more macroscopic, usually hemorrhagic, stroma-poor neuroblastomatous nodules sit in a stroma-rich or stroma-dominant background, the tumor is graded on its nodules, and patients are stratified with neuroblastoma risk criteria. Ganglioneuroblastoma has a malignant ICD-O-3 morphology code (9490/3, as MONDO and NCIT record it), and neither subtype is benign, although some clinical series call the intermixed subtype a benign variant (see notes). This entry covers peripheral ganglioneuroblastoma (MONDO:0005035) in both INPC categories. MONDO and NCIT define the class by a Schwannian stroma making up more than half of the tumor volume; in the INPC an over-half ganglioneuromatous component defines the intermixed category, while in a nodular tumor the proportion of neuroblastomatous nodule to intermixed or ganglioneuroma tissue varies from case to case. Central nervous system ganglioneuroblastoma (NCIT:C92629), a malignant CNS neoplasm defined without a Schwannian stroma criterion, and Hirschsprung disease-ganglioneuroblastoma syndrome (MONDO:0013082) are out of scope. MONDO and NCIT place ganglioneuroblastoma beside neuroblastoma under neuroblastic tumor, while HPO files HP:0006747 Ganglioneuroblastoma under HP:0003006 Neuroblastoma.

Ask OpenScientist

Ask a research question about Ganglioneuroblastoma. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

🏷

Classifications

ICD-O Morphology

Harrison's Part

🔗

Mappings

MONDO

MONDO:0005035 ganglioneuroblastoma

Primary MONDO identifier for this entry. MONDO defines the class by neuroblastic cells, ganglion cells and a Schwannian stroma making up more than half of the tumor volume, and records NCIT:C3790 and Orphanet:251877 as exact matches. The Schwannian stroma criterion matches this entry's peripheral scope; the over-half threshold corresponds to the INPC intermixed category, and the INPC sets no such threshold for the nodular category, which this entry also covers.

NCIT

NCIT:C3790 Ganglioneuroblastoma

NCIT concept that MONDO records as an exact match of MONDO:0005035. NCIT also files Central Nervous System Ganglioneuroblastoma (NCIT:C92629) beneath it, which this entry does not cover. C3790 is used rather than the narrower Peripheral Ganglioneuroblastoma (NCIT:C6594) because NCIT files the intermixed and nodular classes (NCIT:C42057, NCIT:C42058) under C3790, while C6594 holds only the adrenal and mediastinal site classes.

NCIT

NCIT:C3790 Ganglioneuroblastoma

◆

Subtypes

Ganglioneuroblastoma, intermixed (Schwannian stroma-rich) MONDO:0003326 NCIT:C42057

NCIT NCIT:C42057

The INPC Schwannian stroma-rich category: a transitional form between neuroblastoma and ganglioneuroma in which a ganglioneuromatous component makes up more than half of the tumor around scattered microscopic neuroblastic nests, with no macroscopic nodule. It is always classified as favorable histology. Because the category excludes a macroscopic neuroblastomatous nodule, it is typically assigned on examination of the entire resected tumor, since intermixed and nodular ganglioneuroblastoma are hard to tell apart on limited samples (the diagnosis record gives how a biopsy diagnosis is reported). Most patients have localized disease: in a CCG/COG series, 2 of 189 patients with known INSS stage had stage 4 disease. In one referral series, biopsy and resection agreed in 17 of 19 patients with localized disease who had both, and the authors judged a biopsy adequate there, but a biopsy diagnosis of intermixed ganglioneuroblastoma made alongside metastases was not confirmed at resection in 8 of 12 patients, all given chemotherapy first, whose resected tumors showed neuroblastoma. Localized disease has an excellent outcome: in the CCG/COG series no patient with a favorable-histology tumor, intermixed tumors included, died of tumor, and in the referral series none of the 41 patients with locoregional disease relapsed. In that series 6 of the 12 patients with metastases at diagnosis relapsed and 2 died of disease.

NCIT: Ganglioneuroblastoma, Intermixed (skos:exactMatch) NCIT:C42057

Show evidence (9 references)

PMID:19530234 SUPPORT DIRECT BACKGROUND Other

"GNB-Intermixed (Schwannian stroma-rich) and GN (Schwannian stroma-dominant) tumors are always classified into the FH group. GNB-Nodular (composite, Schwannian stroma-rich/stroma-dominant and stroma-poor) tumors are classified into the FH or UH group based on the characteristics of the..."

In the introduction to a Children's Cancer Group and Children's Oncology Group study of 552 ganglioneuroma and ganglioneuroblastoma cases, Okamatsu et al. state the INPC rule: GNB-intermixed (Schwannian stroma-rich) tumors are always classified as Favorable Histology (FH), whereas GNB-nodular tumors are classified as FH or Unfavorable Histology (UH) according to the characteristics of their neuroblastic component. It directly supports this subtype's favorable histology status, in contrast to nodular tumors. The sentences restate the INPC papers, whose 2003 revision added the nodular split to the classification, rather than reporting a result of this cohort.

PMID:19530234 SUPPORT DIRECT PRIMARY RESULT Human clinical

"| GN-maturing N (%) | GNB-intermixed N (%) | GNB-nodular FS N (%) | GNB-nodular US N (%) | ... INSS stage ... | 1, 2, 3 | 36 (100%) | 187 (99%) | 56 (95%) | 116 (47%) | | 4 | 0 (0%) | 2 (1%) | 3 (5%) | 132 (53%) | | Unknown | 7 | 9 | 0 | 4 |"

Table III of this CCG/COG series tabulates INSS stage by centrally reviewed histology; the excerpt quotes its column headings and its three stage rows. In the GNB-intermixed column, 187 patients (99%) had stage 1-3 disease, 2 (1%) had stage 4 disease and 9 had unknown stage, so 2 of the 189 (187 + 2) with known stage presented with distant metastasis. The series covers patients registered on CCG/COG neuroblastoma studies in 1991-2006, not a population-based sample.

PMID:19530234 SUPPORT DIRECT PRIMARY RESULT Human clinical

"The majority of GN-M, GNB-I, and GNB-N-FS patients had localized disease (stage 1, 2, 3) and low or intermediate-risk tumors."

In the Results of this CCG/COG series, the authors summarize Table III: most patients with ganglioneuroma-maturing, GNB-intermixed and GNB-nodular favorable-subset tumors had localized (INSS stage 1, 2 or 3) disease and low- or intermediate-risk tumors. This supports localized disease as the usual presentation of this subtype and shows that the authors class stages 1-3 as localized. The sentence pools three favorable histologies and gives no counts.

+ 6 more references

Ganglioneuroblastoma, nodular (composite) MONDO:0003325 NCIT:C42058

NCIT NCIT:C42058

The INPC composite category: one or more macroscopic, usually hemorrhagic, Schwannian stroma-poor neuroblastomatous nodules coexist with an intermixed ganglioneuroblastoma or ganglioneuroma component. The proportion of nodule to that component varies from case to case. The INPC also recognizes variants of this classical form. In one, neuroblastoma is found at a metastatic site while the primary tumor shows only intermixed ganglioneuroblastoma or ganglioneuroma histology, as when a nodule in the primary was not sampled; in a CCG/COG series the unfavorable nodule was found only at the metastatic site in 6 patients even after complete pathology evaluation of the primary tumor. Very rarely, such a discordance reflects separate primary tumors presumed to be of different clones. Once classed entirely as unfavorable histology, nodular tumors are now divided into favorable and unfavorable subsets by applying the neuroblastoma criteria of age at diagnosis, grade of neuroblastic differentiation and mitosis-karyorrhexis index to the nodules. The nodular component is favorable when poorly differentiated or differentiating with a low or intermediate index in a patient younger than 18 months, or differentiating with a low index from 18 months to 5 years; it is unfavorable when undifferentiated or of high index at any age, poorly differentiated or of intermediate index from 18 months to 5 years, and of any grade or index from 5 years (60 months). Every nodular tumor diagnosed at 5 years or older is therefore in the unfavorable subset; in a CCG/COG series the favorable-subset patients were 4 months to 4 years 11 months old at diagnosis, more than half of them younger than 18 months. Umehara and colleagues defined the two subsets in 2000 from a review of 70 Children's Cancer Group patients. The International Neuroblastoma Pathology Committee re-reviewed the same patients, confirmed the diagnosis in 67 and the survival difference (8-year event-free survival 86.1% in the favorable versus 32.2% in the unfavorable subset), and in 2003 proposed adding the split to the classification. An INRG analysis identified 232 patients with nodular ganglioneuroblastoma among 4,071 with a known INPC category; 83% were older than 18 months, 83% had unfavorable INPC histology and 2% had MYCN-amplified tumors. Outcome in that cohort was very heterogeneous, with event-free and overall survival of 54% and 68%, and in the unfavorable subset of a CCG/COG series 5-year event-free survival was 80.1% without and 16.7% with stage 4 disease. MONDO subdivides the class by background into MONDO:0004408 (stroma-rich) and MONDO:0004407 (stroma-dominant).

NCIT: Ganglioneuroblastoma, Nodular (skos:exactMatch) NCIT:C42058

Show evidence (14 references)

PMID:10421273 SUPPORT DIRECT PRIMARY RESULT Human clinical

"Approximately 99% of cases (224 of 227) had consensus diagnoses for categorization: neuroblastoma (Schwannian stroma-poor), 190 cases; ganglioneuroblastoma, intermixed (Schwannian stroma-rich), 5 cases; ganglioneuroma (Schwannian stroma-dominant) maturing, 1 case; ganglioneuroblastoma, nodular..."

In a review of 227 neuroblastic tumours by the six-member International Neuroblastoma Pathology Committee, consensus diagnoses (five or six of six pathologists agreeing) placed 19 cases in ganglioneuroblastoma, nodular (composite Schwannian stroma-rich/stroma-dominant and stroma-poor) and 5 in ganglioneuroblastoma, intermixed (Schwannian stroma-rich), as separate categories, supporting this subtype as distinct from the intermixed form. The counts describe this review set, not subtype frequency. The abstract gives no morphologic criteria (described separately) and presents the classification as a modified Shimada classification, so it does not show that the split originated here.

PMID:10964346 SUPPORT DIRECT PRIMARY RESULT Human clinical

"Pathology slides and reports from a total of 70 GNBn patients from the Children's Cancer Group (CCG)-3881 and CCG-3891 studies were reviewed. Sixty-eight tumors were classified in the favorable subset (FS) or the unfavorable subset (US) based on the evaluation of nodular components by applying..."

Umehara et al. reviewed the pathology of 70 patients with nodular ganglioneuroblastoma from Children's Cancer Group studies CCG-3881 and CCG-3891. Applying the INPC neuroblastoma criteria (age, grade of differentiation, mitosis-karyorrhexis index) to the nodules, they placed 68 tumors in a favorable (22) or an unfavorable (46) subset, with event-free survival of 86.1% versus 29.0% (P < 0.0005); the sentence does not state the survival time point. This is the study that defined the subsets. The International Neuroblastoma Pathology Committee re-reviewed the same patients (PMID:14601099), so the two papers analyse one cohort and are not independent results.

PMID:14601099 SUPPORT DIRECT PRIMARY RESULT Human clinical

"Histology slides from 70 patients who were enrolled in Children's Cancer Group studies 3881 and 3891 and who had a diagnosis of GNBn were reviewed jointly by the members of International Neuroblastoma Pathology Committee (INPC) ... to identify the FS and US by applying the same age-linked..."

The International Neuroblastoma Pathology Committee reviewed 70 tumours diagnosed as nodular ganglioneuroblastoma in CCG studies 3881 and 3891, confirmed the diagnosis in 67, and applied neuroblastoma's age-linked histology criteria to their neuroblastomatous component, giving favourable (22) and unfavourable (45) subsets. Their 8-year event-free survival differed significantly (86.1% vs 32.2%), and the committee proposed modifying the classification to separate them. These patients had been used in a previous study: Umehara 2000 (PMID:10964346) reviewed 70 patients from the same two studies, and Okamatsu 2009 (PMID:19530234) includes them, so this is not independent confirmation.

+ 11 more references

Discussions and Knowledge Gaps

Is the Schwannian stroma of ganglioneuroblastoma a non-neoplastic host population recruited by the neoplastic neuroblasts, or is it derived from the neoplastic clone?

CONTROVERSY OPEN gnb_schwannian_stroma_origin

Attached to

pathophysiology#Schwannian Stromal Development

Evidence items use this convention: SUPPORT means the stroma is a non-neoplastic, recruited population; REFUTE means it derives from the neoplastic clone. For the non-neoplastic view, a 1996 study of maturing neuroblastomas found normal chromosome numbers in Schwann cells but abnormal numbers in neuroblastic and ganglionic cells, and an 8-case study of nodular ganglioneuroblastoma found the neuroblasts' MYCN gain in ganglion cells but not in Schwann cells. For the neoplastic view, a 2001 study of neuroblastomas found the same DNA content and GD2 staining in stromal and neuroblastic cells by laser-scanning cytometry in 20 tumors, and the same chromosomal makeup by fluorescence in situ hybridization in 7, and concluded that both derive from genetically identical neoplastic cells. A 2009 cooperative-group paper describes the reports as controversial. The answer decides whether ploidy and copy-number results from stroma-rich tumors describe the tumor cells, and whether maturation is an interaction between tumor and host cells.

Posed 2026-10-21T00:00:00Z

Show evidence (5 references)

PMID:8618605 SUPPORT DIRECT PRIMARY RESULT Human clinical

"The normal number of chromosomes in Schwann cells and the abnormal number in neuroblastic ganglionic cells suggests that Schwann cells are a reactive population of normal cells that invade the neuroblastoma."

In 20 maturing and mature neuroblastomas, chromosome counts by in situ hybridization found normal numbers in Schwann cells but abnormal numbers in neuroblastic and ganglionic cells. From this contrast the authors suggest that the Schwann cells are a reactive population of normal cells that invade the tumor, which supports the view that the stroma is a non-neoplastic host population. The evidence is chromosome number alone, which by itself cannot exclude a shared clonal origin, and the abstract does not say which tumors would now be classed as ganglioneuroblastoma.

PMID:25081755 SUPPORT DIRECT PRIMARY RESULT Human clinical

"In contrast, the Schwann cells have a different origin and may be derived from a non-neoplastic neural crest precursor."

Supports the position that the Schwannian stroma is non-neoplastic rather than derived from the neoplastic clone. In eight nodular ganglioneuroblastomas studied by SNP array and in situ hybridization, the authors conclude that the Schwann cells, unlike the genetically related neuroblasts and ganglion cells, have a different origin, possibly a non-neoplastic neural crest precursor. Limitations: the Schwann cell result rests on in situ hybridization, because the arrays used DNA from whole neuroblastomatous and ganglioneuromatous areas, and the precursor origin is proposed, not traced.

PMID:25081755 SUPPORT INDIRECT PRIMARY RESULT Human clinical

"By in situ hybridization, MYCN gain (4-10 gene copies/nucleus) was detected in 7/8 neuroblastoma samples. In ganglioneuromatous regions, gains were also detected in ganglion cells but not in Schwann cells."

Supports the non-neoplastic position with the observation behind it. In this series of eight nodular ganglioneuroblastomas, in situ hybridization found MYCN gain in the neuroblastoma component of seven, and in ganglioneuromatous regions in ganglion cells but not in Schwann cells. The paper reports this as a gain of 4 to 10 copies per nucleus, not as amplification. Limitations: the series is small, and lacking the gain does not by itself show that Schwann cells arise outside the neoplastic clone, the point in dispute.

+ 2 more references

Is the neuroblastomatous nodule of nodular ganglioneuroblastoma a clone genetically distinct from the rest of the tumor, or a part of a single neoplastic clone that differs from the rest only in being less differentiated?

CONTROVERSY OPEN gnb_nodule_clonality

Attached to

pathophysiology#Schwannian Stroma-Poor Neuroblastomatous Nodule has_subtypes#Nodular

Evidence items use this convention: SUPPORT means the nodule is clonally distinct (a multiclonal tumor), that is, a genetically distinct clone, whether it arose independently or as a subclone of a common ancestor; REFUTE means the nodule's neuroblasts and the ganglion cells of the ganglioneuromatous component belong to one clone and differ only in differentiation. A 2026 pathology review of the INPC describes nodular tumors as multi-clonal, and a 1993 single-case study found that the more differentiated portion and the neuroblastic foci of one composite ganglioneuroblastoma differed in DNA content and MYCN copy number. An 8-case genetic study found the nodule neuroblasts and the ganglion cells genetically related and concluded that the behavior of nodular tumors cannot be explained by separate clones with distinct genetic signatures; that argues against independent clonal origins but does not exclude a subclone that evolved from a common ancestor.

Posed 2026-10-21T00:00:00Z

Show evidence (3 references)

PMID:41612478 SUPPORT DIRECT REVIEW SYNTHESIS Other

"Tumors in this category are considered as multi-clonal tumors. In gross appearance, the NB component often forms hemorrhagic and necrotic nodule(s) in a background of elastic and yellowish white component of GNB-i or GN"

In its account of the INPC categories, this 2026 pathology review states that tumours in 'this category' are considered multi-clonal, and that the neuroblastoma component often forms haemorrhagic, necrotic nodules within a ganglioneuroblastoma-intermixed or ganglioneuroma background, which identifies the category as nodular ganglioneuroblastoma. It therefore supports the multiclonal (clonally distinct nodule) position. It is an expert classification statement with no clonality data, so it records how these tumours are classified rather than showing that the nodule is a separate clone.

PMID:8108298 SUPPORT DIRECT PRIMARY RESULT Human clinical

"We analyzed a composite ganglioneuroblastoma for N-myc copy number at initial resection and 2 years later after progressive disease. In the second sample the more differentiated portion of the tumor was analyzed separately from the neuroblastic foci for N-myc copy number and DNA ploidy. The DNA..."

This case report analysed one composite ganglioneuroblastoma (the older name for the nodular subtype) at initial resection and again 2 years later, after progressive disease. In the second sample, the more differentiated portion and the neuroblastic foci differed in DNA content and N-myc (MYCN) copy number, which the authors read as at least two clones, supporting the clonally distinct position. It is one case, and the abstract does not say whether stromal cells were separated from tumour cells, so the two clones are an inference from two tissue portions. The abstract reports the separate analysis of the two areas only for the sample taken after progression, so it does not show whether they already differed at initial resection.

PMID:25081755 REFUTE DIRECT PRIMARY RESULT Human clinical

"Our results suggest that the clinical behavior of nodular ganglioneuroblastoma cannot be explained by the presence of separate clones with distinct genetic signatures."

Analysing eight nodular ganglioneuroblastomas by SNP array and in situ hybridization, with DNA extracted separately from neuroblastomatous and ganglioneuromatous areas, the authors suggest that the clinical behaviour of nodular ganglioneuroblastoma cannot be explained by separate clones with distinct genetic signatures. This favours the single-clone position, arguing against independent clonal origins for the neuroblastoma nodule and the ganglion cells of the ganglioneuromatous component. It neither covers the Schwann cells, which the same abstract assigns a different origin, nor excludes a nodule subclone diverging from a common ancestor; the series is small.

Does telomere maintenance mechanism status predict outcome in ganglioneuroblastoma, as it does in high-risk neuroblastoma?

KNOWLEDGE GAP OPEN gnb_tmm_prognostic_significance

Attached to

pathophysiology#Telomere Maintenance Mechanism Activation

The series that established telomere maintenance in ganglioneuroblastoma says its clinical significance there is not yet assessable, because the cohort needs several more years of follow-up. This matters for how the pathophysiology node is read. In high-risk neuroblastoma, telomere maintenance is a poor-prognostic marker and is proposed for the next International Neuroblastoma Risk Group classification, so the temptation is to carry that prognostic meaning across to ganglioneuroblastoma on the strength of the shared mechanism and the nodular subtype's comparable positive rate. Nothing in the ganglioneuroblastoma data supports that step yet. This gap is why the node has no edge to an outcome or risk node, and why one should not be added from neuroblastoma evidence.

Posed 2026-10-28T00:00:00Z

Show evidence (1 reference)

PMID:41858373 SUPPORT DIRECT PRIMARY RESULT Human clinical

"a solid evaluation of the clinical significance of TMM status in GN and GNB will require several additional years of long-term follow-up."

The authors state the gap themselves, in their discussion, about their own cohort. It is what makes this an absence of evidence rather than a negative result: they do not report that telomere maintenance fails to predict outcome in ganglioneuroblastoma, only that their follow-up is too short to say.

⚙

Pathophysiology

Neoplastic Neuroblast Population

The malignant neuroblastic cells of the tumor, which form the microscopic neuroblastic nests of intermixed tumors and the nodules of nodular tumors. In a 1996 series of 20 maturing and mature neuroblastomas, the neuroblastic and ganglionic cells carried numerical chromosome aberrations, with near-triploidy in 18 of 19 tumors. Flow cytometry nonetheless reads most GN-maturing and intermixed tumors as diploid (160 of 191 in a CCG/COG series), which the authors suggest may reflect the predominance of Schwannian stromal cells in the samples.

neoplastic neuroblast CL:0002676

Downstream

Neuroblast-to-Ganglion Cell Maturation Neoplastic neuroblasts mature into ganglion cells. In nodular tumors, ganglion cells carry the MYCN gain found in the neuroblasts, while Schwann cells do not.

Schwannian Stromal Development In co-culture, neuroblastoma tumors and cell lines stimulate Schwann cell proliferation, which the authors read as a hint that neoplastic neuroblasts drive stromal growth in tumors. The evidence is in vitro and says nothing about where the stromal cells come from.

Schwannian Stroma-Poor Neuroblastomatous Nodule In 7 of 8 nodular tumors studied, the neuroblasts of the nodule carried MYCN copy gain, consistent with the nodule being formed by the neoplastic neuroblast population.

Abdominal Mass The primary tumor forms a mass at its site of origin.

Posterior Mediastinal Mass The primary tumor forms a mass at its site of origin.

Congenital Horner Syndrome Orphanet ties the clinical features of ganglioneuroblastoma, congenital Horner syndrome among them, to the location of the tumor. How the tumor produces the sign is not described.

Show evidence (3 references)

PMID:8618605 SUPPORT INDIRECT PRIMARY RESULT Human clinical

"Neuroblastic and ganglionic cells showed aberrations in the number of chromosomes. In situ hybridization and flow cytometry demonstrated near-trip-loidy in 18 of 19 tumors and pentaploidy in the remaining tumor."

In 20 human maturing and mature neuroblastomas (maturing neuroblastoma being the abstract's term for a tumour that differentiates toward ganglioneuroma), in situ hybridization and flow cytometry found abnormal chromosome numbers in the neuroblastic and ganglionic cells: near-triploidy in 18 of 19 tumours and pentaploidy in the remaining one. The 1996 study predates the International Neuroblastoma Pathology Classification and does not say how many cases would now be classed as ganglioneuroblastoma. Reading these aneuploid cells as tumour cells is an inference from the finding.

PMID:19530234 SUPPORT DIRECT PRIMARY RESULT Human clinical

"In our series, the majority of GN-M and GNB-I tumors, even though they were biologically favorable with an excellent prognosis, had a diploid pattern determined by flow cytometry. This could be attributable to the fact that those tumors were mainly or predominantly composed of Schwannian stromal..."

In this CCG/COG series of 552 centrally reviewed ganglioneuroma and ganglioneuroblastoma tumours, most GN-maturing (a ganglioneuroma subtype) and GNB-intermixed tumours had a diploid pattern by flow cytometry despite being biologically favourable; ploidy data came from COG cases only. The authors suggest, hedging with 'could be attributable', that these tumours are mainly Schwannian stroma, so neuroblastic cells were not the main cells tested. The paper reports no ploidy on separated cell populations, so this is a possible explanation, not evidence of which cells, if any, are hyperdiploid.

PMID:19530234 SUPPORT PRIMARY RESULT Human clinical

"The majority (160/191, 84%) of GN-M and GNB-I tumors had a diploid pattern determined by flow cytometry."

The abstract of this CCG/COG series quantifies the diploid majority: 160 of the 191 GN-maturing and GNB-intermixed tumours with flow-cytometric ploidy data, all from COG cases, had a diploid pattern. The paper's Table III splits this into 28 of 32 GN-maturing (a ganglioneuroma subtype) and 132 of 159 GNB-intermixed tumours. The sentence does not say why these tumours read diploid, and it does not cover nodular tumours, whose DNA indices the paper reports as split almost evenly between diploid and hyperdiploid.

Neuroblast-to-Ganglion Cell Maturation

Neoplastic neuroblasts differentiate into ganglion cells. Biologically favorable peripheral neuroblastic tumors are considered to mature by age-dependent steps from neuroblastoma through intermixed ganglioneuroblastoma to ganglioneuroma.

ganglion cell CL:0011103

maturation of neuroblasts into ganglion cells GO:0030182

Show evidence (1 reference)

PMID:41612478 SUPPORT DIRECT REVIEW SYNTHESIS Other

"To note, tumors in the biologically favorable pNTs are considered to proceed by age-dependent differentiation/maturational steps from NB to GNB-i, and finally to GN."

This 2026 pathology review states that biologically favourable peripheral neuroblastic tumours are considered to proceed by age-dependent differentiation and maturation steps from neuroblastoma to GNB-intermixed and finally to ganglioneuroma, the maturation this node describes. The sentence sits in the review's account of the INPC categories and gives a consensus view ('are considered to') without supporting data. It covers only the favourable path through GNB-intermixed and says nothing about how nodular tumours arise.

Schwannian Stromal Development

The Schwann-cell stroma that makes up more than half of an intermixed tumor and forms the background of a nodular one. The INPC names each category by its Schwannian stromal development, which gives intermixed tumors their elastic, yellowish-white gross appearance. In culture, neuroblastoma tumors and cell lines stimulate Schwann cell proliferation, and Schwann cell products induce neuronal differentiation of neuroblastoma cells. Whether the stromal cells are non-neoplastic cells recruited by the tumor or derive from the neoplastic clone is contested (discussion gnb_schwannian_stroma_origin).

Schwannian stromal cell CL:0002573

Schwann cell proliferation GO:0014010

Downstream

Neuroblast-to-Ganglion Cell Maturation Soluble Schwann cell products induce neuronal differentiation of neuroblastoma cells. The evidence is from cultured neuroblastoma cells, not from ganglioneuroblastoma tissue.

Show evidence (2 references)

PMID:41612478 SUPPORT DIRECT REVIEW SYNTHESIS Other

"Tumors in this category are elastic in consistency and yellowish white in color due to Schwannian stromal development (Fig. 2A)."

In this 2026 pathology review the sentence opens the paragraph on ganglioneuroblastoma, intermixed; it cites Fig. 2A, which shows the gross appearance of an adrenal intermixed tumour with a solid, elastic cut surface, and the next sentence defines the category as more than 50% ganglioneuromatous tissue. It attributes the elastic, yellowish-white gross appearance of these tumours to their Schwannian stromal development. This is the authors' descriptive synthesis rather than a measured cohort result, and the review calls ganglioneuroma elastic and yellowish white too.

PMID:41612478 SUPPORT DIRECT REVIEW SYNTHESIS Other

"INPC defines 4 categories in the pNTs: Neuroblastoma (NB; Schwannian stroma-poor), Ganglioneuroblastoma, intermixed (GNB-i; Schwannian stroma-rich), Ganglioneuroma (GN; Schwannian stroma-dominant), and Ganglioneuroblastoma, nodular (GNB-n; composite, Schwannian stroma-rich/stroma-dominant and..."

This 2026 pathology review restates the four INPC categories with their Schwannian stromal features; ganglioneuroblastoma, intermixed is stroma-rich, and the nodular form is composite, combining stroma-rich or stroma-dominant with stroma-poor tissue. The next sentence, after an omitted citation number, says each parenthetical gives the category's unique feature of Schwannian stromal development. This supports stromal development as a defining feature of both ganglioneuroblastoma subtypes. It restates a classification rule rather than new data and does not address gross appearance.

Schwannian Stroma-Poor Neuroblastomatous Nodule

One or more macroscopic, usually hemorrhagic, Schwannian stroma-poor nodules of neuroblastoma within intermixed ganglioneuroblastoma or ganglioneuroma tissue. The nodular components are not always aggressive, and the age-linked histopathology of the nodules predicts prognosis. Whether the nodule is a clone distinct from the rest of the tumor is contested (discussion gnb_nodule_clonality).

neoplastic neuroblast CL:0002676

Downstream

Distant Metastasis at Diagnosis In the unfavorable subset, distant metastasis from the neuroblastomatous nodule is often already present at diagnosis, even when the primary tumor is completely resected.

Show evidence (1 reference)

PMID:10964346 SUPPORT DIRECT PRIMARY RESULT Human clinical

"The current study demonstrates that the nodular components in GNBn tumors are not always aggressive. The prognosis of these patients can be determined by the analysis of age-linked histopathologic features."

Conclusion of a review of pathology and outcomes for 70 patients with nodular ganglioneuroblastoma in the CCG-3881 and CCG-3891 studies. It states that the nodular components are not always aggressive and that prognosis can be determined from age-linked histopathology, defined in the Methods as the INPC neuroblastoma criteria (age, differentiation grade, mitosis-karyorrhexis index) applied to the nodules. The abstract does not separate stage from histology: 63.0% of unfavourable-subset patients presented with distant metastasis. PMID:14601099 re-reviewed the same patients and PMID:19530234 includes them, so these papers are not independent confirmation.

Telomere Maintenance Mechanism Activation

Mechanism confidence: Provisional

A subset of ganglioneuroblastoma maintains its telomeres, by either of the two routes used in neuroblastoma: alternative lengthening of telomeres, detected as C-circles, or raised TERT expression. In a Japanese series of 48 ganglioneuroblastomas, alternative lengthening was present in 6 and raised TERT expression in 7 of the 31 tested, with 12 of the 48 positive by either route. The activation is concentrated in the nodular subtype, where 10 of 21 were positive, a proportion close to the neuroblastoma figure in the same series. In the 18 ganglioneuromas, alternative lengthening was absent and one tumour had raised TERT expression. Among the positive ganglioneuroblastomas the authors report frequent ATRX alteration and infrequent TERT rearrangement, which they take to mean that TERT-high ganglioneuroblastomas raise TERT expression by some mechanism other than the rearrangement and promoter mutation that predominate in TERT-high MYCN-not-amplified neuroblastoma. Which mechanism that is, the series does not establish.

TERT hgnc:11730 ATRX hgnc:886

telomere maintenance via telomerase GO:0007004 ↑ INCREASED telomere maintenance via recombination GO:0000722 ↑ INCREASED

Downstream

Unlimited Replicative Potential A telomere maintenance mechanism keeps telomeres from eroding, so the tumour cells that carry one can go on dividing. Neuroblastoma cell lines with neither telomerase activity nor alternative lengthening of telomeres shortened their telomeres in culture and mostly lost viability. No ganglioneuroblastoma cell line or cohort has tested the link.

Show evidence (4 references)

PMID:41858373 SUPPORT DIRECT PRIMARY RESULT Human clinical

"ALT was identified in 38 NB cases (38/255, 15%) and 6 GNB cases (6/48, 12.5%), but not in GN. High TERT expression was observed in 38% (64/169), 23% (7/31) and 14% (1/7) of NB, GNB and GN cases, respectively."

The measurement behind the node: both telomere-maintenance routes assayed in ganglioneuroblastoma tumours, with the denominators stated. Note the TERT denominators are smaller than the ALT ones, 31 of 48 ganglioneuroblastomas and 7 of 18 ganglioneuromas, so the two routes were not tested in the same number of tumours and the absence of alternative lengthening in ganglioneuroma rests on 18 cases.

PMID:41858373 SUPPORT DIRECT PRIMARY RESULT Human clinical

"TMM activation, defined as ALT(+) and/or high TERT expression, occurred in 12/48 GNB cases and 1/18 GN cases, particularly in the GNB-nodular type (10/21, 48%), which was similar to 39% (100/255) of NB cases."

The combined figure and the subtype concentration, which is what makes this node more than a curiosity: nearly half of nodular ganglioneuroblastomas are positive, close to the neuroblastoma proportion in the same cohort. The definition is the authors' own and is a disjunction, so a positive tumour need not have both routes. The comparison with neuroblastoma is within this one series.

PMID:41858373 SUPPORT INDIRECT PRIMARY RESULT Human clinical

"Furthermore, TMM(+) GNBs exhibited distinct features, including a high frequency of ATRX alterations and a lower frequency of TERT rearrangements."

Why ATRX is bound on this node alongside TERT. Indirect for the node's own claim: the sentence describes what distinguishes the positive tumours rather than measuring telomere maintenance, and it reports a frequency contrast without giving the counts behind it.

+ 1 more reference

Unlimited Replicative Potential

Mechanism confidence: Provisional

The ability of tumour cells to keep dividing past the limit that telomere shortening sets on normal cells, which a telomere maintenance mechanism provides. In ganglioneuroblastoma it is inferred from the telomere maintenance a subset of tumours shows, not measured: no study has followed the replicative capacity of ganglioneuroblastoma cells.

cell population proliferation GO:0008283 ↑ INCREASED

Tumoral Catecholamine Secretion

Secretion of catecholamines by the tumour, which some ganglioneuroblastomas show. In a 3-year-old girl, epinephrine and norepinephrine production by a ganglioneuroblastoma caused hypertensive cardiomyopathy, and subtotal resection reduced the catecholamine levels. A ganglioneuroblastoma that produced an excess of dopamine alone was followed by its urinary dopamine, which rose with recurrence two years after resection. In localized intermixed ganglioneuroblastoma, raised urinary homovanillic and vanillylmandelic acid are frequent.

catecholamine secretion by the tumour GO:0050432 ↑ INCREASED

Downstream

Elevated Urinary Vanillylmandelic Acid Vanillylmandelic acid is a catecholamine metabolite excreted in urine. It was raised in an adult with a catecholamine-producing ganglioneuroblastoma and in a child with a nodular one, and it fell with declining tumour activity in a stage M cohort.

Elevated Urinary Homovanillic Acid Homovanillic acid is a catecholamine metabolite excreted in urine, the main one of dopamine. It was raised in a child with a nodular ganglioneuroblastoma, and it fell with declining tumour activity in a stage M cohort.

Show evidence (2 references)

PMID:41891982 SUPPORT DIRECT PRIMARY RESULT Human clinical

"We report the case of a 3-year-old girl with growth failure who had hypertensive cardiomyopathy caused by excessive epinephrine and norepinephrine production from a ganglioneuroblastoma. ... subtotal resection was required, which reduced catecholamine levels."

Case report of a girl whose ganglioneuroblastoma produced enough epinephrine and norepinephrine to cause hypertensive cardiomyopathy. Catecholamine levels fell after subtotal resection, which places the excess in the tumour.

PMID:16390613 SUPPORT DIRECT PRIMARY RESULT Human clinical

"A case is described of a patient with a ganglioneuroblastoma, initially located in the right adrenal, which produced an excess of dopamine (7646 and 7959 nmol/24 h), approximately two and a half times the upper limit of the normal daily urine output. ... Two years after surgical resection,..."

Case report of an adrenal ganglioneuroblastoma that produced an excess of dopamine while noradrenaline, adrenaline and their methylated derivatives stayed normal. Urinary dopamine rose again when the tumour recurred after resection, so it tracked the tumour. It shows that the catecholamine a ganglioneuroblastoma secretes can be dopamine alone.

✶

Histopathology

Schwannian Stroma-Rich Ganglioneuromatous Component With Microscopic Neuroblastic Nests

A ganglioneuromatous, Schwannian stroma-rich component that exceeds 50% of the tumor in representative sections, with scattered residual microscopic neuroblastomatous foci: pockets of neuropil containing neuroblasts, differentiating neuroblasts and ganglion cells. The tumor is maturing, but the process is incomplete. Under the INPC the favorable or unfavorable histology group is to be determined only from primary or metastatic tumor tissue obtained before chemotherapy or irradiation, and once assigned it is not to be changed during the clinical course, because therapy-associated changes, including neuroblastic differentiation and even Schwannian stromal development, may not have proven prognostic significance. A diagnosis of intermixed ganglioneuroblastoma made on a tumor resected after neoadjuvant chemotherapy does not take the effect of that chemotherapy into account.

Show evidence (3 references)

PMID:19530234 SUPPORT DIRECT BACKGROUND Other

"Ganglioneuroblastoma-Intermixed (Schwannian stroma-rich): A transitional form between Neuroblastoma and Ganglioneuroma. Tumor is on its way toward full differentiation/maturation; however, the process is not complete, as evidenced by scattered "residual" microscopic neuroblastomatous foci..."

Table I of this CCG/COG clinicopathological study of 552 ganglioneuroma and ganglioneuroblastoma cases restates the International Neuroblastoma Pathology Classification definition of the intermixed category. The definition gives the histology this finding records: a transitional form between neuroblastoma and ganglioneuroma whose maturation is incomplete, with scattered 'residual' microscopic neuroblastomatous foci (pockets of neuropil holding neuroblastic cells) and a ganglioneuromatous component exceeding 50% of the total volume. It is a diagnostic criterion, not cohort data, and the 50% threshold applies to microscopic fields from representative sections, not to the whole tumour volume.

PMID:41612478 SUPPORT DIRECT REVIEW SYNTHESIS Other

"The distinction of FH group or UH group according to the INPC, as summarized in Table 1, should only be determined based on the pathology review of primary or metastatic tumors obtained before starting chemotherapy/irradiation therapy. Once FH or UH group classification is assigned, it should..."

This 2026 pathology review states the INPC rule immediately after noting that the neuroblastoma nodules of nodular ganglioneuroblastoma are graded by age-linked criteria and that intermixed tumors are always of favorable histology. The favorable or unfavorable histology group is to be determined only from pathology review of primary or metastatic tumors obtained before chemotherapy or irradiation starts and, once assigned, is not to be changed during the clinical course, because therapy-associated changes such as neuroblastic cytodifferentiation and even Schwannian stromal development may not have proven prognostic significance. The passage states a classification rule and reports no patient data; it concerns the histology group, not how a tumor first sampled after treatment should be categorized.

PMID:37243318 SUPPORT DIRECT BACKGROUND Other

"Diagnosing GNBI on morphological examination of the definitively resected tumor does not take into account the impact of neoadjuvant chemotherapy that might be administered before definitive tumor resection."

In the Discussion of their Memorial Sloan Kettering series, the authors note that a diagnosis of intermixed ganglioneuroblastoma (GNBI) made by examining the definitively resected tumor does not take into account the effect of any neoadjuvant chemotherapy given before that resection. It is a framing statement, not a result of the series, and does not say how often or in what way chemotherapy changes the histology.

Macroscopic Neuroblastomatous Nodule in a Stroma-Rich or Stroma-Dominant Background

One or more macroscopic, usually hemorrhagic, Schwannian stroma-poor neuroblastomatous nodules coexisting with an intermixed ganglioneuroblastoma (stroma-rich) or ganglioneuroma (stroma-dominant) component. Under the INPC the favorable or unfavorable histology group of a nodular tumor, graded on its nodules, is to be determined only from primary or metastatic tumor tissue obtained before chemotherapy or irradiation, and once assigned it is not to be changed during the clinical course, because therapy-associated changes, including neuroblastic differentiation and even Schwannian stromal development, may not have proven prognostic significance.

Show evidence (2 references)

PMID:19530234 SUPPORT DIRECT BACKGROUND Other

"characterized by the presence of macroscopic, usually hemorrhagic neuroblastomatous nodule(s) of Schwannian stroma-poor component coexisting Ganglioneuroblastoma-intermixed of stroma-rich component or Ganglioneuroma of stroma-dominant component."

Table I of this CCG and COG clinicopathological series gives the International Neuroblastoma Pathology Classification (INPC) definitions used to classify its 552 centrally reviewed ganglioneuroma and ganglioneuroblastoma cases. The quoted clause, from the Ganglioneuroblastoma-Nodular row, states each feature of this finding: one or more macroscopic, usually haemorrhagic, Schwannian stroma-poor neuroblastomatous nodules coexisting with stroma-rich ganglioneuroblastoma-intermixed or stroma-dominant ganglioneuroma. It restates the INPC definition (established 1999, revised 2003) rather than reporting a finding of this cohort, and calls the nodules usually, not always, haemorrhagic.

PMID:41612478 SUPPORT DIRECT REVIEW SYNTHESIS Other

⬡

Pathograph

Use Group by to collapse related nodes into one box. Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.

●

Phenotypes

Digestive 1

Abdominal Mass HP:0031500

Show evidence (2 references)

ORPHA:251877 SUPPORT INDIRECT REVIEW SYNTHESIS Other

"usually occurring in the posterior mediastinum, adrenal medulla and extra-adrenal retroperitoneum (but sometimes in the neck and pelvis)"

Orphanet's disease definition, which reports no patient data, names the posterior mediastinum, adrenal medulla and extra-adrenal retroperitoneum as the usual sites of ganglioneuroblastoma, and the neck and pelvis as occasional ones. A primary tumor in the adrenal medulla or retroperitoneum is an abdominal mass, but that step is inferred: the definition names sites, not a mass, and its list of clinical signs does not include one. It does not rank the sites and lists the posterior mediastinum first, so it does not show that abdominal primaries predominate.

PMID:37243318 SUPPORT INDIRECT PRIMARY RESULT Human clinical

"The primary tumor was abdominal in 39 (74%) and thoracic in 14 patients (26%)."

Retrospective Memorial Sloan Kettering series of 53 patients whose intermixed ganglioneuroblastoma was diagnosed at presentation. The primary tumor was abdominal in 39 (74%) and thoracic in 14 (26%), so most of these tumors arose in the abdomen. Reading an abdominal primary as an abdominal mass is an inference, and the paper does not name the abdominal sites. The figure covers one subtype at a tertiary referral center, where only 16 of the 53 patients were first diagnosed; it is not an estimate for ganglioneuroblastoma as a whole.

Eye 1

Congenital Horner Syndrome HP:0006837

Show evidence (1 reference)

ORPHA:251877 SUPPORT DIRECT REVIEW SYNTHESIS Other

"characterized clinically by pain, stridor, shortness of breath, peripheral neurological signs, superior vena cava syndrome and congenital Horner syndrome, depending on the location of the tumor"

Orphanet's definition of ganglioneuroblastoma, which reports no patient data, names congenital Horner syndrome among its clinical features, alongside pain, stridor, shortness of breath, peripheral neurological signs and superior vena cava syndrome, and says the features depend on the location of the tumor. It gives no frequency, so none is recorded.

Genitourinary 2

Elevated Urinary Homovanillic Acid FREQUENT HP:0011977

Show evidence (1 reference)

PMID:27465021 SUPPORT DIRECT PRIMARY RESULT Human clinical

"| | GN (n = 162) | p1 | GNBI (n = 55) | GN / GNBI (n=217) | p 2 | NB / GNBN (n = 591) | ... | HVA elevated ... | 45/142 | 0.001 ... | 27/44 | 72/186 | <0.001 ... | 327/531 | | 31.7 % | 61.4 % | 38.7 % | 61.6 % |"

Table 1 of this retrospective study of localized neuroblastic tumors registered in the German NB97 and NB2004 trials; the excerpt gives the column headings and the HVA row. Urinary homovanillic acid was elevated in 27 of 44 tested patients with intermixed ganglioneuroblastoma (61.4%), 45 of 142 with ganglioneuroma (31.7%) and 327 of 531 with neuroblastoma or nodular ganglioneuroblastoma (61.6%). The p-values compare ganglioneuroma with intermixed tumors (p1) and the pooled mature tumors with the immature ones (p2); none compares intermixed tumors with neuroblastoma. The abstract's finding that mature tumors less often had elevated metabolites comes from the pooled column, three quarters of which is ganglioneuroma. Metastatic tumors were excluded, and nodular tumors are not reported apart from neuroblastoma.

Elevated Urinary Vanillylmandelic Acid FREQUENT HP:0011978

Show evidence (1 reference)

PMID:27465021 SUPPORT DIRECT PRIMARY RESULT Human clinical

"| | GN (n = 162) | p1 | GNBI (n = 55) | GN / GNBI (n=217) | p 2 | NB / GNBN (n = 591) | ... | VMA elevated ... | 28/145 | <0.001 ... | 23/47 | 51/192 | <0.001 ... | 345/538 | | 19.3 % | 48.9 % | 26.6% | 64.1 % |"

Table 1 of the same German NB97/NB2004 study of localized neuroblastic tumors; the excerpt gives the column headings and the VMA row. Urinary vanillylmandelic acid was elevated in 23 of 47 tested patients with intermixed ganglioneuroblastoma (48.9%), 28 of 145 with ganglioneuroma (19.3%) and 345 of 538 with neuroblastoma or nodular ganglioneuroblastoma (64.1%). No p-value compares intermixed tumors with neuroblastoma, so the lower intermixed proportion is not a tested difference. Metastatic tumors were excluded, and nodular tumors are not reported apart from neuroblastoma.

Respiratory 1

Posterior Mediastinal Mass HP:0033829

Show evidence (2 references)

ORPHA:251877 SUPPORT INDIRECT REVIEW SYNTHESIS Other

"usually occurring in the posterior mediastinum, adrenal medulla and extra-adrenal retroperitoneum (but sometimes in the neck and pelvis)"

Orphanet's definition of ganglioneuroblastoma lists the posterior mediastinum among the sites where the tumor usually occurs, together with the adrenal medulla and the extra-adrenal retroperitoneum (and sometimes the neck and pelvis). A primary tumor in the posterior mediastinum is a posterior mediastinal mass, but that step is inferred: the definition names a site, not a mass. The definition gives no case counts or ranking, so it does not say how often the posterior mediastinum is the primary site.

PMID:37243318 SUPPORT INDIRECT PRIMARY RESULT Human clinical

"The primary tumor was abdominal in 39 (74%) and thoracic in 14 patients (26%)."

Retrospective Memorial Sloan Kettering series of 53 patients whose intermixed ganglioneuroblastoma was diagnosed at presentation. The primary tumor was thoracic in 14 (26%). The paper does not name the thoracic sites, so reading a thoracic primary as a posterior mediastinal mass is an inference. The figure covers one subtype at a tertiary referral center, where only 16 of the 53 patients were first diagnosed; it is not an estimate for ganglioneuroblastoma as a whole.

Neoplasm 1

Distant Metastasis at Diagnosis FREQUENT Neoplasm HP:0002664

Coarse binding: no hpo term

Ontology gap: HPO has no class for metastatic or distant disease. OLS HPO searches on 2026-10-21 for metastasis, metastatic, metastases, distant metastases, metastatic neoplasm, metastatic disease, secondary neoplasm, bone metastases and neoplasm metastasis returned nothing, or only specific tumor types and unrelated findings whose text mentions metastasis.

Show evidence (2 references)

PMID:22137163 SUPPORT INDIRECT PRIMARY RESULT Human clinical

"Amongst 4071 patients in the INRG database with known INPC histological category, 232 patients with GNBn were identified. ... A cohort with superior outcome was identified: OS for GNBn patients younger than 18 months was 95%±5% (n=39) and for GNBn patients with stage 1, 2, 3, 4s was 95%±3%..."

This INRG database analysis of 232 patients with nodular ganglioneuroblastoma reports overall survival of 35% for stage 4 (n=107) and 95% for stages 1, 2, 3 and 4s (n=125); these cover all 232, so 46% had stage 4 disease. The abstract gives no stage table and never mentions metastasis, so the 46% and its reading as distant metastasis are inferences; the 46% excludes stage 4s, and no survival time point is stated. INRG pools cooperative-group data, so this cohort is not independent of the CCG/COG series also cited here.

PMID:19530234 SUPPORT DIRECT PRIMARY RESULT Human clinical

"The UH group included ganglioneuroblastoma-nodular, unfavorable subset (GNB-N-US) tumors. Patients with the UH tumors had a high incidence (53%) of distant metastasis at the time of diagnosis"

In a review of 552 ganglioneuroma and ganglioneuroblastoma cases from CCG and COG studies, 53% of patients with the unfavourable subset of nodular ganglioneuroblastoma had distant metastasis at diagnosis (Table III: 132 of 248 with known stage were stage 4; no patient had stage 4S). The figure covers that subset only; 3 of 59 favourable-subset patients were stage 4. The INRG database pools cooperative-group data including Children's Oncology Group patients, so this series probably overlaps the INRG cohort and does not independently confirm its figure.

🧬

Genetic Associations

MYCN Amplification (Rare Somatic Amplification)

Gene: MYCN hgnc:7559 gene page relationship_type: BIOMARKER variant_origin: SOMATIC

Show evidence (4 references)

PMID:11745206 SUPPORT DIRECT PRIMARY RESULT Human clinical

"MYCN amplification was seen almost exclusively in tumors of the NB category, and no patients with tumors in either the GNBi category or in the GN category and only two patients with tumors in the GNBn category had amplified MYCN."

This Children's Cancer Group series classified 628 neuroblastic tumours under the International Neuroblastoma Pathology Classification and tested each for MYCN status, including 21 intermixed and 63 nodular ganglioneuroblastomas. Amplification was seen almost exclusively in the neuroblastoma category: none of the intermixed and only two of the nodular ganglioneuroblastomas were amplified. The subtype groups are small, and later cooperative-group series drawing on Children's Cancer Group studies may share patients with this one, so they do not independently confirm it.

PMID:19530234 SUPPORT DIRECT PRIMARY RESULT Human clinical

"Results of MYCN status of the individual tumors, either amplified or non-amplified ... were also collected from the patients (N=500) of both CCG and COG studies ... There were 10 patients whose tumor had amplified MYCN in this series: all 4 with FH tumors (2 cases with GN-M; 2 cases with GNB-I)..."

This CCG/COG series shows that MYCN amplification was rare: of 500 ganglioneuroma and ganglioneuroblastoma patients with a MYCN result, 10 had amplified tumours, 4 with favourable histology (2 GN-maturing, 2 GNB-intermixed), all alive and well at last follow-up, and 6 with nodular unfavourable-subset (GNB-N-US) tumours, 2 of whom died of tumour. Limits: only 3 of the 4 favourable-histology patients were followed beyond a year, the GN-maturing cases are ganglioneuromas, and the series includes the 70 nodular cases of Peuchmaur et al. (2003), so it is not independent of other CCG reports.

PMID:11745206 SUPPORT INDIRECT BACKGROUND Human clinical

"MYCN amplification is a known molecular marker for aggressive progression of NTs. These have been used together as important prognostic factors to define risk groups for patient stratification and protocol assignment."

The background of this Children's Cancer Group study states that MYCN amplification is a known marker of aggressive progression in neuroblastic tumors, and that it is used together with INPC histology, the other factor 'These' refers to, to define risk groups for patient stratification and protocol assignment. That is the prognostic use behind this record's BIOMARKER typing. It is said of neuroblastic tumors as a family, most of them neuroblastomas, not of ganglioneuroblastoma alone.

+ 1 more reference

💊

Medical Actions

Watchful Observation

Category: Monitoring Action: watchful active observation Ontology label: Observation Activity NCIT:C25598

For non-metastatic intermixed ganglioneuroblastoma and ganglioneuroma, studied together in retrospective series whose abstracts report no outcome for observed intermixed tumors on their own, a UK nationwide series concluded that watchful active observation can be a safe approach, with surgical resection reserved for symptomatic patients, and a single-center series that these tumors grow slowly and resection can carry significant morbidity, so watch-and-wait approaches should be considered for some patients. Observation rests on the biopsy diagnosis, which is not always upheld at surgery: in the UK series, 14 cases (12%) diagnosed on biopsy as ganglioneuroma or intermixed ganglioneuroblastoma had neuroblastoma or nodular ganglioneuroblastoma on surgical pathology, and a small proportion of observed patients had their diagnosis revised at surgery.

Show evidence (3 references)

PMID:39582110 SUPPORT DIRECT PRIMARY RESULT Human clinical

"Watchful active observation can be a safe approach, with surgical resection reserved for symptomatic patients. However, a small proportion of patients in the observation group had their diagnosis revised to malignant at surgery."

This UK CCLG nationwide retrospective review covers 259 patients with histologically confirmed non-metastatic ganglioneuroma or intermixed ganglioneuroblastoma. It concludes that observation can be safe, with resection reserved for symptomatic patients, though a small proportion of observed patients had their diagnosis revised at surgery. The abstract calls that a revision to malignant, and its background describes both tumors as benign variants, whereas ICD-O-3 codes ganglioneuroblastoma as malignant (9490/3). The two diagnoses are pooled and survival is not reported by management arm, so the safety statement is the authors' judgement. Twenty-one of the 58 observed patients (36%) later needed surgery, with progressive tumour growth cited as a reason; how many of them were reclassified is not stated.

PMID:39582110 SUPPORT DIRECT PRIMARY RESULT Human clinical

"In 45 cases (39%), surgical pathology was different from pathology at biopsy, and in 14 (12%) the pathology changed from GN/GNBi to neuroblastoma/GNB nodular."

In this UK CCLG retrospective series of 259 patients with non-metastatic ganglioneuroma or intermixed ganglioneuroblastoma, surgical pathology differed from the biopsy diagnosis in 45 cases, and in 14 (12%) a biopsy diagnosis of ganglioneuroma or intermixed ganglioneuroblastoma became neuroblastoma or nodular ganglioneuroblastoma at surgery. The abstract gives no denominator for the percentages, does not split the changes by biopsy diagnosis or management arm, and does not say whether they reflect limited sampling, reinterpretation or change in the tumor before surgery.

PMID:29369484 SUPPORT PRIMARY RESULT Human clinical

"GN and GNB-I have a slow growth rate and resection can be associated with significant morbidity. Watch and wait approaches should be considered for some GN and GNB-I."

This single-centre retrospective cohort (Hospital for Sick Children, 1990-2014) covers 67 patients with ganglioneuroma or intermixed ganglioneuroblastoma (17 intermixed), 21 of them observed. Its conclusion recommends considering watch-and-wait for some patients, citing slow tumour growth and the significant morbidity resection can carry. It supports this rationale and recommendation only; metastatic status is not stated, and 6 of the 21 observed patients had progressive disease. Pathology changed at resection in three cases, but the abstract says only that no ganglioneuroma became neuroblastoma, so it does not show the revisions to neuroblastoma or nodular ganglioneuroblastoma reported in the UK series.

Surgical Resection

Category: Therapeutic Action: surgical resection Ontology label: Tumor Resection NCIT:C164212

Platform: Surgery

In localized intermixed ganglioneuroblastoma, studied together with ganglioneuroma, chemotherapy seemed not to be effective and incomplete resection leaving only minor residuals (under 2 cm) appeared sufficient. In nodular ganglioneuroblastoma of the unfavorable subset, a CCG/COG series found no significant survival difference between complete primary tumor resection (at least 95% removed before chemotherapy or irradiation) and biopsy or partial resection, in patients with or without distant metastasis. The non-significant differences favored complete resection, the non-stage 4 comparison included few incompletely resected patients, and prognosis depended significantly on stage.

Mechanism Target:

INHIBITS Neoplastic Neuroblast Population — Resection removes all or most of the primary tumor together with its neoplastic neuroblasts. In a German series of localized intermixed tumors and ganglioneuroma, even incomplete resection leaving minor residuals (under 2 cm) appeared sufficient treatment. How resection affects outcome in nodular disease is described in this treatment's description.

Show evidence (2 references)

PMID:27465021 SUPPORT INDIRECT PRIMARY RESULT Human clinical

"Outcome was excellent and chemotherapy seems not effective while incomplete resection with minor residuals (<2 cm) appears to be sufficient for treatment."

In this retrospective study of localized ganglioneuroma and intermixed ganglioneuroblastoma registered in the German NB97 and NB2004 trials, the authors conclude that resection, even when it left residuals under 2 cm, appears sufficient treatment, while chemotherapy seems not effective. This is a treatment outcome, so reading it as resection reducing the neoplastic neuroblast population is an inference. No tumor progressed after complete resection or with residuals under 2 cm, so control did not depend on removing the whole tumor. The sentence pools the two tumor types.

PMID:27465021 SUPPORT INDIRECT PRIMARY RESULT Human clinical

"However, patients with major residuals (>2 cm) had a worse EFS than patients with complete tumor resection or minor residuals as well for the whole group of mature NT (p < 0.001; Fig. 4a) as for the groups of GN (p = 0.001; Fig. 5a) and GNBI seen individually (p = 0.005; Fig. 6a)."

In the same German series, patients left with residual tumor over 2 cm had worse event-free survival than those with complete resection or minor residuals, and this held for intermixed ganglioneuroblastoma on its own (p = 0.005). More tumor left behind went with more events: all five local progressions, two of them in intermixed tumors, arose in residuals over 2 cm. That this reflects resection reducing the tumor is an inference from outcome, and overall survival was not influenced by the extent of initial surgery.

Show evidence (4 references)

PMID:27465021 SUPPORT DIRECT PRIMARY RESULT Human clinical

"Outcome was excellent and chemotherapy seems not effective while incomplete resection with minor residuals (<2 cm) appears to be sufficient for treatment."

This summarises a retrospective study of localized tumours registered in the German neuroblastoma trials NB97 and NB2004, including 162 ganglioneuroma and 55 intermixed ganglioneuroblastoma (GNBI) patients. None of the 11 patients given chemotherapy, 9 with GNBI, reached a complete or very good partial response. No tumour of either type progressed after complete resection or with residuals under 2 cm, whereas all five progressions had residuals over 2 cm. Few patients received chemotherapy, and the authors allow that single GNBI patients with immature regions in large residuals might benefit.

PMID:41568977 SUPPORT DIRECT PRIMARY RESULT Human clinical

"Four patients received chemotherapy but showed no significant tumor reduction postchemotherapy, and all required surgery afterward."

This abstract reports a retrospective single-centre series of 12 patients with nonmetastatic intermixed ganglioneuroblastoma at Phoenix Children's Hospital. The four patients given chemotherapy showed no significant tumour reduction and all still needed surgery, and chemotherapy caused febrile neutropenia and an anaphylactic reaction. The title and conclusion frame these tumours as unresectable, but the abstract does not say why each patient received chemotherapy. With only four treated patients the evidence is thin, and it says nothing about how complete a resection must be.

PMID:19530234 SUPPORT DIRECT PRIMARY RESULT Human clinical

"Complete primary tumor resection was not beneficial to those GNB-N-US patients, regardless of whether metastasis was present or not."

In a retrospective CCG/COG cohort, the authors report that complete primary resection was not beneficial in nodular unfavourable-subset ganglioneuroblastoma (GNB-N-US), with or without distant metastasis. The analysis compared complete resection (at least 95% removed before chemotherapy or irradiation) with biopsy or partial resection in 226 patients otherwise treated by risk group. Differences were not significant but favoured complete resection (5-year EFS 83.4% vs 60.6%, p = 0.2227, non-stage 4, only 16 incompletely resected; 24.3% vs 5.4%, p = 0.1068, stage 4), so benefit is not excluded.

+ 1 more reference

Risk-Adapted Chemotherapy-Based Therapy

Category: Therapeutic Action: risk-adapted chemotherapy within neuroblastoma risk-group protocols Ontology label: Chemotherapy NCIT:C15632

Patients are treated by neuroblastoma risk group. In Children's Cancer Group and Children's Oncology Group studies that registered patients from 1991 to 2006, low-risk patients had surgery alone, intermediate-risk patients moderate chemotherapy with surgery, and high-risk patients intensive chemotherapy, surgery, radiotherapy and often myeloablative therapy. In one referral series of intermixed ganglioneuroblastoma diagnosed at presentation (1995-2021), the 12 patients presenting with metastases, all diagnosed on biopsy, were treated as high-risk neuroblastoma with high-dose chemotherapy, radiotherapy and anti-GD2 monoclonal antibody immunotherapy. Of the 41 with locoregional disease, 11 received intermediate-risk neoadjuvant chemotherapy and 30 no cytotoxic therapy, and all 41 remained progression-free at a median follow-up of 4 years; in localized intermixed tumors chemotherapy has seemed ineffective (see Surgical Resection). Patients with nodular ganglioneuroblastoma older than 18 months with stage 4 disease form a high-risk subgroup that should be considered for aggressive upfront treatment.

Show evidence (4 references)

PMID:19530234 SUPPORT DIRECT Human clinical

"Among a total of 3,953 patients registered in CCG and COG neuroblastoma studies from August 1, 1991 to December 31, 2006, there were 552 cases whose diagnosis was either GN or GNB. ... Patients were treated by risk group: low-risk patients had surgery alone; intermediate-risk patients had a..."

The Methods of this CCG/COG series of 552 ganglioneuroma and ganglioneuroblastoma cases, registered on neuroblastoma studies from August 1991 to December 2006, state how the patients were treated: by neuroblastoma risk group, with surgery alone for low risk, moderate chemotherapy with surgery for intermediate risk, and intensive chemotherapy, surgery, radiotherapy and often myeloablative therapy for high risk. These are the regimens of that period. It describes the protocols applied, not a comparison of treatments, and about 60% of the patients (329 of 552) were enrolled on therapeutic studies.

PMID:22137163 SUPPORT DIRECT PRIMARY RESULT Human clinical

"Similar to the overall NB cohort, patients with GNBn older than 18 months of age, with stage 4 disease represent a high-risk sub-group and should be considered for aggressive treatment upfront."

In an analysis of the INRG database, Angelini and colleagues identified 232 patients with nodular ganglioneuroblastoma among 4071 with a known INPC category. They conclude that, as in neuroblastoma overall, those older than 18 months with stage 4 disease are a high-risk subgroup who should be considered for aggressive upfront treatment. The recommendation follows from survival outcomes, not a comparison of treatments, and names no specific regimen. The abstract reports overall survival for all stage 4 patients (35%, n=107), not separately for those over 18 months.

PMID:37243318 SUPPORT DIRECT PRIMARY RESULT Human clinical

"All patients with metastatic disease were diagnosed at >18 months of age, were deemed to have high-risk NB, and were treated with multimodality therapy including high-dose chemotherapy, radiotherapy and anti-GD2 monoclonal antibody-mediated immunotherapy."

In this retrospective Memorial Sloan Kettering series of intermixed ganglioneuroblastoma diagnosed at presentation (1995-2021), all 12 patients with metastatic disease were older than 18 months, were treated as high-risk neuroblastoma, and received multimodality therapy including high-dose chemotherapy, radiotherapy and anti-GD2 monoclonal antibody immunotherapy. Table 2 shows that all 12 were diagnosed on biopsy, and 8 of their 12 resections, after chemotherapy, showed neuroblastoma. The paper names no antibody and gives no treatment dates; it reports one center's practice, not a comparison of treatments.

+ 1 more reference

🔬

Biochemical Markers

Neuron-Specific Enolase (INCREASED)

Show evidence (1 reference)

PMID:28465480 SUPPORT DIRECT PRIMARY RESULT Human clinical

"NB patients were more frequently diagnosed with adrenal tumors and had a higher prevalence of abnormal serum ferritin at the time of diagnosis (60.0% vs. 40.0% vs. 12.0%, P<0.001), NSE (96.0% vs. 93.0% vs. 81.0%, P=0.013) when compared with GNBn and GNBi patients."

This retrospective review of 279 children with neuroblastoma (NB) or ganglioneuroblastoma at Xinhua Hospital, Shanghai, reports pretreatment serum markers in the order NB, nodular (GNBn), intermixed (GNBi): serum NSE was abnormal at diagnosis in 96%, 93% and 81%. The Results give the normal-NSE rates in the reverse order (19%, 7% and 4%), which confirms this reading. The paper's Methods list 20 nodular and 31 intermixed patients; the text gives neither the number tested nor a cut-off, and it reports abnormal rather than raised values.

Serum Ferritin (INCREASED)

Show evidence (1 reference)

PMID:28465480 SUPPORT DIRECT PRIMARY RESULT Human clinical

The same sentence reports abnormal serum ferritin at diagnosis in 60% of neuroblastomas, 40% of nodular (GNBn) and 12% of intermixed (GNBi) ganglioneuroblastomas in this single-center series, whose Methods list 20 nodular and 31 intermixed patients. The abstract says abnormal rather than raised and gives no cut-off or number tested.

🔬

Diagnosis

Histopathologic Classification

Ganglioneuroblastoma is diagnosed and subtyped by histopathologic examination of tumor tissue under the INPC. Because a macroscopic neuroblastomatous nodule separates nodular from intermixed tumors, which are hard to tell apart on limited samples, the completely resected tumor is the ideal sample. When only a biopsy or an incompletely resected tumor is available, a favorable classification is reported as based on review of limited material: the CCG/COG central reviewers did so, and a 2026 pathology review advises it for core needle biopsies that show only intermixed ganglioneuroblastoma or ganglioneuroma.

histopathologic examination under the International Neuroblastoma Pathology Classification NCIT:C18190

Show evidence (3 references)

PMID:37243318 SUPPORT DIRECT BACKGROUND Other

"The diagnosis of GNBI is typically made on a diligent morphological examination of the entire resected tumor because distinguishing GNBI from GNBN is particularly challenging on limited samples."

The Discussion of this Memorial Sloan Kettering series opens by restating established practice: intermixed ganglioneuroblastoma (GNBI) is usually diagnosed on careful examination of the entire resected tumor, because it is particularly hard to tell from nodular ganglioneuroblastoma (GNBN) on limited samples. It states practice and reports no data from the series.

PMID:19530234 SUPPORT DIRECT Human clinical

"It was always ideal for pathologist to have a completely resected sample for the final diagnosis, so as not to miss any unfavorable nodules or different clones. However, in real life, we sometimes encountered the situation/clinical decision where we had to evaluate a biopsy or incompletely..."

In the Discussion of this CCG/COG series, the central review pathologists state that a completely resected sample was always the ideal basis for the final diagnosis, so that no unfavorable nodule or different clone was missed. When only a biopsy or an incompletely resected tumor was available, a favorable diagnosis of GN-maturing, GNB-intermixed or favorable-subset GNB-nodular carried the remark that it was based on review of limited material. This describes the series' diagnostic practice, not an outcome.

PMID:41612478 SUPPORT DIRECT REVIEW SYNTHESIS Other

"especially when the samples obtained by PCNB show only GNB-i or GN histology, it is advisable to include a note of "Favorable Histology of this case according to the International Neuroblastoma Pathology Classification is determined based on review of limited material" in the surgical pathology report."

This 2026 pathology review advises, as the authors' routine practice, that when percutaneous core needle biopsy (PCNB) samples show only GNB-intermixed or ganglioneuroma histology, the report should note that the favorable INPC classification was determined on review of limited material. The preceding sentence gives the reason: a core needle biopsy can miss the neuroblastoma nodule of a nodular ganglioneuroblastoma. It is an expert recommendation about core needle biopsy, without case data.

📊

Prevalence

Worldwide

Point prevalence <1 in 1,000,000

Orphanet's prevalence class, which sets only an upper bound; it is not a measured rate.

Show evidence (1 reference)

ORPHA:251877 SUPPORT DIRECT Other

"<1 / 1 000 000 | Worldwide | Point prevalence"

Orphanet's epidemiology table for ganglioneuroblastoma gives a worldwide point-prevalence class of <1 / 1 000 000, which is the classification this record states. The class is a band that sets only an upper bound, and the row gives no numeric estimate, so it does not report a measured rate. The quote stops before the row's Source column, which includes a source typed OTHER and two PubMed records (PMID:36171902, PMID:36405824).

🌍

Epidemiology

Age at diagnosis

In a Children's Cancer Group pathology review of 746 neuroblastic tumors from studies CCG-3881 and CCG-3891, the median age at diagnosis was 3.51 years (range 0.96-14.85) for intermixed and 3.26 years (range 0.57-15.90) for nodular ganglioneuroblastoma. A larger Children's Cancer Group and Children's Oncology Group series, which overlaps this cohort, gives median ages of 4 years 1 month for 198 intermixed tumors, and of 1 year 5 months for 59 favorable-subset and 3 years 9 months for 252 unfavorable-subset nodular tumors.

Show evidence (2 references)

PMID:11745303 SUPPORT DIRECT PRIMARY RESULT Human clinical

"Among patients with FH tumors ... the median ages of patients with GNBi and GN tumors were 3.51 years (range, 0.96-14.85 years) and 4.80 years (range, 1.94-17.05 years), respectively. In contrast, patients with UH tumors generally were older when they were diagnosed, and with median ages of ......"

This Children's Cancer Group review of 746 neuroblastic tumours from studies CCG-3881 and CCG-3891 reports median age at diagnosis of 3.51 years (range 0.96-14.85) for intermixed ganglioneuroblastoma (30 tumours, all favourable histology) and 3.26 years (range 0.57-15.90) for nodular ganglioneuroblastoma (76 tumours, all unfavourable histology in this analysis). The 4.80-year median is for ganglioneuroma, and the omitted text lists only neuroblastoma-subtype medians. The quoted remark that unfavourable-histology patients were generally older does not hold here, as the nodular median is the lower. These are cooperative-group study patients, not a population sample.

PMID:19530234 SUPPORT DIRECT PRIMARY RESULT Human clinical

"There were 43 GN-M tumors, 198 GNB-I tumors, 59 GNB-N-FS tumors, and 252 GNB-N-US tumors in this series. ... the majority of patients with GNB-I (Age between 10 months and 16 years 3 months, mean: 4 years 10 months, median: 4 years 1 months) and with GNB-N-US (Age between 6 months and 18 years 9..."

In this CCG/COG central review of ganglioneuroma and ganglioneuroblastoma cases registered on neuroblastoma studies in 1991-2006, median age at diagnosis was 4 years 1 month for the 198 intermixed tumors (range 10 months to 16 years 3 months), 1 year 5 months for the 59 favorable-subset nodular tumors (4 months to 4 years 11 months) and 3 years 9 months for the 252 unfavorable-subset nodular tumors (6 months to 18 years 9 months). The series overlaps the Children's Cancer Group review above, including the 70 CCG-3881 and CCG-3891 nodular patients of PMID:10964346 and PMID:14601099, and the favorable subset's younger age partly reflects the INPC age criteria. These are cooperative-group study patients, not a population sample.

🔀

Differential Diagnoses

Conditions with similar clinical presentations that must be differentiated from Ganglioneuroblastoma:

Ganglioneuroma MONDO:0005033

Overlapping Features Ganglioneuroma is the Schwannian stroma-dominant category of the peripheral neuroblastic tumors, and intermixed ganglioneuroblastoma is the Schwannian stroma-rich category beside it. Both consist largely of Schwannian stroma containing mature or maturing ganglion cells, and the INPC maturing subtype of ganglioneuroma may also hold a minor component of individually scattered differentiating neuroblasts. Read side by side, their INPC definitions differ in the well-defined microscopic neuroblastic nests that characterize the intermixed category; differentiating neuroblasts scattered as single cells are compatible with maturing ganglioneuroma. For decades ganglioneuroblastoma caused some consternation for pathologists and oncologists, one reason being that there was no clear and objective delineation between it and ganglioneuroma. The INPC maturing subtype of ganglioneuroma is the tumor group that the earlier Shimada classification called ganglioneuroblastoma, well differentiated, so a tumor reported as well-differentiated ganglioneuroblastoma under the Shimada nomenclature is a ganglioneuroma under the INPC. Sampling adds another source of confusion: compared with surgical resection, core needle biopsy seems to be at a disadvantage with nodular ganglioneuroblastoma, in which a neuroblastoma nodule coexists with intermixed ganglioneuroblastoma or ganglioneuroma tissue.

Distinguishing Features

Intermixed ganglioneuroblastoma is defined as tumor tissue more than 50% occupied by a ganglioneuromatous component and is characterized by well-defined microscopic nests of neuroblastic cells whose neurites are segmentally naked within the nests.
In ganglioneuroma, ganglion cells lie individually or in small clusters in Schwannian stroma and are either all completely mature (mature subtype) or a mixture of mature and maturing cells (maturing subtype); completely mature ganglion cells are covered with satellite cells, and naked neurites are not identified around the ganglion cells.
Under the INPC definition the maturing subtype of ganglioneuroma may also contain a minor component of individually scattered differentiating neuroblasts, present as single scattered cells rather than in the microscopic neuroblastic nests that characterize intermixed ganglioneuroblastoma.
Under the INPC, intermixed ganglioneuroblastoma is Schwannian stroma-rich and ganglioneuroma Schwannian stroma-dominant, while nodular ganglioneuroblastoma is a composite of stroma-rich or stroma-dominant tissue with stroma-poor tissue.
Compared with surgical resection, core needle biopsy seems to be at a disadvantage with nodular ganglioneuroblastoma, where a neuroblastoma nodule coexists with intermixed ganglioneuroblastoma or ganglioneuroma tissue; when the tumor is large, multiple cores may give a better chance than incisional biopsy of sampling the nodule, which is often hemorrhagic or necrotic and detected on radiological images.

Show evidence (5 references)

PMID:41612478 SUPPORT DIRECT REVIEW SYNTHESIS Other

"By definition, more than 50% of the tumor tissue in this category is occupied by a ganglioneuromatous component (see below), where well-developed Schwannian stroma contains sporadic mature or maturing ganglion cells. The tumors are characterized by the presence of well-defined microscopic nests..."

In this 2026 pathology review, part one of the quote comes from the section headed 'Ganglioneuroblastoma, intermixed (Schwannian stroma-rich)' and says only 'this category'; the Fig. 2B legend it cites labels the image as ganglioneuroblastoma, intermixed. Part two comes from the section headed 'Ganglioneuroma (Schwannian stroma-dominant)' and names its category through the mature and maturing GN subtypes. Restating the International Neuroblastoma Pathology Classification, the review defines intermixed ganglioneuroblastoma as tumor tissue more than 50% occupied by a ganglioneuromatous component and characterizes it by well-defined microscopic nests of neuroblastic cells whose neurites are segmentally naked within the nests. In ganglioneuroma, ganglion cells lie individually or in small clusters in Schwannian stroma and are either completely mature (mature GN) or a mixture of mature and maturing cells (maturing GN); completely mature ganglion cells are covered with satellite cells, and because their neurites are immediately incorporated into Schwannian stromal cells, naked neurites are not identified around them. The review describes the two categories in separate paragraphs and does not compare them directly; read side by side, the definitions set the neuroblastic nests of the intermixed tumor against the individually distributed or clustered ganglion cells of ganglioneuroma. These are classification criteria, not case data.

PMID:19530234 SUPPORT DIRECT BACKGROUND Other

"Ganglioneuroma-Maturing (Schwannian stroma-dominant): Composed predominantly of ganglioneuromatous stroma with a minor component of individually scattered, evenly or unevenly distributed differentiating neuroblasts and/or maturing ganglion cells, in addition to fully mature ganglion cells. Fully..."

Table I of this CCG/COG clinicopathological series restates the International Neuroblastoma Pathology Classification definition of the ganglioneuroma, maturing subtype (Schwannian stroma-dominant): mostly ganglioneuromatous stroma with a minor component of individually scattered, evenly or unevenly distributed differentiating neuroblasts and/or maturing ganglion cells, beside fully mature ganglion cells that are always covered with satellite cells. So differentiating neuroblasts scattered as single cells can occur in this ganglioneuroma subtype. The intermixed row of the same table instead describes scattered 'residual' microscopic neuroblastomatous foci presenting as pockets of neuropil; the contrast between single scattered cells and those foci is read from the two definitions side by side and is not stated in this row. It is a classification rule restated from the INPC papers, not a result of this cohort.

PMID:10421272 SUPPORT DIRECT PRIMARY RESULT Human clinical

"Based on morphologic criteria defined in this article, NTs were classified into four categories and their subtypes: 1) neuroblastoma (Schwannian stroma-poor), undifferentiated, poorly differentiated, and differentiating; 2) ganglioneuroblastoma, intermixed (Schwannian stroma-rich); 3)..."

This is the 1999 terminology paper of the International Neuroblastoma Pathology Committee, whose six member pathologists defined morphologically based classifications on the basis of a review of 227 cases. It classifies neuroblastic tumors into four categories, each labeled by its Schwannian stroma: neuroblastoma (stroma-poor), ganglioneuroblastoma, intermixed (stroma-rich), ganglioneuroma (stroma-dominant, with maturing and mature subtypes) and ganglioneuroblastoma, nodular, a composite of stroma-rich or stroma-dominant tissue with stroma-poor tissue. The scheme therefore separates ganglioneuroblastoma from stroma-poor neuroblastoma and from stroma-dominant ganglioneuroma. The abstract gives each category its name, its Schwannian stromal label and, for neuroblastoma and ganglioneuroma, the names of its subtypes, but not the morphologic criteria that the article says it defines. 'stroma-richlstroma-dominant' is the source's typo for stroma-rich/stroma-dominant, the spelling in the abstract of the companion INPC article in the same issue (PMID:10421273). In this abstract INPC abbreviates the Committee, which proposes the International Neuroblastoma Pathology Classification.

+ 2 more references

Neuroblastoma MONDO:0005072

Overlapping Features Neuroblastoma is the Schwannian stroma-poor category of the same INPC classification, and nodular ganglioneuroblastoma is a composite of stroma-poor neuroblastoma tissue with stroma-rich or stroma-dominant tissue, so different samples from one patient can be assigned different categories. When core needle biopsy samples from one site show intermixed ganglioneuroblastoma or ganglioneuroma and another site in the same patient shows neuroblastoma, a 2026 pathology review advises considering a variant of nodular ganglioneuroblastoma, in which a neuroblastoma nodule in the primary tumor was not sampled but is found at the metastatic site, or, extremely rarely, multiple primaries presumably composed of different clones. In one tertiary-center retrospective series, 12 patients with stage M disease had intermixed ganglioneuroblastoma diagnosed on biopsy; after neoadjuvant chemotherapy the definitive resection showed neuroblastoma in 8 (67%), so the biopsy diagnosis could not be corroborated, and the authors advise high caution with a biopsy diagnosis of intermixed ganglioneuroblastoma when metastases are present.

Distinguishing Features

Histologically, tumors in the INPC neuroblastoma (Schwannian stroma-poor) category are composed of neuroblastic cells in sheets or nests demarcated by thin fibrovascular septa, with limited or absent Schwannian stromal development.
Under the INPC, neuroblastoma is Schwannian stroma-poor, intermixed ganglioneuroblastoma Schwannian stroma-rich, and nodular ganglioneuroblastoma a composite of stroma-rich or stroma-dominant tissue with stroma-poor tissue.
Under the INPC definition, intermixed ganglioneuroblastoma is a transitional form between neuroblastoma and ganglioneuroma with scattered residual microscopic neuroblastomatous foci presenting as pockets of neuropil, and its ganglioneuromatous component should exceed 50% of the total volume in microscopic fields from representative sections of the tumor.
Nodular ganglioneuroblastoma is characterized by macroscopic, usually hemorrhagic neuroblastomatous nodules of Schwannian stroma-poor component coexisting with stroma-rich intermixed ganglioneuroblastoma or stroma-dominant ganglioneuroma.
When core needle biopsy samples show intermixed ganglioneuroblastoma or ganglioneuroma at one site and neuroblastoma at another in the same patient, a 2026 pathology review advises considering a variant of nodular ganglioneuroblastoma whose primary-site neuroblastoma nodule was not sampled but is found at the metastatic site or, extremely rarely, multiple primaries presumably composed of different clones.
In one tertiary-center series, resection after neoadjuvant chemotherapy showed neuroblastoma in 8 of 12 patients with stage M disease whose biopsy had shown intermixed ganglioneuroblastoma, and the authors advise high caution with such a biopsy diagnosis when metastases are present.

Show evidence (7 references)

PMID:10421272 SUPPORT DIRECT PRIMARY RESULT Human clinical

PMID:41612478 SUPPORT DIRECT REVIEW SYNTHESIS Other

"Histologically the tumors are composed of neuroblastic cells arranged in sheets or nests demarcated by thin fibrovascular septae. Schwannian stromal development is limited or absent."

The quoted sentences come from the section of this 2026 review headed 'Neuroblastoma (Schwannian stroma-poor)', whose first sentence names its subject as tumors in the NB category, so 'the tumors' are tumors of the INPC neuroblastoma category. They consist of neuroblastic cells in sheets or nests demarcated by thin fibrovascular septa ('septae' in the source), with limited or absent Schwannian stromal development. The same review labels intermixed ganglioneuroblastoma Schwannian stroma-rich, so the extent of Schwannian stroma, rather than the neuroblastic architecture, separates neuroblastoma from the intermixed form; that comparison is drawn from the review's definitions and is not stated in this quote. The quote does not by itself separate neuroblastoma from nodular ganglioneuroblastoma, whose neuroblastoma component the review describes as often forming nodules in a background of intermixed ganglioneuroblastoma or ganglioneuroma tissue. The passage restates an INPC criterion and reports no case data.

PMID:19530234 SUPPORT DIRECT BACKGROUND Other

Table I of this CCG/COG clinicopathological series restates the International Neuroblastoma Pathology Classification definition of intermixed ganglioneuroblastoma: a transitional form between neuroblastoma and ganglioneuroma whose maturation is incomplete, with scattered 'residual' microscopic neuroblastomatous foci presenting as pockets of neuropil, and a ganglioneuromatous component that should exceed 50% of the total volume in microscopic fields from representative sections. The quote states only the intermixed side of that threshold; read with the 2026 review's description of neuroblastoma as having limited or absent Schwannian stromal development, it is the quantitative criterion that sets the intermixed form apart from neuroblastoma. It is a diagnostic criterion restated from the INPC, not cohort data.

+ 4 more references

📊

Related Datasets

Two distinct gene signatures identify malignant Neuroblast and Schwannian stromal cells of Neuroblastic Tumors geo:GSE7529

Affymetrix microarray profiles of 19 whole neuroblastic tumours: 10 neuroblastomas, 3 ganglioneuroblastomas (two of them intermixed), 5 ganglioneuromas and one borderline maturing ganglioneuroma. Laser-microdissected areas from four of the tumours, one of them a ganglioneuroblastoma, separate the neuroblastic cells from the Schwannian stromal cells that a ganglioneuroblastoma mixes.

human MICROARRAY

PMID:18671248

The tumour counts are from the GEO sample titles; the GEO summary gives only 10 stroma-poor and 9 stroma-rich tumours.

{ }

Source YAML

click to show

name: Ganglioneuroblastoma
creation_date: '2026-10-21T13:46:41Z'
description: >-
  Ganglioneuroblastoma is a peripheral neuroblastic tumor of childhood, of
  sympathoadrenal (neural crest) lineage, composed of neoplastic neuroblasts,
  ganglion cells and Schwannian stroma and intermediate in differentiation
  between neuroblastoma and ganglioneuroma. The International Neuroblastoma
  Pathology Classification (INPC) divides peripheral neuroblastic tumors into
  four categories, two of which are ganglioneuroblastoma. Intermixed
  ganglioneuroblastoma is Schwannian stroma-rich and always of favorable
  histology. Nodular ganglioneuroblastoma is composite: one or more macroscopic,
  usually hemorrhagic, stroma-poor neuroblastomatous nodules sit in a
  stroma-rich or stroma-dominant background, the tumor is graded on its nodules,
  and patients are stratified with neuroblastoma risk criteria.
  Ganglioneuroblastoma has a malignant ICD-O-3 morphology code (9490/3, as MONDO
  and NCIT record it), and neither subtype is benign, although some clinical
  series call the intermixed subtype a benign variant (see notes). This entry
  covers peripheral ganglioneuroblastoma (MONDO:0005035) in both INPC
  categories. MONDO and NCIT define the class by a Schwannian stroma making up
  more than half of the tumor volume; in the INPC an over-half
  ganglioneuromatous component defines the intermixed category, while in a
  nodular tumor the proportion of neuroblastomatous nodule to intermixed or
  ganglioneuroma tissue varies from case to case. Central nervous system
  ganglioneuroblastoma (NCIT:C92629), a malignant CNS neoplasm defined without a
  Schwannian stroma criterion, and Hirschsprung disease-ganglioneuroblastoma
  syndrome (MONDO:0013082) are out of scope. MONDO and NCIT place
  ganglioneuroblastoma beside neuroblastoma under neuroblastic tumor, while HPO
  files HP:0006747 Ganglioneuroblastoma under HP:0003006 Neuroblastoma.
categories:
- Pediatric Cancer
- Neural Tumor
- Solid Tumor
parents:
- neuroblastic tumor
synonyms:
- ganglioneuroblastoma, malignant
- GNB
notes: >-
  The WHO Classification of Tumours, Paediatric Tumours (5th edition) lists
  ganglioneuroblastoma, intermixed and ganglioneuroblastoma, nodular (and other
  composite neuroblastic tumours) as separate entries beside neuroblastoma and
  ganglioneuroma; the volume is not indexed in PubMed, so it is not cited as
  evidence. NCIT defines ganglioneuroblastoma as a malignant neuroblastic tumor.
  Usage for the intermixed subtype is not uniform in the cited series: the UK
  CCLG nationwide study (Burnand 2025) calls intermixed ganglioneuroblastoma and
  ganglioneuroma benign variants of peripheral neuroblastic tumors, and its
  remark that some observed patients had their diagnosis revised to malignant at
  surgery follows that usage, while the German trial series (Decarolis 2016)
  calls both mature variants and notes that ganglioneuroma is generally
  considered benign whereas intermixed ganglioneuroblastoma is widely seen as a
  malignant entity. The INPC's favorable histology, which every intermixed tumor
  has, is a prognostic grouping and does not make the tumor benign.
  MONDO:0003327 peripheral ganglioneuroblastoma has the same scope as this entry
  (MONDO's editors removed its logical definition because it made the class
  equivalent to its parent), and the site classes adrenal gland
  ganglioneuroblastoma (MONDO:0004477) and mediastinum ganglioneuroblastoma
  (MONDO:0001096) fall within it, although MONDO also files them under the
  matching neuroblastoma site classes. INRG and Children's Oncology Group
  cohorts often pool ganglioneuroblastoma with neuroblastoma, so
  neuroblastoma-wide figures may include it. Several cooperative-group series
  cited here share patients: Umehara 2000 and Peuchmaur 2003 analysed the same
  70 nodular patients from studies CCG-3881 and CCG-3891, Okamatsu 2009 includes
  them, and Goto 2001 and Shimada 2001 are also Children's Cancer Group series.
  Germline predisposition is not modelled in this entry: Orphanet lists ALK as a
  major susceptibility factor for ganglioneuroblastoma, and MONDO treats
  ALK-related predisposition as a separate disease, neuroblastoma,
  susceptibility to, 3 (MONDO:0013083).
epidemiology:
- name: Age at diagnosis
  description: >-
    In a Children's Cancer Group pathology review of 746 neuroblastic tumors
    from studies CCG-3881 and CCG-3891, the median age at diagnosis was 3.51
    years (range 0.96-14.85) for intermixed and 3.26 years (range 0.57-15.90)
    for nodular ganglioneuroblastoma. A larger Children's Cancer Group and
    Children's Oncology Group series, which overlaps this cohort, gives median
    ages of 4 years 1 month for 198 intermixed tumors, and of 1 year 5 months
    for 59 favorable-subset and 3 years 9 months for 252 unfavorable-subset
    nodular tumors.
  evidence:
  - reference: PMID:11745303
    reference_title: "International neuroblastoma pathology classification for prognostic evaluation of patients with peripheral neuroblastic tumors: a report from the Children's Cancer Group."
    supports: SUPPORT
    directness: DIRECT
    quote_role: PRIMARY_RESULT
    evidence_source: HUMAN_CLINICAL
    snippet: "Among patients with FH tumors ... the median ages of patients with GNBi and GN tumors were 3.51 years (range, 0.96-14.85 years) and 4.80 years (range, 1.94-17.05 years), respectively. In contrast, patients with UH tumors generally were older when they were diagnosed, and with median ages of ... 3.26 years (range, 0.57-15.90 years) for patients with GNBn tumors"
    explanation: >-
      This Children's Cancer Group review of 746 neuroblastic tumours from
      studies CCG-3881 and CCG-3891 reports median age at diagnosis of 3.51
      years (range 0.96-14.85) for intermixed ganglioneuroblastoma (30 tumours,
      all favourable histology) and 3.26 years (range 0.57-15.90) for nodular
      ganglioneuroblastoma (76 tumours, all unfavourable histology in this
      analysis). The 4.80-year median is for ganglioneuroma, and the omitted
      text lists only neuroblastoma-subtype medians. The quoted remark that
      unfavourable-histology patients were generally older does not hold here,
      as the nodular median is the lower. These are cooperative-group study
      patients, not a population sample.
  - reference: PMID:19530234
    reference_title: "Clinicopathological characteristics of ganglioneuroma and ganglioneuroblastoma: a report from the CCG and COG."
    supports: SUPPORT
    directness: DIRECT
    quote_role: PRIMARY_RESULT
    evidence_source: HUMAN_CLINICAL
    snippet: "There were 43 GN-M tumors, 198 GNB-I tumors, 59 GNB-N-FS tumors, and 252 GNB-N-US tumors in this series. ... the majority of patients with GNB-I (Age between 10 months and 16 years 3 months, mean: 4 years 10 months, median: 4 years 1 months) and with GNB-N-US (Age between 6 months and 18 years 9 months, mean: 4 years 10 months, median: 3 years 9 months) were diagnosed after 18 months of age. More than half of the patients with GNB-N-FS tumor were diagnosed before 18 months of age (Age between 4 months and 4 years 11 months, mean: 1 year 11 months, median: 1 year 5 months)."
    explanation: >-
      In this CCG/COG central review of ganglioneuroma and ganglioneuroblastoma
      cases registered on neuroblastoma studies in 1991-2006, median age at
      diagnosis was 4 years 1 month for the 198 intermixed tumors (range 10
      months to 16 years 3 months), 1 year 5 months for the 59 favorable-subset
      nodular tumors (4 months to 4 years 11 months) and 3 years 9 months for
      the 252 unfavorable-subset nodular tumors (6 months to 18 years 9 months).
      The series overlaps the Children's Cancer Group review above, including
      the 70 CCG-3881 and CCG-3891 nodular patients of PMID:10964346 and
      PMID:14601099, and the favorable subset's younger age partly reflects the
      INPC age criteria. These are cooperative-group study patients, not a
      population sample.
prevalence:
- population: Worldwide
  measure_type: POINT_PREVALENCE
  prevalence_class: BELOW_1_IN_1000000
  notes: >-
    Orphanet's prevalence class, which sets only an upper bound; it is not a
    measured rate.
  evidence:
  - reference: ORPHA:251877
    reference_title: "Ganglioneuroblastoma"
    supports: SUPPORT
    directness: DIRECT
    evidence_source: OTHER
    snippet: "<1 / 1 000 000 | Worldwide | Point prevalence"
    explanation: >-
      Orphanet's epidemiology table for ganglioneuroblastoma gives a worldwide
      point-prevalence class of <1 / 1 000 000, which is the classification this
      record states. The class is a band that sets only an upper bound, and the
      row gives no numeric estimate, so it does not report a measured rate. The
      quote stops before the row's Source column, which includes a source typed
      OTHER and two PubMed records (PMID:36171902, PMID:36405824).
has_subtypes:
- name: Intermixed
  display_name: "Ganglioneuroblastoma, intermixed (Schwannian stroma-rich)"
  classification: histological
  subtype_term:
    preferred_term: intermixed ganglioneuroblastoma
    term:
      id: MONDO:0003326
      label: intermixed schwannian stroma-rich ganglioneuroblastoma
  mappings:
    ncit_mappings:
    - term:
        id: NCIT:C42057
        label: "Ganglioneuroblastoma, Intermixed"
      mapping_predicate: skos:exactMatch
      mapping_source: NCIT
      mapping_justification: >-
        NCIT concept that MONDO records as an exact match of MONDO:0003326.
  description: >-
    The INPC Schwannian stroma-rich category: a transitional form between
    neuroblastoma and ganglioneuroma in which a ganglioneuromatous component
    makes up more than half of the tumor around scattered microscopic
    neuroblastic nests, with no macroscopic nodule. It is always classified as
    favorable histology. Because the category excludes a macroscopic
    neuroblastomatous nodule, it is typically assigned on examination of the
    entire resected tumor, since intermixed and nodular ganglioneuroblastoma are
    hard to tell apart on limited samples (the diagnosis record gives how a
    biopsy diagnosis is reported). Most patients have localized disease: in a
    CCG/COG series, 2 of 189 patients with known INSS stage had stage 4 disease.
    In one referral series, biopsy and resection agreed in 17 of 19 patients
    with localized disease who had both, and the authors judged a biopsy
    adequate there, but a biopsy diagnosis of intermixed ganglioneuroblastoma
    made alongside metastases was not confirmed at resection in 8 of 12
    patients, all given chemotherapy first, whose resected tumors showed
    neuroblastoma. Localized disease has an excellent outcome: in the CCG/COG
    series no patient with a favorable-histology tumor, intermixed tumors
    included, died of tumor, and in the referral series none of the 41 patients
    with locoregional disease relapsed. In that series 6 of the 12 patients with
    metastases at diagnosis relapsed and 2 died of disease.
  evidence:
  - reference: PMID:19530234
    reference_title: "Clinicopathological characteristics of ganglioneuroma and ganglioneuroblastoma: a report from the CCG and COG."
    supports: SUPPORT
    directness: DIRECT
    quote_role: BACKGROUND
    evidence_source: OTHER
    snippet: "GNB-Intermixed (Schwannian stroma-rich) and GN (Schwannian stroma-dominant) tumors are always classified into the FH group. GNB-Nodular (composite, Schwannian stroma-rich/stroma-dominant and stroma-poor) tumors are classified into the FH or UH group based on the characteristics of the neuroblastic component."
    explanation: >-
      In the introduction to a Children's Cancer Group and Children's Oncology
      Group study of 552 ganglioneuroma and ganglioneuroblastoma cases, Okamatsu
      et al. state the INPC rule: GNB-intermixed (Schwannian stroma-rich) tumors
      are always classified as Favorable Histology (FH), whereas GNB-nodular
      tumors are classified as FH or Unfavorable Histology (UH) according to the
      characteristics of their neuroblastic component. It directly supports this
      subtype's favorable histology status, in contrast to nodular tumors. The
      sentences restate the INPC papers, whose 2003 revision added the nodular
      split to the classification, rather than reporting a result of this
      cohort.
  - reference: PMID:19530234
    reference_title: "Clinicopathological characteristics of ganglioneuroma and ganglioneuroblastoma: a report from the CCG and COG."
    supports: SUPPORT
    directness: DIRECT
    quote_role: PRIMARY_RESULT
    evidence_source: HUMAN_CLINICAL
    snippet: "| GN-maturing N (%) | GNB-intermixed N (%) | GNB-nodular FS N (%) | GNB-nodular US N (%) | ... INSS stage ... | 1, 2, 3 | 36 (100%) | 187 (99%) | 56 (95%) | 116 (47%) | | 4 | 0 (0%) | 2 (1%) | 3 (5%) | 132 (53%) | | Unknown | 7 | 9 | 0 | 4 |"
    explanation: >-
      Table III of this CCG/COG series tabulates INSS stage by centrally
      reviewed histology; the excerpt quotes its column headings and its three
      stage rows. In the GNB-intermixed column, 187 patients (99%) had stage 1-3
      disease, 2 (1%) had stage 4 disease and 9 had unknown stage, so 2 of the
      189 (187 + 2) with known stage presented with distant metastasis. The
      series covers patients registered on CCG/COG neuroblastoma studies in
      1991-2006, not a population-based sample.
  - reference: PMID:19530234
    reference_title: "Clinicopathological characteristics of ganglioneuroma and ganglioneuroblastoma: a report from the CCG and COG."
    supports: SUPPORT
    directness: DIRECT
    quote_role: PRIMARY_RESULT
    evidence_source: HUMAN_CLINICAL
    snippet: "The majority of GN-M, GNB-I, and GNB-N-FS patients had localized disease (stage 1, 2, 3) and low or intermediate-risk tumors."
    explanation: >-
      In the Results of this CCG/COG series, the authors summarize Table III:
      most patients with ganglioneuroma-maturing, GNB-intermixed and GNB-nodular
      favorable-subset tumors had localized (INSS stage 1, 2 or 3) disease and
      low- or intermediate-risk tumors. This supports localized disease as the
      usual presentation of this subtype and shows that the authors class stages
      1-3 as localized. The sentence pools three favorable histologies and gives
      no counts.
  - reference: PMID:37243318
    reference_title: "Ganglioneuroblastoma intermixed: Clinicopathological implications of diagnosis at presentation and genomic correlations."
    supports: SUPPORT
    directness: DIRECT
    quote_role: BACKGROUND
    evidence_source: OTHER
    snippet: "The diagnosis of GNBI is typically made on a diligent morphological examination of the entire resected tumor because distinguishing GNBI from GNBN is particularly challenging on limited samples."
    explanation: >-
      The Discussion of this Memorial Sloan Kettering series opens by restating
      established practice: intermixed ganglioneuroblastoma (GNBI) is usually
      diagnosed on careful examination of the entire resected tumor, because it
      is particularly hard to tell from nodular ganglioneuroblastoma (GNBN) on
      limited samples. It states practice and reports no data from the series.
  - reference: PMID:37243318
    reference_title: "Ganglioneuroblastoma intermixed: Clinicopathological implications of diagnosis at presentation and genomic correlations."
    supports: SUPPORT
    directness: DIRECT
    quote_role: PRIMARY_RESULT
    evidence_source: HUMAN_CLINICAL
    snippet: "In patients with stage M disease, GNBI noted at initial biopsy could not be corroborated in 67% samples examined at definitive resection. Thus, the definitive pathological biopsy diagnosis of GNBI in patients with concurrent metastatic disease requires high level of caution."
    explanation: >-
      In a retrospective Memorial Sloan Kettering archive review (15,827
      neuroblastoma specimens), 53 patients had intermixed ganglioneuroblastoma
      (GNBI) at initial diagnosis, each confirmed on review at that centre. All
      12 with stage M disease were diagnosed on biopsy and received neoadjuvant
      chemotherapy, and 8 of the 12 resections showed neuroblastoma, so the
      authors urge caution with a biopsy diagnosis of GNBI alongside metastases.
      In localized disease about 90% of biopsy diagnoses were upheld at
      resection. The evidence rests on 12 patients from one tertiary centre,
      with chemotherapy between biopsy and resection.
  - reference: PMID:37243318
    reference_title: "Ganglioneuroblastoma intermixed: Clinicopathological implications of diagnosis at presentation and genomic correlations."
    supports: SUPPORT
    directness: INDIRECT
    quote_role: PRIMARY_RESULT
    evidence_source: HUMAN_CLINICAL
    snippet: "Of the 12 patients with metastatic disease, all of whom received neoadjuvant chemotherapy, surgery samples revealed GNBI in 4 (33%) and NB in 8 (67%)."
    explanation: >-
      In this retrospective Memorial Sloan Kettering series of patients with
      intermixed ganglioneuroblastoma (GNBI) at diagnosis, all 12 with
      metastatic disease received neoadjuvant chemotherapy, and resection showed
      GNBI in 4 and neuroblastoma in 8. The quoted sentence does not say how
      they were first diagnosed, but the paper's Table 2 shows that all 12 had
      GNBI diagnosed on biopsy. These are the same 12 patients, from one
      tertiary centre, behind the authors' 67% figure and call for caution, so
      this gives the underlying counts rather than independent support.
  - reference: PMID:37243318
    reference_title: "Ganglioneuroblastoma intermixed: Clinicopathological implications of diagnosis at presentation and genomic correlations."
    supports: SUPPORT
    directness: DIRECT
    quote_role: PRIMARY_RESULT
    evidence_source: HUMAN_CLINICAL
    snippet: "For patients with localized GNBI undergoing both biopsy and resection, GNBI was diagnosed in both in 17/19 (90%). ... For localized GNBI, a biopsy sample is adequate to make the diagnosis."
    explanation: >-
      In this Memorial Sloan Kettering series, biopsy and resection both showed
      intermixed ganglioneuroblastoma (GNBI) in 17 of 19 patients with localized
      disease who had both procedures (the Results give 18 of 20, also 90%), and
      the authors conclude that a biopsy is adequate for diagnosing localized
      GNBI. Eleven of the 41 localized patients had chemotherapy between biopsy
      and resection, and the series comes from one tertiary center.
  - reference: PMID:19530234
    reference_title: "Clinicopathological characteristics of ganglioneuroma and ganglioneuroblastoma: a report from the CCG and COG."
    supports: SUPPORT
    directness: DIRECT
    quote_role: PRIMARY_RESULT
    evidence_source: HUMAN_CLINICAL
    snippet: "Patients with the FH tumors had an excellent prognosis with no tumor-related deaths."
    explanation: >-
      In this CCG/COG review of 552 centrally reviewed ganglioneuroma and
      ganglioneuroblastoma cases, no patient in the favorable-histology group
      (43 GN-maturing, 198 GNB-intermixed and 59 GNB-nodular favorable-subset
      tumors) died of tumor. The sentence pools the three categories. The
      Results give 173 intermixed patients with survival data: 5 had an event
      within 5 years, and the one who died had developed secondary acute myeloid
      leukemia. Nearly all intermixed patients had stage 1-3 disease, and the
      cohort is patients registered on cooperative-group studies, not a
      population sample.
  - reference: PMID:37243318
    reference_title: "Ganglioneuroblastoma intermixed: Clinicopathological implications of diagnosis at presentation and genomic correlations."
    supports: SUPPORT
    directness: DIRECT
    quote_role: PRIMARY_RESULT
    evidence_source: HUMAN_CLINICAL
    snippet: "Disease was locoregional in 41 (77%, 16 stage L1 and 25 L2); none relapsed. Twelve (23%) had metastatic disease at presentation; six (50%) relapsed, and two died of disease."
    explanation: >-
      In this retrospective Memorial Sloan Kettering series of 53 patients with
      intermixed ganglioneuroblastoma at diagnosis (median follow-up 3.5 years),
      none of the 41 with locoregional disease relapsed, while 6 of the 12 with
      metastases relapsed and 2 died of disease. Most patients were referred
      after diagnosis elsewhere. In 8 of the 12 metastatic patients the resected
      tumor showed neuroblastoma, so the metastatic outcomes may not describe
      intermixed tumors classified on a resected specimen.
- name: Nodular
  display_name: "Ganglioneuroblastoma, nodular (composite)"
  classification: histological
  subtype_term:
    preferred_term: nodular ganglioneuroblastoma
    term:
      id: MONDO:0003325
      label: nodular ganglioneuroblastoma
  mappings:
    ncit_mappings:
    - term:
        id: NCIT:C42058
        label: "Ganglioneuroblastoma, Nodular"
      mapping_predicate: skos:exactMatch
      mapping_source: NCIT
      mapping_justification: >-
        NCIT concept that MONDO records as an exact match of MONDO:0003325.
  description: >-
    The INPC composite category: one or more macroscopic, usually hemorrhagic,
    Schwannian stroma-poor neuroblastomatous nodules coexist with an intermixed
    ganglioneuroblastoma or ganglioneuroma component. The proportion of nodule
    to that component varies from case to case. The INPC also recognizes
    variants of this classical form. In one, neuroblastoma is found at a
    metastatic site while the primary tumor shows only intermixed
    ganglioneuroblastoma or ganglioneuroma histology, as when a nodule in the
    primary was not sampled; in a CCG/COG series the unfavorable nodule was
    found only at the metastatic site in 6 patients even after complete
    pathology evaluation of the primary tumor. Very rarely, such a discordance
    reflects separate primary tumors presumed to be of different clones. Once
    classed entirely as unfavorable histology, nodular tumors are now divided
    into favorable and unfavorable subsets by applying the neuroblastoma
    criteria of age at diagnosis, grade of neuroblastic differentiation and
    mitosis-karyorrhexis index to the nodules. The nodular component is
    favorable when poorly differentiated or differentiating with a low or
    intermediate index in a patient younger than 18 months, or differentiating
    with a low index from 18 months to 5 years; it is unfavorable when
    undifferentiated or of high index at any age, poorly differentiated or of
    intermediate index from 18 months to 5 years, and of any grade or index from
    5 years (60 months). Every nodular tumor diagnosed at 5 years or older is
    therefore in the unfavorable subset; in a CCG/COG series the
    favorable-subset patients were 4 months to 4 years 11 months old at
    diagnosis, more than half of them younger than 18 months. Umehara and
    colleagues defined the two subsets in 2000 from a review of 70 Children's
    Cancer Group patients. The International Neuroblastoma Pathology Committee
    re-reviewed the same patients, confirmed the diagnosis in 67 and the
    survival difference (8-year event-free survival 86.1% in the favorable
    versus 32.2% in the unfavorable subset), and in 2003 proposed adding the
    split to the classification. An INRG analysis identified 232 patients with
    nodular ganglioneuroblastoma among 4,071 with a known INPC category; 83%
    were older than 18 months, 83% had unfavorable INPC histology and 2% had
    MYCN-amplified tumors. Outcome in that cohort was very heterogeneous, with
    event-free and overall survival of 54% and 68%, and in the unfavorable
    subset of a CCG/COG series 5-year event-free survival was 80.1% without and
    16.7% with stage 4 disease. MONDO subdivides the class by background into
    MONDO:0004408 (stroma-rich) and MONDO:0004407 (stroma-dominant).
  evidence:
  - reference: PMID:10421273
    reference_title: "The International Neuroblastoma Pathology Classification (the Shimada system)."
    supports: SUPPORT
    directness: DIRECT
    quote_role: PRIMARY_RESULT
    evidence_source: HUMAN_CLINICAL
    snippet: "Approximately 99% of cases (224 of 227) had consensus diagnoses for categorization: neuroblastoma (Schwannian stroma-poor), 190 cases; ganglioneuroblastoma, intermixed (Schwannian stroma-rich), 5 cases; ganglioneuroma (Schwannian stroma-dominant) maturing, 1 case; ganglioneuroblastoma, nodular (composite Schwannian stroma-rich/stroma-dominant and stroma-poor), 19 cases; and NT-unclassifiable, 9 cases."
    explanation: >-
      In a review of 227 neuroblastic tumours by the six-member International
      Neuroblastoma Pathology Committee, consensus diagnoses (five or six of six
      pathologists agreeing) placed 19 cases in ganglioneuroblastoma, nodular
      (composite Schwannian stroma-rich/stroma-dominant and stroma-poor) and 5
      in ganglioneuroblastoma, intermixed (Schwannian stroma-rich), as separate
      categories, supporting this subtype as distinct from the intermixed form.
      The counts describe this review set, not subtype frequency. The abstract
      gives no morphologic criteria (described separately) and presents the
      classification as a modified Shimada classification, so it does not show
      that the split originated here.
  - reference: PMID:10964346
    reference_title: "Histopathology defines prognostic subsets of ganglioneuroblastoma, nodular."
    supports: SUPPORT
    directness: DIRECT
    quote_role: PRIMARY_RESULT
    evidence_source: HUMAN_CLINICAL
    snippet: "Pathology slides and reports from a total of 70 GNBn patients from the Children's Cancer Group (CCG)-3881 and CCG-3891 studies were reviewed. Sixty-eight tumors were classified in the favorable subset (FS) or the unfavorable subset (US) based on the evaluation of nodular components by applying the same histopathologic criteria (patient age, grade of neuroblastic differentiation, mitosis-karyorrhexis index) that are used for neuroblastomas in the International Neuroblastoma Pathology Classification. ... A significant difference in the outcome of the patients between the FS (22 patients; 86.1% EFS; 95.0% survival rate) and the US (46 patients; 29.0% EFS; 40.7% survival rate) of the GNBn subtype (P < 0.0005) was shown."
    explanation: >-
      Umehara et al. reviewed the pathology of 70 patients with nodular
      ganglioneuroblastoma from Children's Cancer Group studies CCG-3881 and
      CCG-3891. Applying the INPC neuroblastoma criteria (age, grade of
      differentiation, mitosis-karyorrhexis index) to the nodules, they placed
      68 tumors in a favorable (22) or an unfavorable (46) subset, with
      event-free survival of 86.1% versus 29.0% (P < 0.0005); the sentence does
      not state the survival time point. This is the study that defined the
      subsets. The International Neuroblastoma Pathology Committee re-reviewed
      the same patients (PMID:14601099), so the two papers analyse one cohort
      and are not independent results.
  - reference: PMID:14601099
    reference_title: "Revision of the International Neuroblastoma Pathology Classification: confirmation of favorable and unfavorable prognostic subsets in ganglioneuroblastoma, nodular."
    supports: SUPPORT
    directness: DIRECT
    quote_role: PRIMARY_RESULT
    evidence_source: HUMAN_CLINICAL
    snippet: "Histology slides from 70 patients who were enrolled in Children's Cancer Group studies 3881 and 3891 and who had a diagnosis of GNBn were reviewed jointly by the members of International Neuroblastoma Pathology Committee (INPC) ... to identify the FS and US by applying the same age-linked criteria that were used to distinguish the favorable histology group and unfavorable histology group in conventional neuroblastoma tumors from the neuroblastomatous component of GNBn tumors ... The diagnosis of GNBn was confirmed in 67 of 70 patients. There were 22 patients with GNBn in the FS and 45 patients with GNBn in the US. The estimated survival differences between the FS and US patients with GNBn were statistically significant (8-year event free survival rate: 86.1% vs. 32.2%; P = 0.0003; overall survival rate: 90.5% vs. 33.2%; P = 0.0003). ... This study confirmed the recently defined prognostic subsets of GNBn. The INPC proposes to modify the International Neuroblastoma Pathology Classification by distinguishing the FS and the US among patients with GNBn tumors."
    explanation: >-
      The International Neuroblastoma Pathology Committee reviewed 70 tumours
      diagnosed as nodular ganglioneuroblastoma in CCG studies 3881 and 3891,
      confirmed the diagnosis in 67, and applied neuroblastoma's age-linked
      histology criteria to their neuroblastomatous component, giving favourable
      (22) and unfavourable (45) subsets. Their 8-year event-free survival
      differed significantly (86.1% vs 32.2%), and the committee proposed
      modifying the classification to separate them. These patients had been
      used in a previous study: Umehara 2000 (PMID:10964346) reviewed 70
      patients from the same two studies, and Okamatsu 2009 (PMID:19530234)
      includes them, so this is not independent confirmation.
  - reference: PMID:19530234
    reference_title: "Clinicopathological characteristics of ganglioneuroma and ganglioneuroblastoma: a report from the CCG and COG."
    supports: SUPPORT
    directness: DIRECT
    quote_role: BACKGROUND
    evidence_source: OTHER
    snippet: "Tumors in this category, once all were Unfavorable Histology, are now classified into favorable subset (Favorable Histology) and unfavorable subset (Unfavorable Histology) based on the age-linked evaluation of grade of neuroblastic differentiation and mitosis-karyorrhexis index of the neuroblastomatous nodule(s)."
    explanation: >-
      Table I of this CCG/COG clinicopathological series restates the
      International Neuroblastoma Pathology Classification definitions; this
      sentence closes its ganglioneuroblastoma-nodular row. Tumors in the
      category, once all classed as unfavorable histology, are now divided into
      favorable and unfavorable subsets by the age-linked grade of neuroblastic
      differentiation and mitosis-karyorrhexis index of the nodules. It is a
      classification rule restated from the INPC papers, not a result of this
      cohort.
  - reference: PMID:19530234
    reference_title: "Clinicopathological characteristics of ganglioneuroma and ganglioneuroblastoma: a report from the CCG and COG."
    supports: SUPPORT
    directness: DIRECT
    quote_role: BACKGROUND
    evidence_source: OTHER
    snippet: "The proportion of neuroblastomatous nodule(s) to Ganglioneuroblastoma-intermixed/Ganglioneuroma area varies from case to case"
    explanation: >-
      Table I of this CCG/COG clinicopathological series restates the INPC
      definitions; this sentence, from its ganglioneuroblastoma-nodular row,
      says the proportion of neuroblastomatous nodule to intermixed
      ganglioneuroblastoma or ganglioneuroma tissue varies from case to case.
      The row sets no stroma threshold, whereas the intermixed row requires the
      ganglioneuromatous component to exceed 50% of the total volume in
      representative microscopic fields, so the over-half criterion that MONDO
      and NCIT apply to the whole class corresponds to the INPC intermixed
      criterion. It is a classification rule restated from the INPC papers, not
      a result of this cohort.
  - reference: PMID:14601099
    reference_title: "Revision of the International Neuroblastoma Pathology Classification: confirmation of favorable and unfavorable prognostic subsets in ganglioneuroblastoma, nodular."
    supports: SUPPORT
    directness: INDIRECT
    quote_role: PRIMARY_RESULT
    evidence_source: HUMAN_CLINICAL
    snippet: "The review clarified and illustrated morphologic characteristics of classical GNBn and it variants."
    explanation: >-
      In the 2003 INPC revision, the committee's joint review of 70 Children's
      Cancer Group cases clarified and illustrated the morphology of classical
      nodular ganglioneuroblastoma and its variants ('it variants' is the
      abstract's wording), so the INPC recognizes variant forms. The abstract
      does not describe them; the metastatic-site variant is stated in the 2026
      review that cites this paper.
  - reference: PMID:41612478
    reference_title: "Pathology of peripheral neuroblastic tumors."
    supports: SUPPORT
    directness: DIRECT
    quote_role: REVIEW_SYNTHESIS
    evidence_source: OTHER
    snippet: "When tumor samples obtained by PNBC from one anatomic site shows either GNB-i or GN histology and the other anatomic site demonstrates NB histology in the same patient, we should consider (1) GNB-n where NB nodule present in the primary site is not sampled but found in the metastatic site (variant of GNB-n) ... or (2) an extremely rare example of multiple primaries presumably composed of different clones"
    explanation: >-
      This 2026 pathology review states that when one site shows GNB-intermixed
      or ganglioneuroma histology and another site in the same patient shows
      neuroblastoma, the tumor should be considered a variant of nodular
      ganglioneuroblastoma, whose primary nodule was not sampled but whose
      neuroblastoma is found at the metastatic site, or, very rarely, separate
      primaries of different clones. It cites the 2003 INPC revision for the
      variant; 'PNBC' is the review's misspelling of PCNB (percutaneous core
      needle biopsy). It is a classification statement without case data.
  - reference: PMID:19530234
    reference_title: "Clinicopathological characteristics of ganglioneuroma and ganglioneuroblastoma: a report from the CCG and COG."
    supports: SUPPORT
    directness: DIRECT
    quote_role: PRIMARY_RESULT
    evidence_source: HUMAN_CLINICAL
    snippet: "In rare cases (6 cases in our series), unfavorable NB nodule was detected only in the metastatic site even after complete pathology evaluation of their primary tumors."
    explanation: >-
      Among the 252 unfavorable-subset nodular tumors in this CCG/COG series,
      the unfavorable neuroblastoma nodule was found only at the metastatic site
      in 6 patients whose primary tumor had been completely resected and fully
      evaluated; the Results report 4 more whose primary was incompletely
      resected. These patients were classed as nodular ganglioneuroblastoma on
      the strength of the metastatic neuroblastoma. The series includes the 70
      patients of the 2003 INPC revision, so the two are not independent.
  - reference: PMID:11745303
    reference_title: "International neuroblastoma pathology classification for prognostic evaluation of patients with peripheral neuroblastic tumors: a report from the Children's Cancer Group."
    supports: SUPPORT
    directness: INDIRECT
    quote_role: PRIMARY_RESULT
    evidence_source: HUMAN_CLINICAL
    snippet: "the favorable histology (FH) subgroup (PD/D and L/I-MKI tumors in patients age < 1.5 years, D and L-MKI tumors in patients ages 1.5-5.0 years; 90.4% 5-year event free survival ... the unfavorable histology (UH) subgroup (U and/or H-MKI tumors in patients of any age, PD and/or I-MKI tumors in patients ages 1.5-5.0 years, any grade of differentiation, and any MKI class in patients age > or = 5 years; 26.9% EFS)"
    explanation: >-
      This Children's Cancer Group review of tumors from studies CCG-3881 and
      CCG-3891 gives the age-linked INPC criteria for the neuroblastoma
      category: favorable histology is a poorly differentiated or
      differentiating tumor with low or intermediate MKI under 1.5 years, or a
      differentiating tumor with low MKI at 1.5-5 years; unfavorable histology
      is an undifferentiated or high-MKI tumor at any age, a poorly
      differentiated or intermediate-MKI tumor at 1.5-5 years, and any tumor at
      5 years or older. The criteria and the quoted survival figures are for
      neuroblastoma-category tumors; that the same criteria are applied to the
      nodules of nodular ganglioneuroblastoma rests on PMID:14601099 and
      PMID:10964346, so the support for the nodular rule is indirect.
  - reference: PMID:19530234
    reference_title: "Clinicopathological characteristics of ganglioneuroma and ganglioneuroblastoma: a report from the CCG and COG."
    supports: SUPPORT
    directness: DIRECT
    quote_role: PRIMARY_RESULT
    evidence_source: HUMAN_CLINICAL
    snippet: "More than half of the patients with GNB-N-FS tumor were diagnosed before 18 months of age (Age between 4 months and 4 years 11 months, mean: 1 year 11 months, median: 1 year 5 months). By definition of the INPC, all GNB-N tumors diagnosed over 60 months of age were classified into US."
    explanation: >-
      In this CCG/COG series, patients with favorable-subset nodular
      ganglioneuroblastoma (GNB-N-FS) were 4 months to 4 years 11 months old at
      diagnosis (median 1 year 5 months), and more than half were younger than
      18 months (31 of 59 in Table III). Every nodular tumor diagnosed over 60
      months was in the unfavorable subset by the INPC definition. The favorable
      subset's age profile is largely set by the age-linked criteria rather than
      being an independent observation. The series includes the 70 nodular
      patients of PMID:10964346 and PMID:14601099.
  - reference: PMID:22137163
    reference_title: "Characteristics and outcome of patients with ganglioneuroblastoma, nodular subtype: a report from the INRG project."
    supports: SUPPORT
    directness: DIRECT
    quote_role: PRIMARY_RESULT
    evidence_source: HUMAN_CLINICAL
    snippet: "Patients with GNBn were older (83% >18 months), a higher proportion had unfavourable INPC pathology (83%), and rarely had MYCN gene amplified tumours (2%)."
    explanation: >-
      This results sentence, from an INRG database analysis of 232 patients with
      nodular ganglioneuroblastoma (GNBn), gives the three proportions recorded
      for this subtype: 83% older than 18 months, 83% with unfavourable INPC
      pathology and 2% with MYCN-amplified tumours. The abstract does not give
      the denominator behind each percentage. The INRG database pools
      cooperative-group cohorts, including Children's Oncology Group patients
      diagnosed 1990-2002 (PMID:19047291), so this cohort may share patients
      with the Children's Cancer Group nodular series cited in this entry and
      does not confirm them independently.
  - reference: PMID:22137163
    reference_title: "Characteristics and outcome of patients with ganglioneuroblastoma, nodular subtype: a report from the INRG project."
    supports: SUPPORT
    directness: DIRECT
    quote_role: PRIMARY_RESULT
    evidence_source: HUMAN_CLINICAL
    snippet: "Amongst 4071 patients in the INRG database with known INPC histological category, 232 patients with GNBn were identified."
    explanation: >-
      This methods sentence, from the INRG report on nodular
      ganglioneuroblastoma (GNBn), identifies the cohort behind this subtype's
      INRG figures: 232 GNBn patients among the 4,071 INRG database patients
      whose INPC histological category was known. It supports the cohort size
      only and states none of the age, histology or MYCN proportions. The
      denominator is INRG patients with a known INPC category, not a general
      population, so 232 of 4,071 should not be read as a frequency of nodular
      ganglioneuroblastoma.
  - reference: PMID:22137163
    reference_title: "Characteristics and outcome of patients with ganglioneuroblastoma, nodular subtype: a report from the INRG project."
    supports: SUPPORT
    directness: DIRECT
    quote_role: PRIMARY_RESULT
    evidence_source: HUMAN_CLINICAL
    snippet: "EFS and OS were 54%±5% and 68%±5%, respectively. ... Patients with GNBn tumours are rare and have a very heterogeneous outcome."
    explanation: >-
      For the 232 INRG patients with nodular ganglioneuroblastoma, event-free
      and overall survival were 54% and 68% (each plus or minus 5%), and the
      authors conclude that outcome is very heterogeneous. The abstract does not
      state the time point of these estimates. INRG pools cooperative-group
      cohorts, including Children's Oncology Group patients, so this cohort is
      not independent of the CCG/COG series cited here.
  - reference: PMID:19530234
    reference_title: "Clinicopathological characteristics of ganglioneuroma and ganglioneuroblastoma: a report from the CCG and COG."
    supports: SUPPORT
    directness: DIRECT
    quote_role: PRIMARY_RESULT
    evidence_source: HUMAN_CLINICAL
    snippet: "Patients with the UH tumors had a high incidence (53%) of distant metastasis at the time of diagnosis, and their prognosis significantly depended on clinical stage (5-year EFS: 80.1% for non-stage 4 patients; 16.7% for stage 4 patients)"
    explanation: >-
      In this CCG/COG series the unfavorable-histology group is the 252 nodular
      unfavorable-subset tumors. Their 5-year event-free survival was 80.1%
      without and 16.7% with stage 4 disease. The series includes the 70 nodular
      patients of Peuchmaur et al. (2003), whose subset survival figures this
      description also gives, so the two are not independent.
pathophysiology:
- name: Neoplastic Neuroblast Population
  description: >-
    The malignant neuroblastic cells of the tumor, which form the microscopic
    neuroblastic nests of intermixed tumors and the nodules of nodular tumors.
    In a 1996 series of 20 maturing and mature neuroblastomas, the neuroblastic
    and ganglionic cells carried numerical chromosome aberrations, with
    near-triploidy in 18 of 19 tumors. Flow cytometry nonetheless reads most
    GN-maturing and intermixed tumors as diploid (160 of 191 in a CCG/COG
    series), which the authors suggest may reflect the predominance of
    Schwannian stromal cells in the samples.
  biological_scale: CELLULAR
  cell_types:
  - preferred_term: neoplastic neuroblast
    term:
      id: CL:0002676
      label: neural crest derived neuroblast
  notes: >-
    No node is marked as the origin node (genetic_context), because the cited
    sources describe no initiating lesion for ganglioneuroblastoma.
  evidence:
  - reference: PMID:8618605
    reference_title: "Role of ploidy, chromosome 1p, and Schwann cells in the maturation of neuroblastoma."
    supports: SUPPORT
    directness: INDIRECT
    quote_role: PRIMARY_RESULT
    evidence_source: HUMAN_CLINICAL
    snippet: "Neuroblastic and ganglionic cells showed aberrations in the number of chromosomes. In situ hybridization and flow cytometry demonstrated near-trip-loidy in 18 of 19 tumors and pentaploidy in the remaining tumor."
    explanation: >-
      In 20 human maturing and mature neuroblastomas (maturing neuroblastoma
      being the abstract's term for a tumour that differentiates toward
      ganglioneuroma), in situ hybridization and flow cytometry found abnormal
      chromosome numbers in the neuroblastic and ganglionic cells:
      near-triploidy in 18 of 19 tumours and pentaploidy in the remaining one.
      The 1996 study predates the International Neuroblastoma Pathology
      Classification and does not say how many cases would now be classed as
      ganglioneuroblastoma. Reading these aneuploid cells as tumour cells is an
      inference from the finding.
  - reference: PMID:19530234
    reference_title: "Clinicopathological characteristics of ganglioneuroma and ganglioneuroblastoma: a report from the CCG and COG."
    supports: SUPPORT
    directness: DIRECT
    quote_role: PRIMARY_RESULT
    evidence_source: HUMAN_CLINICAL
    snippet: "In our series, the majority of GN-M and GNB-I tumors, even though they were biologically favorable with an excellent prognosis, had a diploid pattern determined by flow cytometry. This could be attributable to the fact that those tumors were mainly or predominantly composed of Schwannian stromal cells, and neuroblastic cells were not the main source of cells to be tested."
    explanation: >-
      In this CCG/COG series of 552 centrally reviewed ganglioneuroma and
      ganglioneuroblastoma tumours, most GN-maturing (a ganglioneuroma subtype)
      and GNB-intermixed tumours had a diploid pattern by flow cytometry despite
      being biologically favourable; ploidy data came from COG cases only. The
      authors suggest, hedging with 'could be attributable', that these tumours
      are mainly Schwannian stroma, so neuroblastic cells were not the main
      cells tested. The paper reports no ploidy on separated cell populations,
      so this is a possible explanation, not evidence of which cells, if any,
      are hyperdiploid.
  - reference: PMID:19530234
    reference_title: "Clinicopathological characteristics of ganglioneuroma and ganglioneuroblastoma: a report from the CCG and COG."
    supports: SUPPORT
    quote_role: PRIMARY_RESULT
    evidence_source: HUMAN_CLINICAL
    snippet: "The majority (160/191, 84%) of GN-M and GNB-I tumors had a diploid pattern determined by flow cytometry."
    explanation: >-
      The abstract of this CCG/COG series quantifies the diploid majority: 160
      of the 191 GN-maturing and GNB-intermixed tumours with flow-cytometric
      ploidy data, all from COG cases, had a diploid pattern. The paper's Table
      III splits this into 28 of 32 GN-maturing (a ganglioneuroma subtype) and
      132 of 159 GNB-intermixed tumours. The sentence does not say why these
      tumours read diploid, and it does not cover nodular tumours, whose DNA
      indices the paper reports as split almost evenly between diploid and
      hyperdiploid.
  downstream:
  - target: Neuroblast-to-Ganglion Cell Maturation
    causal_link_type: DIRECT
    description: >-
      Neoplastic neuroblasts mature into ganglion cells. In nodular tumors,
      ganglion cells carry the MYCN gain found in the neuroblasts, while Schwann
      cells do not.
    evidence:
    - reference: PMID:25081755
      reference_title: "The neuroblastoma and ganglion components of nodular ganglioneuroblastoma are genetically similar: evidence against separate clonal origins."
      supports: SUPPORT
      directness: INDIRECT
      quote_role: PRIMARY_RESULT
      evidence_source: HUMAN_CLINICAL
      snippet: "By in situ hybridization, MYCN gain (4-10 gene copies/nucleus) was detected in 7/8 neuroblastoma samples. In ganglioneuromatous regions, gains were also detected in ganglion cells but not in Schwann cells."
      explanation: >-
        In paraffin-embedded tissue from eight nodular ganglioneuroblastomas, in
        situ hybridization detected MYCN gain in 7 of 8 neuroblastoma samples
        and, in ganglioneuromatous regions, also in ganglion cells but not in
        Schwann cells. Sharing the neuroblasts' alteration places the ganglion
        cells in the tumour lineage; that they arise by maturation of the
        neuroblasts, rather than from a common precursor, is an inference the
        abstract does not state. The series is small and limited to nodular
        tumours, and the abstract does not say how many had the gain in ganglion
        cells.
  - target: Schwannian Stromal Development
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: >-
      In co-culture, neuroblastoma tumors and cell lines stimulate Schwann cell
      proliferation, which the authors read as a hint that neoplastic
      neuroblasts drive stromal growth in tumors. The evidence is in vitro and
      says nothing about where the stromal cells come from.
    evidence:
    - reference: PMID:11464875
      reference_title: "Neuroblastoma cells provoke Schwann cell proliferation in vitro."
      supports: SUPPORT
      directness: INDIRECT
      quote_role: PRIMARY_RESULT
      evidence_source: IN_VITRO
      snippet: "Human NB tumours or cell lines unequivocally increased the proliferation of SCs in vitro. ... The results of the cocultivation experiments provide an experimental hint that the in vivo growth of SCs in NBs is caused by the neoplastic neuroblasts"
      explanation: >-
        In co-culture, human neuroblastoma tumours and cell lines increased the
        proliferation of human Schwann cells, and the authors conclude that this
        is an experimental hint that Schwann cell growth within neuroblastomas
        in vivo is caused by the neoplastic neuroblasts. The support for this
        edge is indirect: the stimulation was shown in vitro, so the in vivo
        link is the authors' inference rather than an observation in patients'
        tumours, and no co-cultured tumour is identified as
        ganglioneuroblastoma. The result concerns Schwann cell proliferation,
        not where the stromal cells come from.
  - target: Schwannian Stroma-Poor Neuroblastomatous Nodule
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: >-
      In 7 of 8 nodular tumors studied, the neuroblasts of the nodule carried
      MYCN copy gain, consistent with the nodule being formed by the neoplastic
      neuroblast population.
    evidence:
    - reference: PMID:25081755
      reference_title: "The neuroblastoma and ganglion components of nodular ganglioneuroblastoma are genetically similar: evidence against separate clonal origins."
      supports: SUPPORT
      directness: INDIRECT
      quote_role: PRIMARY_RESULT
      evidence_source: HUMAN_CLINICAL
      snippet: "By in situ hybridization, MYCN gain (4-10 gene copies/nucleus) was detected in 7/8 neuroblastoma samples."
      explanation: >-
        A case series of eight nodular ganglioneuroblastomas found, by in situ
        hybridization, MYCN gain (4-10 gene copies per nucleus) in the
        neuroblastoma component, which forms the nodule, in 7 of 8 tumours.
        Finding this copy-number change in the nodule's neuroblasts supports the
        inference that the nodule is formed by the neoplastic neuroblast
        population. The abstract reports this as MYCN gain and does not describe
        it as amplification. The result does not show whether the nodule is a
        separate clone.
  - target: Abdominal Mass
    causal_link_type: DIRECT
    description: The primary tumor forms a mass at its site of origin.
    evidence:
    - reference: ORPHA:251877
      reference_title: "Ganglioneuroblastoma"
      supports: SUPPORT
      directness: INDIRECT
      quote_role: REVIEW_SYNTHESIS
      evidence_source: OTHER
      snippet: "usually occurring in the posterior mediastinum, adrenal medulla and extra-adrenal retroperitoneum (but sometimes in the neck and pelvis)"
      explanation: >-
        Orphanet's definition, which reports no patient data, names the adrenal
        medulla and the extra-adrenal retroperitoneum among the usual sites of
        ganglioneuroblastoma. A primary tumor at either site is an abdominal
        mass, but that step is inferred: the definition names sites, not a mass,
        and its list of clinical signs does not include one. The edge is
        therefore supported indirectly.
    - reference: PMID:37243318
      reference_title: "Ganglioneuroblastoma intermixed: Clinicopathological implications of diagnosis at presentation and genomic correlations."
      supports: SUPPORT
      directness: INDIRECT
      quote_role: PRIMARY_RESULT
      evidence_source: HUMAN_CLINICAL
      snippet: "The primary tumor was abdominal in 39 (74%) and thoracic in 14 patients (26%)."
      explanation: >-
        In this Memorial Sloan Kettering series of 53 patients with intermixed
        ganglioneuroblastoma at diagnosis, the primary tumor was abdominal in 39
        (74%). Reading an abdominal primary as an abdominal mass is an
        inference, and the figure covers one subtype at a referral center.
  - target: Posterior Mediastinal Mass
    causal_link_type: DIRECT
    description: The primary tumor forms a mass at its site of origin.
    evidence:
    - reference: ORPHA:251877
      reference_title: "Ganglioneuroblastoma"
      supports: SUPPORT
      directness: INDIRECT
      quote_role: REVIEW_SYNTHESIS
      evidence_source: OTHER
      snippet: "usually occurring in the posterior mediastinum, adrenal medulla and extra-adrenal retroperitoneum (but sometimes in the neck and pelvis)"
      explanation: >-
        Orphanet's definition, which reports no patient data, names the
        posterior mediastinum among the usual sites of ganglioneuroblastoma. A
        primary tumor there is a posterior mediastinal mass, but that step is
        inferred: the definition names a site, not a mass, and its list of
        clinical signs does not include one. The edge is therefore supported
        indirectly.
    - reference: PMID:37243318
      reference_title: "Ganglioneuroblastoma intermixed: Clinicopathological implications of diagnosis at presentation and genomic correlations."
      supports: SUPPORT
      directness: INDIRECT
      quote_role: PRIMARY_RESULT
      evidence_source: HUMAN_CLINICAL
      snippet: "The primary tumor was abdominal in 39 (74%) and thoracic in 14 patients (26%)."
      explanation: >-
        In this Memorial Sloan Kettering series of 53 patients with intermixed
        ganglioneuroblastoma at diagnosis, the primary tumor was thoracic in 14
        (26%). The paper does not name the thoracic sites, so reading a thoracic
        primary as a posterior mediastinal mass is an inference, and the figure
        covers one subtype at a referral center.
  - target: Congenital Horner Syndrome
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: >-
      Orphanet ties the clinical features of ganglioneuroblastoma, congenital
      Horner syndrome among them, to the location of the tumor. How the tumor
      produces the sign is not described.
    evidence:
    - reference: ORPHA:251877
      reference_title: "Ganglioneuroblastoma"
      supports: SUPPORT
      directness: INDIRECT
      quote_role: REVIEW_SYNTHESIS
      evidence_source: OTHER
      snippet: "characterized clinically by pain, stridor, shortness of breath, peripheral neurological signs, superior vena cava syndrome and congenital Horner syndrome, depending on the location of the tumor"
      explanation: >-
        Orphanet's definition, which reports no patient data, says the clinical
        features of ganglioneuroblastoma, congenital Horner syndrome among them,
        depend on the location of the tumor, which makes the tumor their source.
        It names neither the sites nor the route from tumor to sign, so the edge
        is indirect.
- name: Neuroblast-to-Ganglion Cell Maturation
  description: >-
    Neoplastic neuroblasts differentiate into ganglion cells. Biologically
    favorable peripheral neuroblastic tumors are considered to mature by
    age-dependent steps from neuroblastoma through intermixed
    ganglioneuroblastoma to ganglioneuroma.
  biological_scale: CELLULAR
  cell_types:
  - preferred_term: ganglion cell
    term:
      id: CL:0011103
      label: sympathetic neuron
  biological_processes:
  - preferred_term: maturation of neuroblasts into ganglion cells
    term:
      id: GO:0030182
      label: neuron differentiation
  evidence:
  - reference: PMID:41612478
    reference_title: "Pathology of peripheral neuroblastic tumors."
    supports: SUPPORT
    directness: DIRECT
    quote_role: REVIEW_SYNTHESIS
    evidence_source: OTHER
    snippet: "To note, tumors in the biologically favorable pNTs are considered to proceed by age-dependent differentiation/maturational steps from NB to GNB-i, and finally to GN."
    explanation: >-
      This 2026 pathology review states that biologically favourable peripheral
      neuroblastic tumours are considered to proceed by age-dependent
      differentiation and maturation steps from neuroblastoma to GNB-intermixed
      and finally to ganglioneuroma, the maturation this node describes. The
      sentence sits in the review's account of the INPC categories and gives a
      consensus view ('are considered to') without supporting data. It covers
      only the favourable path through GNB-intermixed and says nothing about how
      nodular tumours arise.
- name: Schwannian Stromal Development
  description: >-
    The Schwann-cell stroma that makes up more than half of an intermixed tumor
    and forms the background of a nodular one. The INPC names each category by
    its Schwannian stromal development, which gives intermixed tumors their
    elastic, yellowish-white gross appearance. In culture, neuroblastoma tumors
    and cell lines stimulate Schwann cell proliferation, and Schwann cell
    products induce neuronal differentiation of neuroblastoma cells. Whether the
    stromal cells are non-neoplastic cells recruited by the tumor or derive from
    the neoplastic clone is contested (discussion gnb_schwannian_stroma_origin).
  biological_scale: TISSUE
  cell_types:
  - preferred_term: Schwannian stromal cell
    term:
      id: CL:0002573
      label: Schwann cell
  biological_processes:
  - preferred_term: Schwann cell proliferation
    term:
      id: GO:0014010
      label: Schwann cell proliferation
  notes: >-
    The node is named for the INPC term Schwannian stromal development rather
    than for stroma recruitment, because recruitment presumes the non-neoplastic
    origin that is still disputed.
  evidence:
  - reference: PMID:41612478
    reference_title: "Pathology of peripheral neuroblastic tumors."
    supports: SUPPORT
    directness: DIRECT
    quote_role: REVIEW_SYNTHESIS
    evidence_source: OTHER
    snippet: "Tumors in this category are elastic in consistency and yellowish white in color due to Schwannian stromal development (Fig. 2A)."
    explanation: >-
      In this 2026 pathology review the sentence opens the paragraph on
      ganglioneuroblastoma, intermixed; it cites Fig. 2A, which shows the gross
      appearance of an adrenal intermixed tumour with a solid, elastic cut
      surface, and the next sentence defines the category as more than 50%
      ganglioneuromatous tissue. It attributes the elastic, yellowish-white
      gross appearance of these tumours to their Schwannian stromal development.
      This is the authors' descriptive synthesis rather than a measured cohort
      result, and the review calls ganglioneuroma elastic and yellowish white
      too.
  - reference: PMID:41612478
    reference_title: "Pathology of peripheral neuroblastic tumors."
    supports: SUPPORT
    directness: DIRECT
    quote_role: REVIEW_SYNTHESIS
    evidence_source: OTHER
    snippet: "INPC defines 4 categories in the pNTs: Neuroblastoma (NB; Schwannian stroma-poor), Ganglioneuroblastoma, intermixed (GNB-i; Schwannian stroma-rich), Ganglioneuroma (GN; Schwannian stroma-dominant), and Ganglioneuroblastoma, nodular (GNB-n; composite, Schwannian stroma-rich/stroma-dominant and stroma-poor) ... In order to clarify their histologic characteristics, each category is often followed by its unique feature of Schwannian stromal development in parenthesis."
    explanation: >-
      This 2026 pathology review restates the four INPC categories with their
      Schwannian stromal features; ganglioneuroblastoma, intermixed is
      stroma-rich, and the nodular form is composite, combining stroma-rich or
      stroma-dominant with stroma-poor tissue. The next sentence, after an
      omitted citation number, says each parenthetical gives the category's
      unique feature of Schwannian stromal development. This supports stromal
      development as a defining feature of both ganglioneuroblastoma subtypes.
      It restates a classification rule rather than new data and does not
      address gross appearance.
  downstream:
  - target: Neuroblast-to-Ganglion Cell Maturation
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: >-
      Soluble Schwann cell products induce neuronal differentiation of
      neuroblastoma cells. The evidence is from cultured neuroblastoma cells,
      not from ganglioneuroblastoma tissue.
    evidence:
    - reference: PMID:9788610
      reference_title: "Schwann cell-conditioned medium promotes neuroblastoma survival and differentiation."
      supports: SUPPORT
      directness: INDIRECT
      quote_role: PRIMARY_RESULT
      evidence_source: IN_VITRO
      snippet: "Schwann cell-conditioned medium induced extensive neurite outgrowth in all of the neuroblastoma cell lines, and these processes contained mature neurofilament in three of the cell lines."
      explanation: >-
        Four human neuroblastoma cell lines were cultured for 7 days in medium
        conditioned by human Schwann cells, which carries their secreted
        products but no Schwann cells. All four lines grew extensive neurites,
        and in three the processes contained mature neurofilament, so soluble
        Schwann cell products induced neuritic differentiation, supporting this
        edge. The abstract does not name the active factors, and the model is
        cell lines rather than ganglioneuroblastoma tissue, so the support is
        indirect.
    - reference: PMID:33712610
      reference_title: "Schwann cell plasticity regulates neuroblastic tumor cell differentiation via epidermal growth factor-like protein 8."
      supports: SUPPORT
      directness: INDIRECT
      quote_role: PRIMARY_RESULT
      evidence_source: IN_VITRO
      snippet: "Neuroblastoma cells, derived from aggressive tumors, respond to primary repair-related SCs and their secretome with increased neuronal differentiation and reduced proliferation."
      explanation: >-
        Three neuroblastoma cell lines and two patient-derived short-term
        cultures were grown with primary human Schwann cells from excised
        peripheral nerve, either in contact or on a trans-well insert that let
        soluble molecules diffuse without contact. Without contact the neuronal
        differentiation marker NF200 rose significantly by day 16 in four of the
        five cultures, which places the effect on released Schwann cell factors
        rather than cell contact. The experiments are in vitro, the no-contact
        readout was NF200 rather than neurite length, and no
        ganglioneuroblastoma tissue was studied.
    - reference: PMID:11792807
      reference_title: "Pigment epithelium-derived factor (PEDF) in neuroblastoma: a multifunctional mediator of Schwann cell antitumor activity."
      supports: SUPPORT
      directness: INDIRECT
      quote_role: PRIMARY_RESULT
      evidence_source: IN_VITRO
      snippet: "PEDF was the major factor responsible for Schwann cell's ability to induce tumor cell differentiation in vitro"
      explanation: >-
        In culture, pigment epithelium-derived factor (PEDF) was the major
        factor behind Schwann cells' ability to induce differentiation of
        neuroblastoma tumor cells. The abstract also reports that PEDF is
        produced by ganglionic cells and Schwann cells but not by more primitive
        tumor cells, so it names one Schwann cell product behind this edge. The
        support is indirect: the result is in vitro, and the abstract does not
        say which Schwann cells or tumor cells were used or whether any tumor
        studied was a ganglioneuroblastoma. 'Major' does not mean sole;
        PMID:33712610 identifies another secreted Schwann cell protein, EGFL8,
        as a neuritogen.
- name: Schwannian Stroma-Poor Neuroblastomatous Nodule
  subtypes:
  - Nodular
  description: >-
    One or more macroscopic, usually hemorrhagic, Schwannian stroma-poor nodules
    of neuroblastoma within intermixed ganglioneuroblastoma or ganglioneuroma
    tissue. The nodular components are not always aggressive, and the age-linked
    histopathology of the nodules predicts prognosis. Whether the nodule is a
    clone distinct from the rest of the tumor is contested (discussion
    gnb_nodule_clonality).
  biological_scale: TISSUE
  cell_types:
  - preferred_term: neoplastic neuroblast
    term:
      id: CL:0002676
      label: neural crest derived neuroblast
  evidence:
  - reference: PMID:10964346
    reference_title: "Histopathology defines prognostic subsets of ganglioneuroblastoma, nodular."
    supports: SUPPORT
    directness: DIRECT
    quote_role: PRIMARY_RESULT
    evidence_source: HUMAN_CLINICAL
    snippet: "The current study demonstrates that the nodular components in GNBn tumors are not always aggressive. The prognosis of these patients can be determined by the analysis of age-linked histopathologic features."
    explanation: >-
      Conclusion of a review of pathology and outcomes for 70 patients with
      nodular ganglioneuroblastoma in the CCG-3881 and CCG-3891 studies. It
      states that the nodular components are not always aggressive and that
      prognosis can be determined from age-linked histopathology, defined in the
      Methods as the INPC neuroblastoma criteria (age, differentiation grade,
      mitosis-karyorrhexis index) applied to the nodules. The abstract does not
      separate stage from histology: 63.0% of unfavourable-subset patients
      presented with distant metastasis. PMID:14601099 re-reviewed the same
      patients and PMID:19530234 includes them, so these papers are not
      independent confirmation.
  downstream:
  - target: Distant Metastasis at Diagnosis
    causal_link_type: DIRECT
    description: >-
      In the unfavorable subset, distant metastasis from the neuroblastomatous
      nodule is often already present at diagnosis, even when the primary tumor
      is completely resected.
    evidence:
    - reference: PMID:19530234
      reference_title: "Clinicopathological characteristics of ganglioneuroma and ganglioneuroblastoma: a report from the CCG and COG."
      supports: SUPPORT
      directness: DIRECT
      quote_role: PRIMARY_RESULT
      evidence_source: HUMAN_CLINICAL
      snippet: "It was also noted that 44.0% (70/159) of GNB-N-US cases with completely resected primary tumor had already established distant metastasis from unfavorable NB nodule at the time of diagnosis."
      explanation: >-
        In a CCG/COG central pathology review of 552 ganglioneuroma and
        ganglioneuroblastoma tumours, the authors state that 70 (44.0%) of 159
        patients in the unfavourable nodular subset (GNB-N-US) with a completely
        resected primary tumour already had distant metastasis from the
        unfavourable neuroblastomatous nodule at diagnosis. It supports this
        edge for the unfavourable subset only. The attribution rests on
        histological findings, and in 6 completely resected cases no
        unfavourable nodule was found in the primary, only at the metastatic
        site. Elsewhere the paper counts 74 of the 159, not 70.
- name: Telomere Maintenance Mechanism Activation
  biological_scale: MOLECULAR
  conforms_to:
  - "enabling_replicative_immortality#Telomere Maintenance Reactivation"
  - "enabling_replicative_immortality#Telomere Maintenance via Recombination"
  mechanism_confidence: PROVISIONAL
  description: >-
    A subset of ganglioneuroblastoma maintains its telomeres, by either of the
    two routes used in neuroblastoma: alternative lengthening of telomeres,
    detected as C-circles, or raised TERT expression. In a Japanese series of
    48 ganglioneuroblastomas, alternative lengthening was present in 6 and
    raised TERT expression in 7 of the 31 tested, with 12 of the 48 positive
    by either route. The activation is concentrated in the nodular subtype,
    where 10 of 21 were positive, a proportion close to the neuroblastoma
    figure in the same series. In the 18 ganglioneuromas, alternative
    lengthening was absent and one tumour had raised TERT expression. Among
    the positive ganglioneuroblastomas the authors report frequent ATRX
    alteration and infrequent TERT rearrangement, which they take to mean
    that TERT-high ganglioneuroblastomas raise TERT expression by some
    mechanism other than the rearrangement and promoter mutation that
    predominate in TERT-high MYCN-not-amplified neuroblastoma. Which
    mechanism that is, the series does not establish.
  genes:
  - preferred_term: TERT
    term:
      id: hgnc:11730
      label: TERT
  - preferred_term: ATRX
    term:
      id: hgnc:886
      label: ATRX
  biological_processes:
  - preferred_term: telomere maintenance via telomerase
    modifier: INCREASED
    term:
      id: GO:0007004
      label: telomere maintenance via telomerase
  - preferred_term: telomere maintenance via recombination
    modifier: INCREASED
    term:
      id: GO:0000722
      label: telomere maintenance via recombination
  notes: >-
    The node binds both routes rather than splitting them, because the one
    series that measured them in ganglioneuroblastoma reports both and
    defines its positive group as either. Neuroblastoma models them as
    separate nodes, which that entry's larger evidence base supports; this
    entry should split them when a second series makes the two separately
    characterisable here.
    No causal edge is drawn to or from the nodular subtype node. The
    relationship reported is enrichment within a histological subtype, not
    one mechanism producing the other, and the subtype is already carried
    structurally in has_subtypes. The node is marked PROVISIONAL because the
    whole ganglioneuroblastoma claim rests on one cohort of 48, and because
    the series was assembled in Japan from tumours resected between 2014 and
    2018 in children under 10, so neither the proportions nor their absence
    in ganglioneuroma should be read as population estimates.
    The same paper's chromosomal-aberration findings are deliberately not
    cited here; arm-level aberration evidence is curated in the neuroblastoma
    entry, not this one.
    No cell type is bound. The C-circle and TERT assays were run on bulk
    tumour nucleic acid, and a ganglioneuroblastoma is by definition a mixture
    of neuroblastic, ganglionic and Schwannian stromal components, so a bulk
    measurement cannot say which of them carries the telomere-maintenance
    activity. Attributing it to the neoplastic neuroblast would assert a
    cell-type localisation the assay does not resolve, and in this entry that
    is the very question the Schwannian-stroma-origin discussion records as
    unsettled. Whether the activity sits in the neuroblastic component is a
    separate claim needing a cell-resolved measurement.
  evidence:
  - reference: PMID:41858373
    reference_title: "Telomere maintenance mechanisms are activated in ganglioneuroblastoma and ganglioneuroma."
    supports: SUPPORT
    directness: DIRECT
    quote_role: PRIMARY_RESULT
    evidence_source: HUMAN_CLINICAL
    snippet: "ALT was identified in 38 NB cases (38/255, 15%) and 6 GNB cases (6/48, 12.5%), but not in GN. High TERT expression was observed in 38% (64/169), 23% (7/31) and 14% (1/7) of NB, GNB and GN cases, respectively."
    explanation: >-
      The measurement behind the node: both telomere-maintenance routes
      assayed in ganglioneuroblastoma tumours, with the denominators stated.
      Note the TERT denominators are smaller than the ALT ones, 31 of 48
      ganglioneuroblastomas and 7 of 18 ganglioneuromas, so the two routes
      were not tested in the same number of tumours and the absence of
      alternative lengthening in ganglioneuroma rests on 18 cases.
  - reference: PMID:41858373
    reference_title: "Telomere maintenance mechanisms are activated in ganglioneuroblastoma and ganglioneuroma."
    supports: SUPPORT
    directness: DIRECT
    quote_role: PRIMARY_RESULT
    evidence_source: HUMAN_CLINICAL
    snippet: "TMM activation, defined as ALT(+) and/or high TERT expression, occurred in 12/48 GNB cases and 1/18 GN cases, particularly in the GNB-nodular type (10/21, 48%), which was similar to 39% (100/255) of NB cases."
    explanation: >-
      The combined figure and the subtype concentration, which is what makes
      this node more than a curiosity: nearly half of nodular
      ganglioneuroblastomas are positive, close to the neuroblastoma
      proportion in the same cohort. The definition is the authors' own and
      is a disjunction, so a positive tumour need not have both routes. The
      comparison with neuroblastoma is within this one series.
  - reference: PMID:41858373
    reference_title: "Telomere maintenance mechanisms are activated in ganglioneuroblastoma and ganglioneuroma."
    supports: SUPPORT
    directness: INDIRECT
    quote_role: PRIMARY_RESULT
    evidence_source: HUMAN_CLINICAL
    snippet: "Furthermore, TMM(+) GNBs exhibited distinct features, including a high frequency of ATRX alterations and a lower frequency of TERT rearrangements."
    explanation: >-
      Why ATRX is bound on this node alongside TERT. Indirect for the node's
      own claim: the sentence describes what distinguishes the positive
      tumours rather than measuring telomere maintenance, and it reports a
      frequency contrast without giving the counts behind it.
  - reference: PMID:41858373
    reference_title: "Telomere maintenance mechanisms are activated in ganglioneuroblastoma and ganglioneuroma."
    supports: SUPPORT
    directness: DIRECT
    quote_role: PRIMARY_RESULT
    evidence_source: HUMAN_CLINICAL
    snippet: "mutations or structural abnormalities in the TERT promoter region are the main mechanisms of TERT-high MYCN-not amplified NBs, whereas they are less frequent in TERT-high GNBs. This suggests that GNB utilizes other mechanisms to achieve TERT-high phenotype."
    explanation: >-
      The authors' own reading of the low TERT-rearrangement frequency, and the
      reason the description now states it rather than an inference drawn from
      it. The claim is about the TERT-high ganglioneuroblastomas specifically:
      whatever raises TERT in them is not the rearrangement or promoter
      mutation that does so in MYCN-not-amplified neuroblastoma. It is not a
      claim that the recombination route predominates in ganglioneuroblastoma
      overall, and the series' own counts would not support that: alternative
      lengthening in 6 of 48 against raised TERT in 7 of 31 tested are
      comparable rates. The replacement mechanism is left unnamed because the
      paper does not identify it.
  downstream:
  - target: Unlimited Replicative Potential
    description: >-
      A telomere maintenance mechanism keeps telomeres from eroding, so the tumour cells
      that carry one can go on dividing. Neuroblastoma cell lines with neither
      telomerase activity nor alternative lengthening of telomeres shortened their
      telomeres in culture and mostly lost viability. No ganglioneuroblastoma cell line
      or cohort has tested the link.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:32291317
      reference_title: "Telomere Maintenance Mechanisms Define Clinical Outcome in High-Risk Neuroblastoma."
      supports: SUPPORT
      directness: INDIRECT
      quote_role: PRIMARY_RESULT
      evidence_source: IN_VITRO
      snippet: "high-risk neuroblastoma cell lines that were non-ALT, low TERT expressing, and lacked telomerase activity showed continuous shortening of telomeres with growth in vitro and 2 of 3 TERT-L/non-ALT cell lines spontaneously lost viability after multiple passages in culture"
      explanation: >-
        Three patient-derived high-risk neuroblastoma cell lines that lacked alternative
        lengthening of telomeres and were negative for telomerase activity shortened
        their telomeres continuously in culture, and 2 of 3 spontaneously lost
        viability. Losing both maintenance mechanisms therefore costs replicative
        capacity, which supports this edge by its converse. The cells are neuroblastoma
        lines, not ganglioneuroblastoma, so applying the result here assumes that
        whichever ganglioneuroblastoma component maintains its telomeres behaves like
        these cells; that is the inference step.
- name: Unlimited Replicative Potential
  biological_scale: CELLULAR
  conforms_to: "enabling_replicative_immortality#Replicative Immortality"
  mechanism_confidence: PROVISIONAL
  description: >-
    The ability of tumour cells to keep dividing past the limit that telomere shortening
    sets on normal cells, which a telomere maintenance mechanism provides. In
    ganglioneuroblastoma it is inferred from the telomere maintenance a subset of
    tumours shows, not measured: no study has followed the replicative capacity of
    ganglioneuroblastoma cells.
  biological_processes:
  - preferred_term: cell population proliferation
    modifier: INCREASED
    term:
      id: GO:0008283
      label: cell population proliferation
  notes: >-
    Marked PROVISIONAL for the same reason as its upstream node: the telomere
    maintenance evidence in ganglioneuroblastoma rests on one series of 48 tumours, and
    the evidence that maintenance confers replicative capacity comes from neuroblastoma
    cell lines, cited on the incoming edge rather than repeated here. The cell
    population proliferation binding records expansion continuing past the telomere
    limit, as in the module node it conforms to, not a faster division rate. No cell
    type is bound, for the reason the upstream node's notes give.
- name: Tumoral Catecholamine Secretion
  biological_scale: CELLULAR
  description: >-
    Secretion of catecholamines by the tumour, which some ganglioneuroblastomas show. In
    a 3-year-old girl, epinephrine and norepinephrine production by a
    ganglioneuroblastoma caused hypertensive cardiomyopathy, and subtotal resection
    reduced the catecholamine levels. A ganglioneuroblastoma that produced an excess of
    dopamine alone was followed by its urinary dopamine, which rose with recurrence two
    years after resection. In localized intermixed ganglioneuroblastoma, raised urinary
    homovanillic and vanillylmandelic acid are frequent.
  biological_processes:
  - preferred_term: catecholamine secretion by the tumour
    term:
      id: GO:0050432
      label: catecholamine secretion
    modifier: INCREASED
  notes: >-
    No cell type is bound, because the cited reports do not say which tumour component
    secretes the catecholamines, and a ganglioneuroblastoma mixes neuroblastic,
    ganglionic and Schwannian stromal components. The node mirrors the one in the
    ganglioneuroma entry, whose evidence concerns ganglioneuroma and is not reused here.
  evidence:
  - reference: PMID:41891982
    reference_title: "Infantile Ganglioneuroblastoma Causing Growth Failure and Hypertensive Cardiomyopathy From Excessive Catecholamine Production."
    supports: SUPPORT
    directness: DIRECT
    quote_role: PRIMARY_RESULT
    evidence_source: HUMAN_CLINICAL
    snippet: "We report the case of a 3-year-old girl with growth failure who had hypertensive cardiomyopathy caused by excessive epinephrine and norepinephrine production from a ganglioneuroblastoma. ... subtotal resection was required, which reduced catecholamine levels."
    explanation: >-
      Case report of a girl whose ganglioneuroblastoma produced enough epinephrine and
      norepinephrine to cause hypertensive cardiomyopathy. Catecholamine levels fell
      after subtotal resection, which places the excess in the tumour.
  - reference: PMID:16390613
    reference_title: "A rare ganglioneuroblastoma secreting dopamine and the value of its measurement in diagnosis and prognosis."
    supports: SUPPORT
    directness: DIRECT
    quote_role: PRIMARY_RESULT
    evidence_source: HUMAN_CLINICAL
    snippet: "A case is described of a patient with a ganglioneuroblastoma, initially located in the right adrenal, which produced an excess of dopamine (7646 and 7959 nmol/24 h), approximately two and a half times the upper limit of the normal daily urine output. ... Two years after surgical resection, recurrence was indicated by an increase in urinary dopamine (8507 nmol/24 h)"
    explanation: >-
      Case report of an adrenal ganglioneuroblastoma that produced an excess of dopamine
      while noradrenaline, adrenaline and their methylated derivatives stayed normal.
      Urinary dopamine rose again when the tumour recurred after resection, so it
      tracked the tumour. It shows that the catecholamine a ganglioneuroblastoma
      secretes can be dopamine alone.
  downstream:
  - target: Elevated Urinary Vanillylmandelic Acid
    description: >-
      Vanillylmandelic acid is a catecholamine metabolite excreted in urine. It was
      raised in an adult with a catecholamine-producing ganglioneuroblastoma and in a
      child with a nodular one, and it fell with declining tumour activity in a stage M
      cohort.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:30225726
      reference_title: "Surgical strategy for an adult patient with a catecholamine-producing ganglioneuroblastoma and a cerebral aneurysm: a case report."
      supports: SUPPORT
      directness: DIRECT
      quote_role: PRIMARY_RESULT
      evidence_source: HUMAN_CLINICAL
      snippet: "In addition, 24-h urinary excretion of metanephrine, normetanephrine, and vanillylmandelic acid were all increased. ... Histopathologically, the tumor was diagnosed as a catecholamine-producing ganglioneuroblastoma."
      explanation: >-
        Case report of a 73-year-old woman with an adrenal tumour first taken for a
        pheochromocytoma, with raised urinary catecholamines, metanephrines and
        vanillylmandelic acid. Histopathology showed a catecholamine-producing
        ganglioneuroblastoma. A single adult case, and the report does not say which
        tumour component produced the catecholamines.
    - reference: PMID:29720264
      reference_title: "Usefulness of fluorodeoxyglucose positron emission tomography/computed tomography for detection of a neuroblastic nodule in a ganglioneuroblastoma: a case report."
      supports: SUPPORT
      directness: DIRECT
      quote_role: PRIMARY_RESULT
      evidence_source: HUMAN_CLINICAL
      snippet: "We report a case of a Japanese boy aged 3 years, 8 months, with an unresectable abdominal tumor and elevated vanillylmandelic acid and homovanillic acid levels. ... we reached the diagnosis of ganglioneuroblastoma, nodular."
      explanation: >-
        Case report of a boy with an unresectable abdominal tumour and raised urinary
        vanillylmandelic and homovanillic acid, first biopsied as ganglioneuroma and
        diagnosed as nodular ganglioneuroblastoma once a second biopsy sampled the
        neuroblastoma nodule. It shows both metabolites raised in a
        ganglioneuroblastoma. It does not show which component produced them, and the
        nodule is a plausible source.
    - reference: PMID:33885033
      reference_title: "Refractory Stage M Ganglioneuroblastoma With Bone Metastases and a Favorable, Chronic Course of Disease: Description of a Patient Cohort."
      supports: SUPPORT
      directness: INDIRECT
      quote_role: PRIMARY_RESULT
      evidence_source: HUMAN_CLINICAL
      snippet: "Metabolically, a slow decrease of urinary homovanillic acid and vanillylmandelic acid levels and iodine-123-metaiodobenzylguanidine avidity was observed."
      explanation: >-
        Cohort of seven patients with stage M disease and a chronic course, six of them
        with ganglioneuroblastoma morphology. Urinary homovanillic and vanillylmandelic
        acid fell slowly together with MIBG avidity, so the metabolite levels tracked
        the tumour. Indirect: the levels follow tumour activity, which points to the
        tumour as their source without showing it, and the cohort includes one
        differentiating neuroblastoma.
  - target: Elevated Urinary Homovanillic Acid
    description: >-
      Homovanillic acid is a catecholamine metabolite excreted in urine, the main one of
      dopamine. It was raised in a child with a nodular ganglioneuroblastoma, and it
      fell with declining tumour activity in a stage M cohort.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:29720264
      reference_title: "Usefulness of fluorodeoxyglucose positron emission tomography/computed tomography for detection of a neuroblastic nodule in a ganglioneuroblastoma: a case report."
      supports: SUPPORT
      directness: DIRECT
      quote_role: PRIMARY_RESULT
      evidence_source: HUMAN_CLINICAL
      snippet: "We report a case of a Japanese boy aged 3 years, 8 months, with an unresectable abdominal tumor and elevated vanillylmandelic acid and homovanillic acid levels. ... we reached the diagnosis of ganglioneuroblastoma, nodular."
      explanation: >-
        Case report of a boy with an unresectable abdominal tumour and raised urinary
        vanillylmandelic and homovanillic acid, first biopsied as ganglioneuroma and
        diagnosed as nodular ganglioneuroblastoma once a second biopsy sampled the
        neuroblastoma nodule. It shows both metabolites raised in a
        ganglioneuroblastoma. It does not show which component produced them, and the
        nodule is a plausible source.
    - reference: PMID:33885033
      reference_title: "Refractory Stage M Ganglioneuroblastoma With Bone Metastases and a Favorable, Chronic Course of Disease: Description of a Patient Cohort."
      supports: SUPPORT
      directness: INDIRECT
      quote_role: PRIMARY_RESULT
      evidence_source: HUMAN_CLINICAL
      snippet: "Metabolically, a slow decrease of urinary homovanillic acid and vanillylmandelic acid levels and iodine-123-metaiodobenzylguanidine avidity was observed."
      explanation: >-
        Cohort of seven patients with stage M disease and a chronic course, six of them
        with ganglioneuroblastoma morphology. Urinary homovanillic and vanillylmandelic
        acid fell slowly together with MIBG avidity, so the metabolite levels tracked
        the tumour. Indirect: the levels follow tumour activity, which points to the
        tumour as their source without showing it, and the cohort includes one
        differentiating neuroblastoma.
histopathology:
- name: Schwannian Stroma-Rich Ganglioneuromatous Component With Microscopic Neuroblastic Nests
  finding_term:
    preferred_term: ganglioneuromatous (Schwannian stroma-rich) component over 50% of the tumor with residual microscopic neuroblastic nests
    term:
      id: NCIT:C42062
      label: Schwannian Stroma More than 50 Percent of the Tumor Volume
  description: >-
    A ganglioneuromatous, Schwannian stroma-rich component that exceeds 50% of
    the tumor in representative sections, with scattered residual microscopic
    neuroblastomatous foci: pockets of neuropil containing neuroblasts,
    differentiating neuroblasts and ganglion cells. The tumor is maturing, but
    the process is incomplete. Under the INPC the favorable or unfavorable
    histology group is to be determined only from primary or metastatic tumor
    tissue obtained before chemotherapy or irradiation, and once assigned it is
    not to be changed during the clinical course, because therapy-associated
    changes, including neuroblastic differentiation and even Schwannian stromal
    development, may not have proven prognostic significance. A diagnosis of
    intermixed ganglioneuroblastoma made on a tumor resected after neoadjuvant
    chemotherapy does not take the effect of that chemotherapy into account.
  diagnostic: true
  context: Primary or metastatic tumor tissue obtained before chemotherapy or irradiation, classified by the INPC
  subtype: Intermixed
  notes: >-
    NCIT:C42057 Ganglioneuroblastoma, Intermixed names the neoplasm rather than
    a microscopic finding, so the finding is bound to the morphologic-finding
    term NCIT:C42062.
  evidence:
  - reference: PMID:19530234
    reference_title: "Clinicopathological characteristics of ganglioneuroma and ganglioneuroblastoma: a report from the CCG and COG."
    supports: SUPPORT
    directness: DIRECT
    quote_role: BACKGROUND
    evidence_source: OTHER
    snippet: "Ganglioneuroblastoma-Intermixed (Schwannian stroma-rich): A transitional form between Neuroblastoma and Ganglioneuroma. Tumor is on its way toward full differentiation/maturation; however, the process is not complete, as evidenced by scattered \"residual\" microscopic neuroblastomatous foci presenting as pockets of neuropil containing varying numbers of neuroblastic cells with various stages of maturation including neuroblasts, differentiating neuroblasts, and/or ganglion cells. The proportion of the ganglioneuromatous component to \"residual\" neuroblastomatous foci should exceed 50% of the total volume in microscopic field(s) from representative section(s) of the tumor."
    explanation: >-
      Table I of this CCG/COG clinicopathological study of 552 ganglioneuroma
      and ganglioneuroblastoma cases restates the International Neuroblastoma
      Pathology Classification definition of the intermixed category. The
      definition gives the histology this finding records: a transitional form
      between neuroblastoma and ganglioneuroma whose maturation is incomplete,
      with scattered 'residual' microscopic neuroblastomatous foci (pockets of
      neuropil holding neuroblastic cells) and a ganglioneuromatous component
      exceeding 50% of the total volume. It is a diagnostic criterion, not
      cohort data, and the 50% threshold applies to microscopic fields from
      representative sections, not to the whole tumour volume.
  - reference: PMID:41612478
    reference_title: "Pathology of peripheral neuroblastic tumors."
    supports: SUPPORT
    directness: DIRECT
    quote_role: REVIEW_SYNTHESIS
    evidence_source: OTHER
    snippet: "The distinction of FH group or UH group according to the INPC, as summarized in Table 1, should only be determined based on the pathology review of primary or metastatic tumors obtained before starting chemotherapy/irradiation therapy. Once FH or UH group classification is assigned, it should not be changed throughout the clinical course of individual cases, since therapy-associated histology changes including neuroblastic cytodifferentiation and even Schwannian stromal development, if present, may not have proven prognostic significance"
    explanation: >-
      This 2026 pathology review states the INPC rule immediately after noting
      that the neuroblastoma nodules of nodular ganglioneuroblastoma are graded
      by age-linked criteria and that intermixed tumors are always of favorable
      histology. The favorable or unfavorable histology group is to be
      determined only from pathology review of primary or metastatic tumors
      obtained before chemotherapy or irradiation starts and, once assigned, is
      not to be changed during the clinical course, because therapy-associated
      changes such as neuroblastic cytodifferentiation and even Schwannian
      stromal development may not have proven prognostic significance. The
      passage states a classification rule and reports no patient data; it
      concerns the histology group, not how a tumor first sampled after
      treatment should be categorized.
  - reference: PMID:37243318
    reference_title: "Ganglioneuroblastoma intermixed: Clinicopathological implications of diagnosis at presentation and genomic correlations."
    supports: SUPPORT
    directness: DIRECT
    quote_role: BACKGROUND
    evidence_source: OTHER
    snippet: "Diagnosing GNBI on morphological examination of the definitively resected tumor does not take into account the impact of neoadjuvant chemotherapy that might be administered before definitive tumor resection."
    explanation: >-
      In the Discussion of their Memorial Sloan Kettering series, the authors
      note that a diagnosis of intermixed ganglioneuroblastoma (GNBI) made by
      examining the definitively resected tumor does not take into account the
      effect of any neoadjuvant chemotherapy given before that resection. It is
      a framing statement, not a result of the series, and does not say how
      often or in what way chemotherapy changes the histology.
- name: Macroscopic Neuroblastomatous Nodule in a Stroma-Rich or Stroma-Dominant Background
  finding_term:
    preferred_term: "macroscopic, usually hemorrhagic, Schwannian stroma-poor neuroblastomatous nodule"
    term:
      id: NCIT:C42066
      label: Hemorrhagic Neuroblastic Nodules Present
  description: >-
    One or more macroscopic, usually hemorrhagic, Schwannian stroma-poor
    neuroblastomatous nodules coexisting with an intermixed ganglioneuroblastoma
    (stroma-rich) or ganglioneuroma (stroma-dominant) component. Under the INPC
    the favorable or unfavorable histology group of a nodular tumor, graded on
    its nodules, is to be determined only from primary or metastatic tumor
    tissue obtained before chemotherapy or irradiation, and once assigned it is
    not to be changed during the clinical course, because therapy-associated
    changes, including neuroblastic differentiation and even Schwannian stromal
    development, may not have proven prognostic significance.
  diagnostic: true
  context: Primary or metastatic tumor tissue obtained before chemotherapy or irradiation, classified by the INPC
  subtype: Nodular
  notes: >-
    The INPC describes the nodules as usually hemorrhagic, while the NCIT and
    MONDO definitions say hemorrhagic without qualification. NCIT:C42058
    Ganglioneuroblastoma, Nodular names the neoplasm and is not used as the
    finding.
  evidence:
  - reference: PMID:19530234
    reference_title: "Clinicopathological characteristics of ganglioneuroma and ganglioneuroblastoma: a report from the CCG and COG."
    supports: SUPPORT
    directness: DIRECT
    quote_role: BACKGROUND
    evidence_source: OTHER
    snippet: "characterized by the presence of macroscopic, usually hemorrhagic neuroblastomatous nodule(s) of Schwannian stroma-poor component coexisting Ganglioneuroblastoma-intermixed of stroma-rich component or Ganglioneuroma of stroma-dominant component."
    explanation: >-
      Table I of this CCG and COG clinicopathological series gives the
      International Neuroblastoma Pathology Classification (INPC) definitions
      used to classify its 552 centrally reviewed ganglioneuroma and
      ganglioneuroblastoma cases. The quoted clause, from the
      Ganglioneuroblastoma-Nodular row, states each feature of this finding: one
      or more macroscopic, usually haemorrhagic, Schwannian stroma-poor
      neuroblastomatous nodules coexisting with stroma-rich
      ganglioneuroblastoma-intermixed or stroma-dominant ganglioneuroma. It
      restates the INPC definition (established 1999, revised 2003) rather than
      reporting a finding of this cohort, and calls the nodules usually, not
      always, haemorrhagic.
  - reference: PMID:41612478
    reference_title: "Pathology of peripheral neuroblastic tumors."
    supports: SUPPORT
    directness: DIRECT
    quote_role: REVIEW_SYNTHESIS
    evidence_source: OTHER
    snippet: "The distinction of FH group or UH group according to the INPC, as summarized in Table 1, should only be determined based on the pathology review of primary or metastatic tumors obtained before starting chemotherapy/irradiation therapy. Once FH or UH group classification is assigned, it should not be changed throughout the clinical course of individual cases, since therapy-associated histology changes including neuroblastic cytodifferentiation and even Schwannian stromal development, if present, may not have proven prognostic significance"
    explanation: >-
      This 2026 pathology review states the INPC rule immediately after noting
      that the neuroblastoma nodules of nodular ganglioneuroblastoma are graded
      by age-linked criteria and that intermixed tumors are always of favorable
      histology. The favorable or unfavorable histology group is to be
      determined only from pathology review of primary or metastatic tumors
      obtained before chemotherapy or irradiation starts and, once assigned, is
      not to be changed during the clinical course, because therapy-associated
      changes such as neuroblastic cytodifferentiation and even Schwannian
      stromal development may not have proven prognostic significance. The
      passage states a classification rule and reports no patient data; it
      concerns the histology group, not how a tumor first sampled after
      treatment should be categorized.
phenotypes:
- category: Abdominal
  name: Abdominal Mass
  description: >-
    A primary tumor of the adrenal medulla or extra-adrenal retroperitoneum
    forms an abdominal mass. In one referral series of intermixed
    ganglioneuroblastoma, 74% of primary tumors were abdominal.
  phenotype_term:
    preferred_term: abdominal mass
    term:
      id: HP:0031500
      label: Abdominal mass
  evidence:
  - reference: ORPHA:251877
    reference_title: "Ganglioneuroblastoma"
    supports: SUPPORT
    directness: INDIRECT
    quote_role: REVIEW_SYNTHESIS
    evidence_source: OTHER
    snippet: "usually occurring in the posterior mediastinum, adrenal medulla and extra-adrenal retroperitoneum (but sometimes in the neck and pelvis)"
    explanation: >-
      Orphanet's disease definition, which reports no patient data, names the
      posterior mediastinum, adrenal medulla and extra-adrenal retroperitoneum
      as the usual sites of ganglioneuroblastoma, and the neck and pelvis as
      occasional ones. A primary tumor in the adrenal medulla or retroperitoneum
      is an abdominal mass, but that step is inferred: the definition names
      sites, not a mass, and its list of clinical signs does not include one. It
      does not rank the sites and lists the posterior mediastinum first, so it
      does not show that abdominal primaries predominate.
  - reference: PMID:37243318
    reference_title: "Ganglioneuroblastoma intermixed: Clinicopathological implications of diagnosis at presentation and genomic correlations."
    supports: SUPPORT
    directness: INDIRECT
    quote_role: PRIMARY_RESULT
    evidence_source: HUMAN_CLINICAL
    snippet: "The primary tumor was abdominal in 39 (74%) and thoracic in 14 patients (26%)."
    explanation: >-
      Retrospective Memorial Sloan Kettering series of 53 patients whose
      intermixed ganglioneuroblastoma was diagnosed at presentation. The primary
      tumor was abdominal in 39 (74%) and thoracic in 14 (26%), so most of these
      tumors arose in the abdomen. Reading an abdominal primary as an abdominal
      mass is an inference, and the paper does not name the abdominal sites. The
      figure covers one subtype at a tertiary referral center, where only 16 of
      the 53 patients were first diagnosed; it is not an estimate for
      ganglioneuroblastoma as a whole.
- category: Thoracic
  name: Posterior Mediastinal Mass
  description: >-
    The posterior mediastinum is one of the usual primary sites of
    ganglioneuroblastoma. In one referral series of intermixed
    ganglioneuroblastoma, 26% of primary tumors were thoracic.
  phenotype_term:
    preferred_term: posterior mediastinal mass
    term:
      id: HP:0033829
      label: Posterior mediastinal mass
  evidence:
  - reference: ORPHA:251877
    reference_title: "Ganglioneuroblastoma"
    supports: SUPPORT
    directness: INDIRECT
    quote_role: REVIEW_SYNTHESIS
    evidence_source: OTHER
    snippet: "usually occurring in the posterior mediastinum, adrenal medulla and extra-adrenal retroperitoneum (but sometimes in the neck and pelvis)"
    explanation: >-
      Orphanet's definition of ganglioneuroblastoma lists the posterior
      mediastinum among the sites where the tumor usually occurs, together with
      the adrenal medulla and the extra-adrenal retroperitoneum (and sometimes
      the neck and pelvis). A primary tumor in the posterior mediastinum is a
      posterior mediastinal mass, but that step is inferred: the definition
      names a site, not a mass. The definition gives no case counts or ranking,
      so it does not say how often the posterior mediastinum is the primary
      site.
  - reference: PMID:37243318
    reference_title: "Ganglioneuroblastoma intermixed: Clinicopathological implications of diagnosis at presentation and genomic correlations."
    supports: SUPPORT
    directness: INDIRECT
    quote_role: PRIMARY_RESULT
    evidence_source: HUMAN_CLINICAL
    snippet: "The primary tumor was abdominal in 39 (74%) and thoracic in 14 patients (26%)."
    explanation: >-
      Retrospective Memorial Sloan Kettering series of 53 patients whose
      intermixed ganglioneuroblastoma was diagnosed at presentation. The primary
      tumor was thoracic in 14 (26%). The paper does not name the thoracic
      sites, so reading a thoracic primary as a posterior mediastinal mass is an
      inference. The figure covers one subtype at a tertiary referral center,
      where only 16 of the 53 patients were first diagnosed; it is not an
      estimate for ganglioneuroblastoma as a whole.
- category: Neoplasm
  name: Distant Metastasis at Diagnosis
  subtype: Nodular
  frequency: FREQUENT
  description: >-
    Nearly half of patients with nodular ganglioneuroblastoma have stage 4
    disease at diagnosis: 107 of 232 in an INRG analysis, in which overall
    survival for stage 4 was 35%. In a CCG/COG series, 53% of patients with the
    unfavorable subset had distant metastasis at diagnosis.
  phenotype_term:
    preferred_term: distant metastasis at diagnosis
    term:
      id: HP:0002664
      label: Neoplasm
    coarse_binding_basis: NO_HPO_TERM
    term_gap: >-
      HPO has no class for metastatic or distant disease. OLS HPO searches on
      2026-10-21 for metastasis, metastatic, metastases, distant metastases,
      metastatic neoplasm, metastatic disease, secondary neoplasm, bone
      metastases and neoplasm metastasis returned nothing, or only specific
      tumor types and unrelated findings whose text mentions metastasis.
  evidence:
  - reference: PMID:22137163
    reference_title: "Characteristics and outcome of patients with ganglioneuroblastoma, nodular subtype: a report from the INRG project."
    supports: SUPPORT
    directness: INDIRECT
    quote_role: PRIMARY_RESULT
    evidence_source: HUMAN_CLINICAL
    snippet: "Amongst 4071 patients in the INRG database with known INPC histological category, 232 patients with GNBn were identified. ... A cohort with superior outcome was identified: OS for GNBn patients younger than 18 months was 95%±5% (n=39) and for GNBn patients with stage 1, 2, 3, 4s was 95%±3% (n=125). Conversely, a poor outcome sub-group could also be identified: OS for stage 4 was 35%±7% (n=107)."
    explanation: >-
      This INRG database analysis of 232 patients with nodular
      ganglioneuroblastoma reports overall survival of 35% for stage 4 (n=107)
      and 95% for stages 1, 2, 3 and 4s (n=125); these cover all 232, so 46% had
      stage 4 disease. The abstract gives no stage table and never mentions
      metastasis, so the 46% and its reading as distant metastasis are
      inferences; the 46% excludes stage 4s, and no survival time point is
      stated. INRG pools cooperative-group data, so this cohort is not
      independent of the CCG/COG series also cited here.
  - reference: PMID:19530234
    reference_title: "Clinicopathological characteristics of ganglioneuroma and ganglioneuroblastoma: a report from the CCG and COG."
    supports: SUPPORT
    directness: DIRECT
    quote_role: PRIMARY_RESULT
    evidence_source: HUMAN_CLINICAL
    snippet: "The UH group included ganglioneuroblastoma-nodular, unfavorable subset (GNB-N-US) tumors. Patients with the UH tumors had a high incidence (53%) of distant metastasis at the time of diagnosis"
    explanation: >-
      In a review of 552 ganglioneuroma and ganglioneuroblastoma cases from CCG
      and COG studies, 53% of patients with the unfavourable subset of nodular
      ganglioneuroblastoma had distant metastasis at diagnosis (Table III: 132
      of 248 with known stage were stage 4; no patient had stage 4S). The figure
      covers that subset only; 3 of 59 favourable-subset patients were stage 4.
      The INRG database pools cooperative-group data including Children's
      Oncology Group patients, so this series probably overlaps the INRG cohort
      and does not independently confirm its figure.
- category: Neurologic
  name: Congenital Horner Syndrome
  description: >-
    Congenital Horner syndrome is one of the clinical features of
    ganglioneuroblastoma that depend on where the tumor lies. The cited source
    gives no frequency.
  phenotype_term:
    preferred_term: congenital Horner syndrome
    term:
      id: HP:0006837
      label: Congenital Horner syndrome
  evidence:
  - reference: ORPHA:251877
    reference_title: "Ganglioneuroblastoma"
    supports: SUPPORT
    directness: DIRECT
    quote_role: REVIEW_SYNTHESIS
    evidence_source: OTHER
    snippet: "characterized clinically by pain, stridor, shortness of breath, peripheral neurological signs, superior vena cava syndrome and congenital Horner syndrome, depending on the location of the tumor"
    explanation: >-
      Orphanet's definition of ganglioneuroblastoma, which reports no patient
      data, names congenital Horner syndrome among its clinical features,
      alongside pain, stridor, shortness of breath, peripheral neurological
      signs and superior vena cava syndrome, and says the features depend on the
      location of the tumor. It gives no frequency, so none is recorded.
- category: Laboratory
  name: Elevated Urinary Homovanillic Acid
  subtype: Intermixed
  frequency: FREQUENT
  description: >-
    In localized tumors registered in the German NB97 and NB2004 trials, urinary
    homovanillic acid was elevated in 27 of 44 tested patients with intermixed
    ganglioneuroblastoma (61.4%), a proportion similar to that in localized
    neuroblastoma and nodular ganglioneuroblastoma combined (61.6%) and higher
    than in ganglioneuroma (31.7%), so a normal result does not exclude the
    tumor.
  phenotype_term:
    preferred_term: elevated urinary homovanillic acid
    term:
      id: HP:0011977
      label: Elevated urinary homovanillic acid
  evidence:
  - reference: PMID:27465021
    reference_title: "Treatment and outcome of Ganglioneuroma and Ganglioneuroblastoma intermixed."
    supports: SUPPORT
    directness: DIRECT
    quote_role: PRIMARY_RESULT
    evidence_source: HUMAN_CLINICAL
    snippet: "| | GN (n = 162) | p1 | GNBI (n = 55) | GN / GNBI (n=217) | p 2 | NB / GNBN (n = 591) | ... | HVA elevated ... | 45/142 | 0.001 ... | 27/44 | 72/186 | <0.001 ... | 327/531 | | 31.7 % | 61.4 % | 38.7 % | 61.6 % |"
    explanation: >-
      Table 1 of this retrospective study of localized neuroblastic tumors
      registered in the German NB97 and NB2004 trials; the excerpt gives the
      column headings and the HVA row. Urinary homovanillic acid was elevated in
      27 of 44 tested patients with intermixed ganglioneuroblastoma (61.4%), 45
      of 142 with ganglioneuroma (31.7%) and 327 of 531 with neuroblastoma or
      nodular ganglioneuroblastoma (61.6%). The p-values compare ganglioneuroma
      with intermixed tumors (p1) and the pooled mature tumors with the immature
      ones (p2); none compares intermixed tumors with neuroblastoma. The
      abstract's finding that mature tumors less often had elevated metabolites
      comes from the pooled column, three quarters of which is ganglioneuroma.
      Metastatic tumors were excluded, and nodular tumors are not reported apart
      from neuroblastoma.
- category: Laboratory
  name: Elevated Urinary Vanillylmandelic Acid
  subtype: Intermixed
  frequency: FREQUENT
  description: >-
    In the same series, urinary vanillylmandelic acid was elevated in 23 of 47
    tested patients with intermixed ganglioneuroblastoma (48.9%), against 64.1%
    of patients with localized neuroblastoma or nodular ganglioneuroblastoma and
    19.3% with ganglioneuroma.
  phenotype_term:
    preferred_term: elevated urinary vanillylmandelic acid
    term:
      id: HP:0011978
      label: Elevated urinary vanillylmandelic acid
  evidence:
  - reference: PMID:27465021
    reference_title: "Treatment and outcome of Ganglioneuroma and Ganglioneuroblastoma intermixed."
    supports: SUPPORT
    directness: DIRECT
    quote_role: PRIMARY_RESULT
    evidence_source: HUMAN_CLINICAL
    snippet: "| | GN (n = 162) | p1 | GNBI (n = 55) | GN / GNBI (n=217) | p 2 | NB / GNBN (n = 591) | ... | VMA elevated ... | 28/145 | <0.001 ... | 23/47 | 51/192 | <0.001 ... | 345/538 | | 19.3 % | 48.9 % | 26.6% | 64.1 % |"
    explanation: >-
      Table 1 of the same German NB97/NB2004 study of localized neuroblastic
      tumors; the excerpt gives the column headings and the VMA row. Urinary
      vanillylmandelic acid was elevated in 23 of 47 tested patients with
      intermixed ganglioneuroblastoma (48.9%), 28 of 145 with ganglioneuroma
      (19.3%) and 345 of 538 with neuroblastoma or nodular ganglioneuroblastoma
      (64.1%). No p-value compares intermixed tumors with neuroblastoma, so the
      lower intermixed proportion is not a tested difference. Metastatic tumors
      were excluded, and nodular tumors are not reported apart from
      neuroblastoma.
biochemical:
- name: Neuron-Specific Enolase
  presence: INCREASED
  biomarker_term:
    preferred_term: neuron-specific enolase
    term:
      id: NCIT:C62216
      label: Gamma-Enolase
  notes: >-
    In a retrospective review of 279 children with neuroblastoma or
    ganglioneuroblastoma diagnosed at one Shanghai hospital in 2005-2015, serum
    NSE was abnormal at diagnosis in 93% of nodular and 81% of intermixed
    ganglioneuroblastomas, against 96% of neuroblastomas. The groups were small
    (the Methods list 20 nodular and 31 intermixed patients), and the paper
    gives no cut-off or number tested.
  evidence:
  - reference: PMID:28465480
    reference_title: "Clinical and biological features of neuroblastic tumors: A comparison of neuroblastoma and ganglioneuroblastoma."
    supports: SUPPORT
    directness: DIRECT
    quote_role: PRIMARY_RESULT
    evidence_source: HUMAN_CLINICAL
    snippet: "NB patients were more frequently diagnosed with adrenal tumors and had a higher prevalence of abnormal serum ferritin at the time of diagnosis (60.0% vs. 40.0% vs. 12.0%, P<0.001), NSE (96.0% vs. 93.0% vs. 81.0%, P=0.013) when compared with GNBn and GNBi patients."
    explanation: >-
      This retrospective review of 279 children with neuroblastoma (NB) or
      ganglioneuroblastoma at Xinhua Hospital, Shanghai, reports pretreatment
      serum markers in the order NB, nodular (GNBn), intermixed (GNBi): serum
      NSE was abnormal at diagnosis in 96%, 93% and 81%. The Results give the
      normal-NSE rates in the reverse order (19%, 7% and 4%), which confirms
      this reading. The paper's Methods list 20 nodular and 31 intermixed
      patients; the text gives neither the number tested nor a cut-off, and it
      reports abnormal rather than raised values.
- name: Serum Ferritin
  presence: INCREASED
  biomarker_term:
    preferred_term: serum ferritin
    term:
      id: NCIT:C224202
      label: Serum Ferritin
  notes: >-
    In the same single-center series, serum ferritin was abnormal at diagnosis
    in 40% of nodular and 12% of intermixed ganglioneuroblastomas, against 60%
    of neuroblastomas.
  evidence:
  - reference: PMID:28465480
    reference_title: "Clinical and biological features of neuroblastic tumors: A comparison of neuroblastoma and ganglioneuroblastoma."
    supports: SUPPORT
    directness: DIRECT
    quote_role: PRIMARY_RESULT
    evidence_source: HUMAN_CLINICAL
    snippet: "NB patients were more frequently diagnosed with adrenal tumors and had a higher prevalence of abnormal serum ferritin at the time of diagnosis (60.0% vs. 40.0% vs. 12.0%, P<0.001), NSE (96.0% vs. 93.0% vs. 81.0%, P=0.013) when compared with GNBn and GNBi patients."
    explanation: >-
      The same sentence reports abnormal serum ferritin at diagnosis in 60% of
      neuroblastomas, 40% of nodular (GNBn) and 12% of intermixed (GNBi)
      ganglioneuroblastomas in this single-center series, whose Methods list 20
      nodular and 31 intermixed patients. The abstract says abnormal rather than
      raised and gives no cut-off or number tested.
genetic:
- name: MYCN Amplification
  association: Rare Somatic Amplification
  gene_term:
    preferred_term: MYCN
    term:
      id: hgnc:7559
      label: MYCN
  relationship_type: BIOMARKER
  variant_origin: SOMATIC
  frequency: VERY_RARE
  notes: >-
    MYCN amplification is rare in ganglioneuroblastoma. In a Children's Cancer
    Group series it was found in none of 21 intermixed and 2 of 63 nodular
    tumors. In a CCG/COG series of ganglioneuroma and ganglioneuroblastoma, 10
    of 500 patients with a MYCN result had amplified tumors: 2 GN-maturing and 2
    intermixed tumors, all alive and well at last follow-up, and 6 nodular
    tumors of the unfavorable subset. These cooperative-group series overlap.
    MYCN status is used with INPC histology to assign neuroblastic tumors to
    risk groups. A single-center series (PMID:28465480) reported amplification
    in 14% of nodular and none of the intermixed tumors; its Results record a
    single amplified nodular tumor, and the authors note that only a small
    number of patients were tested.
  evidence:
  - reference: PMID:11745206
    reference_title: "Histopathology (International Neuroblastoma Pathology Classification) and MYCN status in patients with peripheral neuroblastic tumors: a report from the Children's Cancer Group."
    supports: SUPPORT
    directness: DIRECT
    quote_role: PRIMARY_RESULT
    evidence_source: HUMAN_CLINICAL
    snippet: "MYCN amplification was seen almost exclusively in tumors of the NB category, and no patients with tumors in either the GNBi category or in the GN category and only two patients with tumors in the GNBn category had amplified MYCN."
    explanation: >-
      This Children's Cancer Group series classified 628 neuroblastic tumours
      under the International Neuroblastoma Pathology Classification and tested
      each for MYCN status, including 21 intermixed and 63 nodular
      ganglioneuroblastomas. Amplification was seen almost exclusively in the
      neuroblastoma category: none of the intermixed and only two of the nodular
      ganglioneuroblastomas were amplified. The subtype groups are small, and
      later cooperative-group series drawing on Children's Cancer Group studies
      may share patients with this one, so they do not independently confirm it.
  - reference: PMID:19530234
    reference_title: "Clinicopathological characteristics of ganglioneuroma and ganglioneuroblastoma: a report from the CCG and COG."
    supports: SUPPORT
    directness: DIRECT
    quote_role: PRIMARY_RESULT
    evidence_source: HUMAN_CLINICAL
    snippet: "Results of MYCN status of the individual tumors, either amplified or non-amplified ... were also collected from the patients (N=500) of both CCG and COG studies ... There were 10 patients whose tumor had amplified MYCN in this series: all 4 with FH tumors (2 cases with GN-M; 2 cases with GNB-I) were alive and well at the time of last follow-up: 3 of them had more than one year of follow-up period, while 2 of 6 patients whose tumor had UH (GNB-N-US) and amplified MYCN died of tumor."
    explanation: >-
      This CCG/COG series shows that MYCN amplification was rare: of 500
      ganglioneuroma and ganglioneuroblastoma patients with a MYCN result, 10
      had amplified tumours, 4 with favourable histology (2 GN-maturing, 2
      GNB-intermixed), all alive and well at last follow-up, and 6 with nodular
      unfavourable-subset (GNB-N-US) tumours, 2 of whom died of tumour. Limits:
      only 3 of the 4 favourable-histology patients were followed beyond a year,
      the GN-maturing cases are ganglioneuromas, and the series includes the 70
      nodular cases of Peuchmaur et al. (2003), so it is not independent of
      other CCG reports.
  - reference: PMID:11745206
    reference_title: "Histopathology (International Neuroblastoma Pathology Classification) and MYCN status in patients with peripheral neuroblastic tumors: a report from the Children's Cancer Group."
    supports: SUPPORT
    directness: INDIRECT
    quote_role: BACKGROUND
    evidence_source: HUMAN_CLINICAL
    snippet: "MYCN amplification is a known molecular marker for aggressive progression of NTs. These have been used together as important prognostic factors to define risk groups for patient stratification and protocol assignment."
    explanation: >-
      The background of this Children's Cancer Group study states that MYCN
      amplification is a known marker of aggressive progression in neuroblastic
      tumors, and that it is used together with INPC histology, the other factor
      'These' refers to, to define risk groups for patient stratification and
      protocol assignment. That is the prognostic use behind this record's
      BIOMARKER typing. It is said of neuroblastic tumors as a family, most of
      them neuroblastomas, not of ganglioneuroblastoma alone.
  - reference: PMID:28465480
    reference_title: "Clinical and biological features of neuroblastic tumors: A comparison of neuroblastoma and ganglioneuroblastoma."
    supports: SUPPORT
    directness: DIRECT
    quote_role: PRIMARY_RESULT
    evidence_source: HUMAN_CLINICAL
    snippet: "The prevalence rates of disseminated tumors and MYCN amplified tumors were lower in the GNBi group than in the GNBn and NB groups (13.0% vs. 25.0% vs. 44.0%, P=0.002; 0 vs. 14.0% vs. 26.0%, P=0.032, respectively)."
    explanation: >-
      In this retrospective series of 279 patients with neuroblastoma (NB) or
      ganglioneuroblastoma diagnosed at Xinhua Hospital, Shanghai, in 2005-2015,
      MYCN amplification was found in none of the intermixed (GNBi), 14% of the
      nodular (GNBn) and 26% of the neuroblastoma tumors tested, so it occurs in
      ganglioneuroblastoma, mainly nodular, and less often than in
      neuroblastoma. The Results record a single amplified nodular tumor among
      20 nodular patients, and the authors list as a limitation that only a
      small number of patients were tested, so the 14% rests on very few tests
      and does not set aside the very-rare band from the larger
      cooperative-group series.
diagnosis:
- name: Histopathologic Classification
  description: >-
    Ganglioneuroblastoma is diagnosed and subtyped by histopathologic
    examination of tumor tissue under the INPC. Because a macroscopic
    neuroblastomatous nodule separates nodular from intermixed tumors, which are
    hard to tell apart on limited samples, the completely resected tumor is the
    ideal sample. When only a biopsy or an incompletely resected tumor is
    available, a favorable classification is reported as based on review of
    limited material: the CCG/COG central reviewers did so, and a 2026 pathology
    review advises it for core needle biopsies that show only intermixed
    ganglioneuroblastoma or ganglioneuroma.
  diagnosis_term:
    preferred_term: histopathologic examination under the International Neuroblastoma Pathology Classification
    term:
      id: NCIT:C18190
      label: Histopathologic Examination
  evidence:
  - reference: PMID:37243318
    reference_title: "Ganglioneuroblastoma intermixed: Clinicopathological implications of diagnosis at presentation and genomic correlations."
    supports: SUPPORT
    directness: DIRECT
    quote_role: BACKGROUND
    evidence_source: OTHER
    snippet: "The diagnosis of GNBI is typically made on a diligent morphological examination of the entire resected tumor because distinguishing GNBI from GNBN is particularly challenging on limited samples."
    explanation: >-
      The Discussion of this Memorial Sloan Kettering series opens by restating
      established practice: intermixed ganglioneuroblastoma (GNBI) is usually
      diagnosed on careful examination of the entire resected tumor, because it
      is particularly hard to tell from nodular ganglioneuroblastoma (GNBN) on
      limited samples. It states practice and reports no data from the series.
  - reference: PMID:19530234
    reference_title: "Clinicopathological characteristics of ganglioneuroma and ganglioneuroblastoma: a report from the CCG and COG."
    supports: SUPPORT
    directness: DIRECT
    evidence_source: HUMAN_CLINICAL
    snippet: "It was always ideal for pathologist to have a completely resected sample for the final diagnosis, so as not to miss any unfavorable nodules or different clones. However, in real life, we sometimes encountered the situation/clinical decision where we had to evaluate a biopsy or incompletely resected material. For those Inco-R cases, FH diagnosis of GN-M, GNB-I, or GNB-N-FS was accompanied by the remark of \"the diagnosis is made based on review of a limited material\""
    explanation: >-
      In the Discussion of this CCG/COG series, the central review pathologists
      state that a completely resected sample was always the ideal basis for the
      final diagnosis, so that no unfavorable nodule or different clone was
      missed. When only a biopsy or an incompletely resected tumor was
      available, a favorable diagnosis of GN-maturing, GNB-intermixed or
      favorable-subset GNB-nodular carried the remark that it was based on
      review of limited material. This describes the series' diagnostic
      practice, not an outcome.
  - reference: PMID:41612478
    reference_title: "Pathology of peripheral neuroblastic tumors."
    supports: SUPPORT
    directness: DIRECT
    quote_role: REVIEW_SYNTHESIS
    evidence_source: OTHER
    snippet: "especially when the samples obtained by PCNB show only GNB-i or GN histology, it is advisable to include a note of \"Favorable Histology of this case according to the International Neuroblastoma Pathology Classification is determined based on review of limited material\" in the surgical pathology report."
    explanation: >-
      This 2026 pathology review advises, as the authors' routine practice, that
      when percutaneous core needle biopsy (PCNB) samples show only
      GNB-intermixed or ganglioneuroma histology, the report should note that
      the favorable INPC classification was determined on review of limited
      material. The preceding sentence gives the reason: a core needle biopsy
      can miss the neuroblastoma nodule of a nodular ganglioneuroblastoma. It is
      an expert recommendation about core needle biopsy, without case data.
differential_diagnoses:
- name: Ganglioneuroma
  description: >-
    Ganglioneuroma is the Schwannian stroma-dominant category of the peripheral
    neuroblastic tumors, and intermixed ganglioneuroblastoma is the Schwannian
    stroma-rich category beside it. Both consist largely of Schwannian stroma
    containing mature or maturing ganglion cells, and the INPC maturing subtype
    of ganglioneuroma may also hold a minor component of individually scattered
    differentiating neuroblasts. Read side by side, their INPC definitions
    differ in the well-defined microscopic neuroblastic nests that characterize
    the intermixed category; differentiating neuroblasts scattered as single
    cells are compatible with maturing ganglioneuroma. For decades
    ganglioneuroblastoma caused some consternation for pathologists and
    oncologists, one reason being that there was no clear and objective
    delineation between it and ganglioneuroma. The INPC maturing subtype of
    ganglioneuroma is the tumor group that the earlier Shimada classification
    called ganglioneuroblastoma, well differentiated, so a tumor reported as
    well-differentiated ganglioneuroblastoma under the Shimada nomenclature is
    a ganglioneuroma under the INPC. Sampling adds another source of confusion: compared with
    surgical resection, core needle biopsy seems to be at a disadvantage with
    nodular ganglioneuroblastoma, in which a neuroblastoma nodule coexists with
    intermixed ganglioneuroblastoma or ganglioneuroma tissue.
  disease_term:
    preferred_term: ganglioneuroma
    term:
      id: MONDO:0005033
      label: ganglioneuroma
  distinguishing_features:
  - "Intermixed ganglioneuroblastoma is defined as tumor tissue more than 50% occupied by a ganglioneuromatous component and is characterized by well-defined microscopic nests of neuroblastic cells whose neurites are segmentally naked within the nests."
  - "In ganglioneuroma, ganglion cells lie individually or in small clusters in Schwannian stroma and are either all completely mature (mature subtype) or a mixture of mature and maturing cells (maturing subtype); completely mature ganglion cells are covered with satellite cells, and naked neurites are not identified around the ganglion cells."
  - "Under the INPC definition the maturing subtype of ganglioneuroma may also contain a minor component of individually scattered differentiating neuroblasts, present as single scattered cells rather than in the microscopic neuroblastic nests that characterize intermixed ganglioneuroblastoma."
  - "Under the INPC, intermixed ganglioneuroblastoma is Schwannian stroma-rich and ganglioneuroma Schwannian stroma-dominant, while nodular ganglioneuroblastoma is a composite of stroma-rich or stroma-dominant tissue with stroma-poor tissue."
  - "Compared with surgical resection, core needle biopsy seems to be at a disadvantage with nodular ganglioneuroblastoma, where a neuroblastoma nodule coexists with intermixed ganglioneuroblastoma or ganglioneuroma tissue; when the tumor is large, multiple cores may give a better chance than incisional biopsy of sampling the nodule, which is often hemorrhagic or necrotic and detected on radiological images."
  notes: >-
    MONDO:0005033 also has central nervous system parents (MONDO:0000640 central
    nervous system primitive neuroectodermal neoplasm and MONDO:0016729 mixed
    neuronal-glial tumor); this row concerns the neuroblastic tumor of the
    sympathetic nervous system that the MONDO definition describes.
  evidence:
  - reference: PMID:41612478
    reference_title: "Pathology of peripheral neuroblastic tumors."
    supports: SUPPORT
    directness: DIRECT
    quote_role: REVIEW_SYNTHESIS
    evidence_source: OTHER
    snippet: "By definition, more than 50% of the tumor tissue in this category is occupied by a ganglioneuromatous component (see below), where well-developed Schwannian stroma contains sporadic mature or maturing ganglion cells. The tumors are characterized by the presence of well-defined microscopic nests of neuroblastic cells in various stages of differentiation with actively producing and easily recognizable neurites around their cytoplasm (Fig. 2B). Their neurites are segmentally naked in those microscopic nests and eventually incorporated in the cytoplasm of Schwannian cells in the stromal areas. ... Tumor cells (ganglion cells) are distributed individually or making small clusters in Schwannian stroma (Fig. 2C). They are either completely mature (mature GN) or a mixture of mature and maturing ganglion cells (maturing GN). Completely mature ganglion cells are covered with satellite cells. Neurites produced by the ganglion cells are immediately incorporated in the cytoplasm of Schwannian stromal cells, so that naked neurites are not identified around the ganglion cells."
    explanation: >-
      In this 2026 pathology review, part one of the quote comes from the
      section headed 'Ganglioneuroblastoma, intermixed (Schwannian stroma-rich)'
      and says only 'this category'; the Fig. 2B legend it cites labels the
      image as ganglioneuroblastoma, intermixed. Part two comes from the section
      headed 'Ganglioneuroma (Schwannian stroma-dominant)' and names its
      category through the mature and maturing GN subtypes. Restating the
      International Neuroblastoma Pathology Classification, the review defines
      intermixed ganglioneuroblastoma as tumor tissue more than 50% occupied by
      a ganglioneuromatous component and characterizes it by well-defined
      microscopic nests of neuroblastic cells whose neurites are segmentally
      naked within the nests. In ganglioneuroma, ganglion cells lie individually
      or in small clusters in Schwannian stroma and are either completely mature
      (mature GN) or a mixture of mature and maturing cells (maturing GN);
      completely mature ganglion cells are covered with satellite cells, and
      because their neurites are immediately incorporated into Schwannian
      stromal cells, naked neurites are not identified around them. The review
      describes the two categories in separate paragraphs and does not compare
      them directly; read side by side, the definitions set the neuroblastic
      nests of the intermixed tumor against the individually distributed or
      clustered ganglion cells of ganglioneuroma. These are classification
      criteria, not case data.
  - reference: PMID:19530234
    reference_title: "Clinicopathological characteristics of ganglioneuroma and ganglioneuroblastoma: a report from the CCG and COG."
    supports: SUPPORT
    directness: DIRECT
    quote_role: BACKGROUND
    evidence_source: OTHER
    snippet: "Ganglioneuroma-Maturing (Schwannian stroma-dominant): Composed predominantly of ganglioneuromatous stroma with a minor component of individually scattered, evenly or unevenly distributed differentiating neuroblasts and/or maturing ganglion cells, in addition to fully mature ganglion cells. Fully mature ganglion cells are always covered with satellite cells."
    explanation: >-
      Table I of this CCG/COG clinicopathological series restates the
      International Neuroblastoma Pathology Classification definition of the
      ganglioneuroma, maturing subtype (Schwannian stroma-dominant): mostly
      ganglioneuromatous stroma with a minor component of individually
      scattered, evenly or unevenly distributed differentiating neuroblasts
      and/or maturing ganglion cells, beside fully mature ganglion cells that
      are always covered with satellite cells. So differentiating neuroblasts
      scattered as single cells can occur in this ganglioneuroma subtype. The
      intermixed row of the same table instead describes scattered
      'residual' microscopic neuroblastomatous foci presenting as pockets of
      neuropil; the contrast between single scattered cells and those foci is
      read from the two definitions side by side and is not stated in this
      row. It is a classification rule restated from the INPC papers, not a
      result of this cohort.
  - reference: PMID:10421272
    reference_title: "Terminology and morphologic criteria of neuroblastic tumors: recommendations by the International Neuroblastoma Pathology Committee."
    supports: SUPPORT
    directness: DIRECT
    quote_role: PRIMARY_RESULT
    evidence_source: HUMAN_CLINICAL
    snippet: "Based on morphologic criteria defined in this article, NTs were classified into four categories and their subtypes: 1) neuroblastoma (Schwannian stroma-poor), undifferentiated, poorly differentiated, and differentiating; 2) ganglioneuroblastoma, intermixed (Schwannian stroma-rich); 3) ganglioneuroma (Schwannian stroma-dominant), maturing and mature; and 4) ganglioneuroblastoma, nodular (composite Schwannian stroma-richlstroma-dominant and stroma-poor)."
    explanation: >-
      This is the 1999 terminology paper of the International Neuroblastoma
      Pathology Committee, whose six member pathologists defined morphologically
      based classifications on the basis of a review of 227 cases. It classifies
      neuroblastic tumors into four categories, each labeled by its Schwannian
      stroma: neuroblastoma (stroma-poor), ganglioneuroblastoma, intermixed
      (stroma-rich), ganglioneuroma (stroma-dominant, with maturing and mature
      subtypes) and ganglioneuroblastoma, nodular, a composite of stroma-rich or
      stroma-dominant tissue with stroma-poor tissue. The scheme therefore
      separates ganglioneuroblastoma from stroma-poor neuroblastoma and from
      stroma-dominant ganglioneuroma. The abstract gives each category its name,
      its Schwannian stromal label and, for neuroblastoma and ganglioneuroma,
      the names of its subtypes, but not the morphologic criteria that the
      article says it defines. 'stroma-richlstroma-dominant' is the source's
      typo for stroma-rich/stroma-dominant, the spelling in the abstract of the
      companion INPC article in the same issue (PMID:10421273). In this abstract
      INPC abbreviates the Committee, which proposes the International
      Neuroblastoma Pathology Classification.
  - reference: PMID:19530234
    reference_title: "Clinicopathological characteristics of ganglioneuroma and ganglioneuroblastoma: a report from the CCG and COG."
    supports: SUPPORT
    directness: DIRECT
    quote_role: BACKGROUND
    evidence_source: OTHER
    snippet: "For decades, GNB caused some consternation for both pathologists and oncologists for several reasons: Firstly, there were no clear and objective delineations between NB and GNB, and between GNB and GN, and secondly, there were no well-defined guidelines to predict tumor biology and clinical outcome of the patients with GNB. ... According to the INPC, tumors in the GN category are further classified into GN-Maturing subtype (the same tumor group described as \"Ganglioneuroblastoma, well differentiated\" in the Shimada classification system3) and GN-Mature subtype (completely mature form of neuroblastic tumor)."
    explanation: >-
      Two sentences from the introduction of this Children's Cancer Group and
      Children's Oncology Group clinicopathological series of ganglioneuroma and
      ganglioneuroblastoma carry the claim. The first is the authors' account of
      the period before the INPC: for decades ganglioneuroblastoma caused some
      consternation for pathologists and oncologists, firstly because there were
      no clear and objective delineations between neuroblastoma and
      ganglioneuroblastoma, or between ganglioneuroblastoma and ganglioneuroma.
      The second restates the INPC subdivision of the ganglioneuroma category
      into GN-Maturing and GN-Mature subtypes and equates GN-Maturing with the
      tumor group that the Shimada classification described as
      ganglioneuroblastoma, well differentiated. So the boundary between
      ganglioneuroblastoma and ganglioneuroma was long unclear, and a tumor
      reported as well-differentiated ganglioneuroblastoma under the earlier
      Shimada nomenclature falls in the INPC ganglioneuroma, maturing subtype,
      not in an INPC ganglioneuroblastoma category. In 'system3' the paper's
      citation number 3 runs into the word. Both sentences are introductory
      framing and restated nomenclature, not results from this cohort.
  - reference: PMID:41612478
    reference_title: "Pathology of peripheral neuroblastic tumors."
    supports: SUPPORT
    directness: DIRECT
    quote_role: REVIEW_SYNTHESIS
    evidence_source: OTHER
    snippet: "Compared with surgical resection, PCNB seems to have disadvantages when dealing with pNTs having intra-tumoral heterogeneity, such as GNB-n where a NB nodule is co-existing with GNB-i or GN. When the given tumor is large in size, however, PCNB with multiple cores may offer a better chance to obtain samples from a NB nodule, that is often hemorrhagic and/or necrotic and detected by radiology images, than incisional biopsy."
    explanation: >-
      This 2026 pathology review states that, compared with surgical resection,
      percutaneous core needle biopsy (PCNB) seems to be at a disadvantage for
      peripheral neuroblastic tumors with intra-tumoral heterogeneity, such as
      nodular ganglioneuroblastoma (GNB-n), where a neuroblastoma (NB) nodule
      coexists with GNB-intermixed (GNB-i) or ganglioneuroma (GN) tissue. When
      the tumor is large, PCNB with multiple cores may give a better chance than
      incisional biopsy of sampling the NB nodule, which is often hemorrhagic or
      necrotic and seen on imaging. So a core showing only GN or GNB-i tissue
      may come from a nodular tumor whose nodule was missed, and the review's
      next sentence advises reporting such a favorable classification as based
      on limited material. It is an expert statement without case data.
- name: Neuroblastoma
  description: >-
    Neuroblastoma is the Schwannian stroma-poor category of the same INPC
    classification, and nodular ganglioneuroblastoma is a composite of
    stroma-poor neuroblastoma tissue with stroma-rich or stroma-dominant tissue,
    so different samples from one patient can be assigned different categories.
    When core needle biopsy samples from one site show intermixed
    ganglioneuroblastoma or ganglioneuroma and another site in the same patient
    shows neuroblastoma, a 2026 pathology review advises considering a variant
    of nodular ganglioneuroblastoma, in which a neuroblastoma nodule in the
    primary tumor was not sampled but is found at the metastatic site, or,
    extremely rarely, multiple primaries presumably composed of different
    clones. In one tertiary-center retrospective series, 12 patients with stage
    M disease had intermixed ganglioneuroblastoma diagnosed on biopsy; after
    neoadjuvant chemotherapy the definitive resection showed neuroblastoma in 8
    (67%), so the biopsy diagnosis could not be corroborated, and the authors
    advise high caution with a biopsy diagnosis of intermixed
    ganglioneuroblastoma when metastases are present.
  disease_term:
    preferred_term: neuroblastoma
    term:
      id: MONDO:0005072
      label: neuroblastoma
  distinguishing_features:
  - "Histologically, tumors in the INPC neuroblastoma (Schwannian stroma-poor) category are composed of neuroblastic cells in sheets or nests demarcated by thin fibrovascular septa, with limited or absent Schwannian stromal development."
  - "Under the INPC, neuroblastoma is Schwannian stroma-poor, intermixed ganglioneuroblastoma Schwannian stroma-rich, and nodular ganglioneuroblastoma a composite of stroma-rich or stroma-dominant tissue with stroma-poor tissue."
  - "Under the INPC definition, intermixed ganglioneuroblastoma is a transitional form between neuroblastoma and ganglioneuroma with scattered residual microscopic neuroblastomatous foci presenting as pockets of neuropil, and its ganglioneuromatous component should exceed 50% of the total volume in microscopic fields from representative sections of the tumor."
  - "Nodular ganglioneuroblastoma is characterized by macroscopic, usually hemorrhagic neuroblastomatous nodules of Schwannian stroma-poor component coexisting with stroma-rich intermixed ganglioneuroblastoma or stroma-dominant ganglioneuroma."
  - "When core needle biopsy samples show intermixed ganglioneuroblastoma or ganglioneuroma at one site and neuroblastoma at another in the same patient, a 2026 pathology review advises considering a variant of nodular ganglioneuroblastoma whose primary-site neuroblastoma nodule was not sampled but is found at the metastatic site or, extremely rarely, multiple primaries presumably composed of different clones."
  - "In one tertiary-center series, resection after neoadjuvant chemotherapy showed neuroblastoma in 8 of 12 patients with stage M disease whose biopsy had shown intermixed ganglioneuroblastoma, and the authors advise high caution with such a biopsy diagnosis when metastases are present."
  evidence:
  - reference: PMID:10421272
    reference_title: "Terminology and morphologic criteria of neuroblastic tumors: recommendations by the International Neuroblastoma Pathology Committee."
    supports: SUPPORT
    directness: DIRECT
    quote_role: PRIMARY_RESULT
    evidence_source: HUMAN_CLINICAL
    snippet: "Based on morphologic criteria defined in this article, NTs were classified into four categories and their subtypes: 1) neuroblastoma (Schwannian stroma-poor), undifferentiated, poorly differentiated, and differentiating; 2) ganglioneuroblastoma, intermixed (Schwannian stroma-rich); 3) ganglioneuroma (Schwannian stroma-dominant), maturing and mature; and 4) ganglioneuroblastoma, nodular (composite Schwannian stroma-richlstroma-dominant and stroma-poor)."
    explanation: >-
      This is the 1999 terminology paper of the International Neuroblastoma
      Pathology Committee, whose six member pathologists defined morphologically
      based classifications on the basis of a review of 227 cases. It classifies
      neuroblastic tumors into four categories, each labeled by its Schwannian
      stroma: neuroblastoma (stroma-poor), ganglioneuroblastoma, intermixed
      (stroma-rich), ganglioneuroma (stroma-dominant, with maturing and mature
      subtypes) and ganglioneuroblastoma, nodular, a composite of stroma-rich or
      stroma-dominant tissue with stroma-poor tissue. The scheme therefore
      separates ganglioneuroblastoma from stroma-poor neuroblastoma and from
      stroma-dominant ganglioneuroma. The abstract gives each category its name,
      its Schwannian stromal label and, for neuroblastoma and ganglioneuroma,
      the names of its subtypes, but not the morphologic criteria that the
      article says it defines. 'stroma-richlstroma-dominant' is the source's
      typo for stroma-rich/stroma-dominant, the spelling in the abstract of the
      companion INPC article in the same issue (PMID:10421273). In this abstract
      INPC abbreviates the Committee, which proposes the International
      Neuroblastoma Pathology Classification.
  - reference: PMID:41612478
    reference_title: "Pathology of peripheral neuroblastic tumors."
    supports: SUPPORT
    directness: DIRECT
    quote_role: REVIEW_SYNTHESIS
    evidence_source: OTHER
    snippet: "Histologically the tumors are composed of neuroblastic cells arranged in sheets or nests demarcated by thin fibrovascular septae. Schwannian stromal development is limited or absent."
    explanation: >-
      The quoted sentences come from the section of this 2026 review headed
      'Neuroblastoma (Schwannian stroma-poor)', whose first sentence names its
      subject as tumors in the NB category, so 'the tumors' are tumors of the
      INPC neuroblastoma category. They consist of neuroblastic cells in sheets
      or nests demarcated by thin fibrovascular septa ('septae' in the source),
      with limited or absent Schwannian stromal development. The same review
      labels intermixed ganglioneuroblastoma Schwannian stroma-rich, so the
      extent of Schwannian stroma, rather than the neuroblastic architecture,
      separates neuroblastoma from the intermixed form; that comparison is drawn
      from the review's definitions and is not stated in this quote. The quote
      does not by itself separate neuroblastoma from nodular
      ganglioneuroblastoma, whose neuroblastoma component the review describes
      as often forming nodules in a background of intermixed
      ganglioneuroblastoma or ganglioneuroma tissue. The passage restates an
      INPC criterion and reports no case data.
  - reference: PMID:19530234
    reference_title: "Clinicopathological characteristics of ganglioneuroma and ganglioneuroblastoma: a report from the CCG and COG."
    supports: SUPPORT
    directness: DIRECT
    quote_role: BACKGROUND
    evidence_source: OTHER
    snippet: "Ganglioneuroblastoma-Intermixed (Schwannian stroma-rich): A transitional form between Neuroblastoma and Ganglioneuroma. Tumor is on its way toward full differentiation/maturation; however, the process is not complete, as evidenced by scattered \"residual\" microscopic neuroblastomatous foci presenting as pockets of neuropil containing varying numbers of neuroblastic cells with various stages of maturation including neuroblasts, differentiating neuroblasts, and/or ganglion cells. The proportion of the ganglioneuromatous component to \"residual\" neuroblastomatous foci should exceed 50% of the total volume in microscopic field(s) from representative section(s) of the tumor."
    explanation: >-
      Table I of this CCG/COG clinicopathological series restates the
      International Neuroblastoma Pathology Classification definition of
      intermixed ganglioneuroblastoma: a transitional form between
      neuroblastoma and ganglioneuroma whose maturation is incomplete, with
      scattered 'residual' microscopic neuroblastomatous foci presenting as
      pockets of neuropil, and a ganglioneuromatous component that should
      exceed 50% of the total volume in microscopic fields from representative
      sections. The quote states only the intermixed side of that threshold;
      read with the 2026 review's description of neuroblastoma as having
      limited or absent Schwannian stromal development, it is the quantitative
      criterion that sets the intermixed form apart from neuroblastoma. It is a
      diagnostic criterion restated from the INPC, not cohort data.
  - reference: PMID:19530234
    reference_title: "Clinicopathological characteristics of ganglioneuroma and ganglioneuroblastoma: a report from the CCG and COG."
    supports: SUPPORT
    directness: DIRECT
    quote_role: BACKGROUND
    evidence_source: OTHER
    snippet: "Ganglioneuroblastoma-Nodular (composite, Schwannian stroma-rich/stroma-dominant and stroma-poor): Composed of biologically different clones characterized by the presence of macroscopic, usually hemorrhagic neuroblastomatous nodule(s) of Schwannian stroma-poor component coexisting Ganglioneuroblastoma-intermixed of stroma-rich component or Ganglioneuroma of stroma-dominant component."
    explanation: >-
      The quoted sentence is the definition in the Ganglioneuroblastoma-Nodular
      row of Table I of this CCG/COG series, which restates the INPC
      definitions used to classify its centrally reviewed cases. A nodular
      tumor is composed of biologically different clones: one or more
      macroscopic, usually hemorrhagic, Schwannian stroma-poor
      neuroblastomatous nodules coexisting with stroma-rich intermixed
      ganglioneuroblastoma or stroma-dominant ganglioneuroma. The nodule is
      itself Schwannian stroma-poor, the stromal category of neuroblastoma, so
      what the definition adds is the coexisting stroma-rich or
      stroma-dominant component. It restates the INPC definition rather than
      reporting a finding of this cohort.
  - reference: PMID:37243318
    reference_title: "Ganglioneuroblastoma intermixed: Clinicopathological implications of diagnosis at presentation and genomic correlations."
    supports: SUPPORT
    directness: DIRECT
    quote_role: PRIMARY_RESULT
    evidence_source: HUMAN_CLINICAL
    snippet: "In patients with stage M disease, GNBI noted at initial biopsy could not be corroborated in 67% samples examined at definitive resection. Thus, the definitive pathological biopsy diagnosis of GNBI in patients with concurrent metastatic disease requires high level of caution."
    explanation: >-
      In this retrospective Memorial Sloan Kettering series of 53 patients with
      intermixed ganglioneuroblastoma (GNBI) at diagnosis, 16 were first
      diagnosed at the center and the rest elsewhere before referral, and every
      included GNBI diagnosis was reviewed and confirmed at the center. All 12
      with INRG stage M disease had GNBI diagnosed on biopsy and received
      neoadjuvant chemotherapy before resection, and the resected tumor showed
      neuroblastoma in 8 and GNBI in 4. The authors therefore urge high caution
      with a biopsy diagnosis of GNBI when metastases are present, and recommend
      a note in the pathology report that the biopsy may not represent the whole
      tumor. The figure rests on 12 patients from one tertiary center, all given
      chemotherapy between biopsy and resection.
  - reference: PMID:37243318
    reference_title: "Ganglioneuroblastoma intermixed: Clinicopathological implications of diagnosis at presentation and genomic correlations."
    supports: SUPPORT
    directness: INDIRECT
    quote_role: PRIMARY_RESULT
    evidence_source: HUMAN_CLINICAL
    snippet: "Of the 12 patients with metastatic disease, all of whom received neoadjuvant chemotherapy, surgery samples revealed GNBI in 4 (33%) and NB in 8 (67%)."
    explanation: >-
      In this retrospective Memorial Sloan Kettering series of patients with
      intermixed ganglioneuroblastoma (GNBI) at diagnosis, all 12 with
      metastatic disease received neoadjuvant chemotherapy, and the resected
      tumor showed neuroblastoma in 8 and GNBI in 4. The quoted sentence does
      not say how they were first diagnosed, but the paper's Table 2 shows that
      all 12 had GNBI diagnosed on biopsy. These are the same 12 patients, from
      one tertiary center, behind the authors' 67% figure and call for caution,
      so the sentence gives the underlying counts rather than independent
      support.
  - reference: PMID:41612478
    reference_title: "Pathology of peripheral neuroblastic tumors."
    supports: SUPPORT
    directness: DIRECT
    quote_role: REVIEW_SYNTHESIS
    evidence_source: OTHER
    snippet: "When tumor samples obtained by PNBC from one anatomic site shows either GNB-i or GN histology and the other anatomic site demonstrates NB histology in the same patient, we should consider (1) GNB-n where NB nodule present in the primary site is not sampled but found in the metastatic site (variant of GNB-n) ... or (2) an extremely rare example of multiple primaries presumably composed of different clones"
    explanation: >-
      This 2026 pathology review discusses percutaneous core needle biopsy and
      how the INPC is applied to it. It advises that when core needle biopsy
      samples from one site show intermixed ganglioneuroblastoma or
      ganglioneuroma histology and another site in the same patient shows
      neuroblastoma, the pathologist should consider two readings. The first is
      a variant of nodular ganglioneuroblastoma: a neuroblastoma nodule in the
      primary tumor was not sampled, and the neuroblastoma is found at the
      metastatic site. The second, extremely rare, is multiple primaries
      presumably composed of different clones. For the first reading the review
      cites its reference for the 2003 modification of the INPC; for the second
      it cites a separate source. 'PNBC' is the review's misspelling of PCNB
      (percutaneous core needle biopsy), the abbreviation it uses elsewhere in
      the same paragraph. The sentence is an interpretive recommendation with
      citations, not case data.
treatments:
- name: Watchful Observation
  description: >-
    For non-metastatic intermixed ganglioneuroblastoma and ganglioneuroma,
    studied together in retrospective series whose abstracts report no outcome
    for observed intermixed tumors on their own, a UK nationwide series
    concluded that watchful active observation can be a safe approach, with
    surgical resection reserved for symptomatic patients, and a single-center
    series that these tumors grow slowly and resection can carry significant
    morbidity, so watch-and-wait approaches should be considered for some
    patients. Observation rests on the biopsy diagnosis, which is not always
    upheld at surgery: in the UK series, 14 cases (12%) diagnosed on biopsy as
    ganglioneuroma or intermixed ganglioneuroblastoma had neuroblastoma or
    nodular ganglioneuroblastoma on surgical pathology, and a small proportion
    of observed patients had their diagnosis revised at surgery.
  action_category: MONITORING
  treatment_term:
    preferred_term: watchful active observation
    term:
      id: NCIT:C25598
      label: Observation Activity
  context: Non-metastatic intermixed ganglioneuroblastoma (evidence pooled with ganglioneuroma)
  notes: >-
    NCIT:C15722 Patient Observation (synonyms include watchful waiting and
    active surveillance) fits the action more closely, but neither of its
    parents, Surveillance (NCIT:C15719) and Healthcare Activity (NCIT:C16205),
    is under NCIT:C25218, so the treatment-action enum rejects it. NCIT:C25598
    Observation Activity (watching something and taking note of what happens)
    reaches NCIT:C25218 only through Diagnostic Procedure (NCIT:C18020). It is
    bound here for the observation step of a monitoring strategy
    (action_category MONITORING), not for a diagnostic test; Acoustic_Neuroma
    and Infantile_Myofibromatosis bind it to their observation rows in the same
    way. NCIT:C61256 Monitoring and NCIT:C53607 Patient Monitoring are also
    outside NCIT:C25218.
  evidence:
  - reference: PMID:39582110
    reference_title: "Management of Ganglioneuroma and Ganglioneuroblastoma Intermixed: A United Kingdom Children's Cancer and Leukaemia Group (UK CCLG) Nationwide Study Report."
    supports: SUPPORT
    directness: DIRECT
    quote_role: PRIMARY_RESULT
    evidence_source: HUMAN_CLINICAL
    snippet: "Watchful active observation can be a safe approach, with surgical resection reserved for symptomatic patients. However, a small proportion of patients in the observation group had their diagnosis revised to malignant at surgery."
    explanation: >-
      This UK CCLG nationwide retrospective review covers 259 patients with
      histologically confirmed non-metastatic ganglioneuroma or intermixed
      ganglioneuroblastoma. It concludes that observation can be safe, with
      resection reserved for symptomatic patients, though a small proportion of
      observed patients had their diagnosis revised at surgery. The abstract
      calls that a revision to malignant, and its background describes both
      tumors as benign variants, whereas ICD-O-3 codes ganglioneuroblastoma as
      malignant (9490/3). The two diagnoses are pooled and survival is not
      reported by management arm, so the safety statement is the authors'
      judgement. Twenty-one of the 58 observed patients (36%) later needed
      surgery, with progressive tumour growth cited as a reason; how many of
      them were reclassified is not stated.
  - reference: PMID:39582110
    reference_title: "Management of Ganglioneuroma and Ganglioneuroblastoma Intermixed: A United Kingdom Children's Cancer and Leukaemia Group (UK CCLG) Nationwide Study Report."
    supports: SUPPORT
    directness: DIRECT
    quote_role: PRIMARY_RESULT
    evidence_source: HUMAN_CLINICAL
    snippet: "In 45 cases (39%), surgical pathology was different from pathology at biopsy, and in 14 (12%) the pathology changed from GN/GNBi to neuroblastoma/GNB nodular."
    explanation: >-
      In this UK CCLG retrospective series of 259 patients with non-metastatic
      ganglioneuroma or intermixed ganglioneuroblastoma, surgical pathology
      differed from the biopsy diagnosis in 45 cases, and in 14 (12%) a biopsy
      diagnosis of ganglioneuroma or intermixed ganglioneuroblastoma became
      neuroblastoma or nodular ganglioneuroblastoma at surgery. The abstract
      gives no denominator for the percentages, does not split the changes by
      biopsy diagnosis or management arm, and does not say whether they reflect
      limited sampling, reinterpretation or change in the tumor before surgery.
  - reference: PMID:29369484
    reference_title: "Characteristics and management of ganglioneuroma and ganglioneuroblastoma-intermixed in children and adolescents."
    supports: SUPPORT
    quote_role: PRIMARY_RESULT
    evidence_source: HUMAN_CLINICAL
    snippet: "GN and GNB-I have a slow growth rate and resection can be associated with significant morbidity. Watch and wait approaches should be considered for some GN and GNB-I."
    explanation: >-
      This single-centre retrospective cohort (Hospital for Sick Children,
      1990-2014) covers 67 patients with ganglioneuroma or intermixed
      ganglioneuroblastoma (17 intermixed), 21 of them observed. Its conclusion
      recommends considering watch-and-wait for some patients, citing slow
      tumour growth and the significant morbidity resection can carry. It
      supports this rationale and recommendation only; metastatic status is not
      stated, and 6 of the 21 observed patients had progressive disease.
      Pathology changed at resection in three cases, but the abstract says only
      that no ganglioneuroma became neuroblastoma, so it does not show the
      revisions to neuroblastoma or nodular ganglioneuroblastoma reported in the
      UK series.
- name: Surgical Resection
  description: >-
    In localized intermixed ganglioneuroblastoma, studied together with
    ganglioneuroma, chemotherapy seemed not to be effective and incomplete
    resection leaving only minor residuals (under 2 cm) appeared sufficient. In
    nodular ganglioneuroblastoma of the unfavorable subset, a CCG/COG series
    found no significant survival difference between complete primary tumor
    resection (at least 95% removed before chemotherapy or irradiation) and
    biopsy or partial resection, in patients with or without distant metastasis.
    The non-significant differences favored complete resection, the non-stage 4
    comparison included few incompletely resected patients, and prognosis
    depended significantly on stage.
  action_category: THERAPEUTIC
  treatment_term:
    preferred_term: surgical resection
    term:
      id: NCIT:C164212
      label: Tumor Resection
  therapeutic_modality: SURGERY
  target_mechanisms:
  - target: Neoplastic Neuroblast Population
    treatment_effect: INHIBITS
    description: >-
      Resection removes all or most of the primary tumor together with its
      neoplastic neuroblasts. In a German series of localized intermixed tumors
      and ganglioneuroma, even incomplete resection leaving minor residuals
      (under 2 cm) appeared sufficient treatment. How resection affects outcome
      in nodular disease is described in this treatment's description.
    evidence:
    - reference: PMID:27465021
      reference_title: "Treatment and outcome of Ganglioneuroma and Ganglioneuroblastoma intermixed."
      supports: SUPPORT
      directness: INDIRECT
      quote_role: PRIMARY_RESULT
      evidence_source: HUMAN_CLINICAL
      snippet: "Outcome was excellent and chemotherapy seems not effective while incomplete resection with minor residuals (<2 cm) appears to be sufficient for treatment."
      explanation: >-
        In this retrospective study of localized ganglioneuroma and intermixed
        ganglioneuroblastoma registered in the German NB97 and NB2004 trials,
        the authors conclude that resection, even when it left residuals under 2
        cm, appears sufficient treatment, while chemotherapy seems not
        effective. This is a treatment outcome, so reading it as resection
        reducing the neoplastic neuroblast population is an inference. No tumor
        progressed after complete resection or with residuals under 2 cm, so
        control did not depend on removing the whole tumor. The sentence pools
        the two tumor types.
    - reference: PMID:27465021
      reference_title: "Treatment and outcome of Ganglioneuroma and Ganglioneuroblastoma intermixed."
      supports: SUPPORT
      directness: INDIRECT
      quote_role: PRIMARY_RESULT
      evidence_source: HUMAN_CLINICAL
      snippet: "However, patients with major residuals (>2 cm) had a worse EFS than patients with complete tumor resection or minor residuals as well for the whole group of mature NT (p < 0.001; Fig. 4a) as for the groups of GN (p = 0.001; Fig. 5a) and GNBI seen individually (p = 0.005; Fig. 6a)."
      explanation: >-
        In the same German series, patients left with residual tumor over 2 cm
        had worse event-free survival than those with complete resection or
        minor residuals, and this held for intermixed ganglioneuroblastoma on
        its own (p = 0.005). More tumor left behind went with more events: all
        five local progressions, two of them in intermixed tumors, arose in
        residuals over 2 cm. That this reflects resection reducing the tumor is
        an inference from outcome, and overall survival was not influenced by
        the extent of initial surgery.
  evidence:
  - reference: PMID:27465021
    reference_title: "Treatment and outcome of Ganglioneuroma and Ganglioneuroblastoma intermixed."
    supports: SUPPORT
    directness: DIRECT
    quote_role: PRIMARY_RESULT
    evidence_source: HUMAN_CLINICAL
    snippet: "Outcome was excellent and chemotherapy seems not effective while incomplete resection with minor residuals (<2 cm) appears to be sufficient for treatment."
    explanation: >-
      This summarises a retrospective study of localized tumours registered in
      the German neuroblastoma trials NB97 and NB2004, including 162
      ganglioneuroma and 55 intermixed ganglioneuroblastoma (GNBI) patients.
      None of the 11 patients given chemotherapy, 9 with GNBI, reached a
      complete or very good partial response. No tumour of either type
      progressed after complete resection or with residuals under 2 cm, whereas
      all five progressions had residuals over 2 cm. Few patients received
      chemotherapy, and the authors allow that single GNBI patients with
      immature regions in large residuals might benefit.
  - reference: PMID:41568977
    reference_title: "Is There a Role for Chemotherapy in Unresectable Ganglioneuroblastoma Intermixed?: A Case Series Analysis."
    supports: SUPPORT
    directness: DIRECT
    quote_role: PRIMARY_RESULT
    evidence_source: HUMAN_CLINICAL
    snippet: "Four patients received chemotherapy but showed no significant tumor reduction postchemotherapy, and all required surgery afterward."
    explanation: >-
      This abstract reports a retrospective single-centre series of 12 patients
      with nonmetastatic intermixed ganglioneuroblastoma at Phoenix Children's
      Hospital. The four patients given chemotherapy showed no significant
      tumour reduction and all still needed surgery, and chemotherapy caused
      febrile neutropenia and an anaphylactic reaction. The title and conclusion
      frame these tumours as unresectable, but the abstract does not say why
      each patient received chemotherapy. With only four treated patients the
      evidence is thin, and it says nothing about how complete a resection must
      be.
  - reference: PMID:19530234
    reference_title: "Clinicopathological characteristics of ganglioneuroma and ganglioneuroblastoma: a report from the CCG and COG."
    supports: SUPPORT
    directness: DIRECT
    quote_role: PRIMARY_RESULT
    evidence_source: HUMAN_CLINICAL
    snippet: "Complete primary tumor resection was not beneficial to those GNB-N-US patients, regardless of whether metastasis was present or not."
    explanation: >-
      In a retrospective CCG/COG cohort, the authors report that complete
      primary resection was not beneficial in nodular unfavourable-subset
      ganglioneuroblastoma (GNB-N-US), with or without distant metastasis. The
      analysis compared complete resection (at least 95% removed before
      chemotherapy or irradiation) with biopsy or partial resection in 226
      patients otherwise treated by risk group. Differences were not significant
      but favoured complete resection (5-year EFS 83.4% vs 60.6%, p = 0.2227,
      non-stage 4, only 16 incompletely resected; 24.3% vs 5.4%, p = 0.1068,
      stage 4), so benefit is not excluded.
  - reference: PMID:19530234
    reference_title: "Clinicopathological characteristics of ganglioneuroma and ganglioneuroblastoma: a report from the CCG and COG."
    supports: SUPPORT
    directness: DIRECT
    quote_role: PRIMARY_RESULT
    evidence_source: HUMAN_CLINICAL
    snippet: "Complete resection: Complete or gross (≥95% of volume) tumor resection was achieved by single or multiple surgeries from the primary site before starting chemotherapy/irradiation therapy. ... the prognosis of patients with GNB-N-US was significantly dependent on clinical stage. ... For non-stage 4 patients, there was no significant difference in survival between patients with complete primary resection (85 cases) and with incomplete primary resection (16 cases), with 5-year EFS of 83.4% ± 9.1% vs. 60.6% ± 26.9% (p = 0.2227) and OS of 90.5% ± 7.2% vs. 80.0% ± 25.3% (p = 0.7176) ... The 5-year EFS for stage 4 patients with completely (74 cases) and incompletely resected (51 cases) primary tumors, respectively, was 24.3% ± 9.5% vs. 5.4% ± 5.2% (p = 0.1068) and OS was 38.5% ± 9.6% vs. 28.2% ± 11.9% (p = 0.5797)"
    explanation: >-
      Table II of this CCG/COG series defines complete resection as removal of
      at least 95% of the primary tumor before chemotherapy or irradiation; the
      comparison group had biopsy or partial resection. In nodular
      unfavorable-subset ganglioneuroblastoma, whose prognosis depended
      significantly on stage, neither event-free nor overall survival differed
      significantly by resection status, but every estimate favored complete
      resection: 5-year EFS 83.4% vs 60.6% in non-stage 4 patients, of whom only
      16 were incompletely resected, and 24.3% vs 5.4% in stage 4 patients (74
      vs 51). Resection after chemotherapy was not analysed, so the comparison
      does not address delayed surgery, and a benefit of complete resection is
      not excluded.
- name: Risk-Adapted Chemotherapy-Based Therapy
  description: >-
    Patients are treated by neuroblastoma risk group. In Children's Cancer Group
    and Children's Oncology Group studies that registered patients from 1991 to
    2006, low-risk patients had surgery alone, intermediate-risk patients
    moderate chemotherapy with surgery, and high-risk patients intensive
    chemotherapy, surgery, radiotherapy and often myeloablative therapy. In one
    referral series of intermixed ganglioneuroblastoma diagnosed at presentation
    (1995-2021), the 12 patients presenting with metastases, all diagnosed on
    biopsy, were treated as high-risk neuroblastoma with high-dose chemotherapy,
    radiotherapy and anti-GD2 monoclonal antibody immunotherapy. Of the 41 with
    locoregional disease, 11 received intermediate-risk neoadjuvant chemotherapy
    and 30 no cytotoxic therapy, and all 41 remained progression-free at a
    median follow-up of 4 years; in localized intermixed tumors chemotherapy has
    seemed ineffective (see Surgical Resection). Patients with nodular
    ganglioneuroblastoma older than 18 months with stage 4 disease form a
    high-risk subgroup that should be considered for aggressive upfront
    treatment.
  action_category: THERAPEUTIC
  treatment_term:
    preferred_term: risk-adapted chemotherapy within neuroblastoma risk-group protocols
    term:
      id: NCIT:C15632
      label: Chemotherapy
  context: Ganglioneuroblastoma assigned to a neuroblastoma risk group, notably high-risk nodular disease
  notes: >-
    Bound to Chemotherapy, the component shared by the intermediate- and
    high-risk arms; the high-risk arm also includes surgery, radiotherapy,
    myeloablative therapy and, in the referral series, anti-GD2 immunotherapy,
    so the binding is narrower than the protocols this row describes. No
    therapeutic_agent is recorded, because no cited source names a regimen or
    antibody for ganglioneuroblastoma.
  evidence:
  - reference: PMID:19530234
    reference_title: "Clinicopathological characteristics of ganglioneuroma and ganglioneuroblastoma: a report from the CCG and COG."
    supports: SUPPORT
    directness: DIRECT
    evidence_source: HUMAN_CLINICAL
    snippet: "Among a total of 3,953 patients registered in CCG and COG neuroblastoma studies from August 1, 1991 to December 31, 2006, there were 552 cases whose diagnosis was either GN or GNB. ... Patients were treated by risk group: low-risk patients had surgery alone; intermediate-risk patients had a moderate chemotherapy treatment in addition to surgery; and high-risk patients had intensive chemotherapy, surgery, radiotherapy, and in many cases, myeloablative therapy."
    explanation: >-
      The Methods of this CCG/COG series of 552 ganglioneuroma and
      ganglioneuroblastoma cases, registered on neuroblastoma studies from
      August 1991 to December 2006, state how the patients were treated: by
      neuroblastoma risk group, with surgery alone for low risk, moderate
      chemotherapy with surgery for intermediate risk, and intensive
      chemotherapy, surgery, radiotherapy and often myeloablative therapy for
      high risk. These are the regimens of that period. It describes the
      protocols applied, not a comparison of treatments, and about 60% of the
      patients (329 of 552) were enrolled on therapeutic studies.
  - reference: PMID:22137163
    reference_title: "Characteristics and outcome of patients with ganglioneuroblastoma, nodular subtype: a report from the INRG project."
    supports: SUPPORT
    directness: DIRECT
    quote_role: PRIMARY_RESULT
    evidence_source: HUMAN_CLINICAL
    snippet: "Similar to the overall NB cohort, patients with GNBn older than 18 months of age, with stage 4 disease represent a high-risk sub-group and should be considered for aggressive treatment upfront."
    explanation: >-
      In an analysis of the INRG database, Angelini and colleagues identified
      232 patients with nodular ganglioneuroblastoma among 4071 with a known
      INPC category. They conclude that, as in neuroblastoma overall, those
      older than 18 months with stage 4 disease are a high-risk subgroup who
      should be considered for aggressive upfront treatment. The recommendation
      follows from survival outcomes, not a comparison of treatments, and names
      no specific regimen. The abstract reports overall survival for all stage 4
      patients (35%, n=107), not separately for those over 18 months.
  - reference: PMID:37243318
    reference_title: "Ganglioneuroblastoma intermixed: Clinicopathological implications of diagnosis at presentation and genomic correlations."
    supports: SUPPORT
    directness: DIRECT
    quote_role: PRIMARY_RESULT
    evidence_source: HUMAN_CLINICAL
    snippet: "All patients with metastatic disease were diagnosed at >18 months of age, were deemed to have high-risk NB, and were treated with multimodality therapy including high-dose chemotherapy, radiotherapy and anti-GD2 monoclonal antibody-mediated immunotherapy."
    explanation: >-
      In this retrospective Memorial Sloan Kettering series of intermixed
      ganglioneuroblastoma diagnosed at presentation (1995-2021), all 12
      patients with metastatic disease were older than 18 months, were treated
      as high-risk neuroblastoma, and received multimodality therapy including
      high-dose chemotherapy, radiotherapy and anti-GD2 monoclonal antibody
      immunotherapy. Table 2 shows that all 12 were diagnosed on biopsy, and 8
      of their 12 resections, after chemotherapy, showed neuroblastoma. The
      paper names no antibody and gives no treatment dates; it reports one
      center's practice, not a comparison of treatments.
  - reference: PMID:37243318
    reference_title: "Ganglioneuroblastoma intermixed: Clinicopathological implications of diagnosis at presentation and genomic correlations."
    supports: SUPPORT
    directness: DIRECT
    quote_role: PRIMARY_RESULT
    evidence_source: HUMAN_CLINICAL
    snippet: "Of the 41 patients with locoregional disease, 30 received no cytotoxic therapy and 11 received intermediate-risk neoadjuvant chemotherapy. All 41 remain alive progression-free at a median follow up of 4 years."
    explanation: >-
      In the same series, 11 of the 41 patients with locoregional intermixed
      ganglioneuroblastoma at diagnosis received intermediate-risk neoadjuvant
      chemotherapy and 30 received no cytotoxic therapy, and all 41 were alive
      and progression-free at a median follow-up of 4 years. This shows that
      some locoregional intermixed tumors are treated as intermediate risk. It
      is not a comparison of treatments, the paper reports no tumor response to
      chemotherapy, and the authors conclude that localized intermixed tumors do
      well even without cytotoxic therapy.
datasets:
- accession: geo:GSE7529
  title: Two distinct gene signatures identify malignant Neuroblast and Schwannian stromal cells of Neuroblastic Tumors
  description: >-
    Affymetrix microarray profiles of 19 whole neuroblastic tumours: 10 neuroblastomas,
    3 ganglioneuroblastomas (two of them intermixed), 5 ganglioneuromas and one
    borderline maturing ganglioneuroma. Laser-microdissected areas from four of the
    tumours, one of them a ganglioneuroblastoma, separate the neuroblastic cells from
    the Schwannian stromal cells that a ganglioneuroblastoma mixes.
  organism:
    preferred_term: human
    term:
      id: NCBITaxon:9606
      label: Homo sapiens
  data_type: MICROARRAY
  publication: PMID:18671248
  notes: >-
    The tumour counts are from the GEO sample titles; the GEO summary gives only 10
    stroma-poor and 9 stroma-rich tumours.
discussions:
- discussion_id: gnb_schwannian_stroma_origin
  prompt: >-
    Is the Schwannian stroma of ganglioneuroblastoma a non-neoplastic host
    population recruited by the neoplastic neuroblasts, or is it derived from
    the neoplastic clone?
  kind: CONTROVERSY
  status: OPEN
  attaches_to:
  - pathophysiology#Schwannian Stromal Development
  rationale: >-
    Evidence items use this convention: SUPPORT means the stroma is a
    non-neoplastic, recruited population; REFUTE means it derives from the
    neoplastic clone. For the non-neoplastic view, a 1996 study of maturing
    neuroblastomas found normal chromosome numbers in Schwann cells but abnormal
    numbers in neuroblastic and ganglionic cells, and an 8-case study of nodular
    ganglioneuroblastoma found the neuroblasts' MYCN gain in ganglion cells but
    not in Schwann cells. For the neoplastic view, a 2001 study of
    neuroblastomas found the same DNA content and GD2 staining in stromal and
    neuroblastic cells by laser-scanning cytometry in 20 tumors, and the same
    chromosomal makeup by fluorescence in situ hybridization in 7, and concluded
    that both derive from genetically identical neoplastic cells. A 2009
    cooperative-group paper describes the reports as controversial. The answer
    decides whether ploidy and copy-number results from stroma-rich tumors
    describe the tumor cells, and whether maturation is an interaction between
    tumor and host cells.
  posed_date: '2026-10-21T00:00:00Z'
  evidence:
  - reference: PMID:8618605
    reference_title: "Role of ploidy, chromosome 1p, and Schwann cells in the maturation of neuroblastoma."
    supports: SUPPORT
    directness: DIRECT
    quote_role: PRIMARY_RESULT
    evidence_source: HUMAN_CLINICAL
    snippet: "The normal number of chromosomes in Schwann cells and the abnormal number in neuroblastic ganglionic cells suggests that Schwann cells are a reactive population of normal cells that invade the neuroblastoma."
    explanation: >-
      In 20 maturing and mature neuroblastomas, chromosome counts by in situ
      hybridization found normal numbers in Schwann cells but abnormal numbers
      in neuroblastic and ganglionic cells. From this contrast the authors
      suggest that the Schwann cells are a reactive population of normal cells
      that invade the tumor, which supports the view that the stroma is a
      non-neoplastic host population. The evidence is chromosome number alone,
      which by itself cannot exclude a shared clonal origin, and the abstract
      does not say which tumors would now be classed as ganglioneuroblastoma.
  - reference: PMID:25081755
    reference_title: "The neuroblastoma and ganglion components of nodular ganglioneuroblastoma are genetically similar: evidence against separate clonal origins."
    supports: SUPPORT
    directness: DIRECT
    quote_role: PRIMARY_RESULT
    evidence_source: HUMAN_CLINICAL
    snippet: "In contrast, the Schwann cells have a different origin and may be derived from a non-neoplastic neural crest precursor."
    explanation: >-
      Supports the position that the Schwannian stroma is non-neoplastic rather
      than derived from the neoplastic clone. In eight nodular
      ganglioneuroblastomas studied by SNP array and in situ hybridization, the
      authors conclude that the Schwann cells, unlike the genetically related
      neuroblasts and ganglion cells, have a different origin, possibly a
      non-neoplastic neural crest precursor. Limitations: the Schwann cell
      result rests on in situ hybridization, because the arrays used DNA from
      whole neuroblastomatous and ganglioneuromatous areas, and the precursor
      origin is proposed, not traced.
  - reference: PMID:25081755
    reference_title: "The neuroblastoma and ganglion components of nodular ganglioneuroblastoma are genetically similar: evidence against separate clonal origins."
    supports: SUPPORT
    directness: INDIRECT
    quote_role: PRIMARY_RESULT
    evidence_source: HUMAN_CLINICAL
    snippet: "By in situ hybridization, MYCN gain (4-10 gene copies/nucleus) was detected in 7/8 neuroblastoma samples. In ganglioneuromatous regions, gains were also detected in ganglion cells but not in Schwann cells."
    explanation: >-
      Supports the non-neoplastic position with the observation behind it. In
      this series of eight nodular ganglioneuroblastomas, in situ hybridization
      found MYCN gain in the neuroblastoma component of seven, and in
      ganglioneuromatous regions in ganglion cells but not in Schwann cells. The
      paper reports this as a gain of 4 to 10 copies per nucleus, not as
      amplification. Limitations: the series is small, and lacking the gain does
      not by itself show that Schwann cells arise outside the neoplastic clone,
      the point in dispute.
  - reference: PMID:11559566
    reference_title: "Neuroblastic and Schwannian stromal cells of neuroblastoma are derived from a tumoral progenitor cell."
    supports: REFUTE
    directness: INDIRECT
    quote_role: PRIMARY_RESULT
    evidence_source: HUMAN_CLINICAL
    snippet: "In all 20 cases studied by Laser-Scanning Cytometry, SS cells identified by morphology and S-100 immunostaining had identical DNA content and GD2-staining pattern as their neuroblastic counterparts. In 7 cases, fluorescence in situ hybridization demonstrated the same chromosomal makeup for SS and neuroblastic cells. These results provide unequivocal evidence that neuroblastic and SS cells in NB are derived from genetically identical neoplastic cells and support the classical paradigm that NB arises from tumoral cells capable of development along multiple lineages."
    explanation: >-
      Laser-scanning cytometry of neuroblastoma touch imprints showed Schwannian
      stromal cells, identified by morphology and S-100 staining, with the same
      DNA content and GD2 staining as the neuroblastic cells in all 20 cases. In
      7 of the cases, bicolor fluorescence in situ hybridization on touch
      imprints from manually microdissected neuroblast and stroma-rich areas
      showed the same chromosomal makeup in the two populations. From their
      combined results, the authors concluded that both cell types derive from
      genetically identical neoplastic cells, supporting derivation of the
      stroma from the neoplastic clone rather than recruitment of non-neoplastic
      cells. The abstract gives no INPC category for the tumours, so applying
      this to ganglioneuroblastoma assumes the stroma has the same origin in
      both tumour types.
  - reference: PMID:19530234
    reference_title: "Clinicopathological characteristics of ganglioneuroma and ganglioneuroblastoma: a report from the CCG and COG."
    supports: SUPPORT
    directness: DIRECT
    quote_role: BACKGROUND
    evidence_source: HUMAN_CLINICAL
    snippet: "Though there have been controversial reports on cellular origin of Schwannian stromal cells (28) (29), Ambros et al. report that Schwannian cells in GN-M and GNB-I are not neoplastic and do not share the same cellular origin of neural crest with neuroblastic cells, but they are normal diploid cells recruited by biologically favorable hyperdiploid neuroblastic cells."
    explanation: >-
      In a Children's Cancer Group/Children's Oncology Group clinicopathological
      study of ganglioneuroma and ganglioneuroblastoma, the authors note
      controversial reports on the cellular origin of Schwannian stromal cells,
      then restate Ambros et al.'s report that, in ganglioneuroma-maturing and
      intermixed ganglioneuroblastoma, these cells are not neoplastic but normal
      diploid cells recruited by biologically favourable hyperdiploid
      neuroblastic cells. The sentence records the disagreement and supports the
      non-neoplastic, recruited-stroma position. It restates another group's
      work without new data, and states this only for those two categories, not
      for nodular ganglioneuroblastoma.
- discussion_id: gnb_nodule_clonality
  prompt: >-
    Is the neuroblastomatous nodule of nodular ganglioneuroblastoma a clone
    genetically distinct from the rest of the tumor, or a part of a single
    neoplastic clone that differs from the rest only in being less
    differentiated?
  kind: CONTROVERSY
  status: OPEN
  attaches_to:
  - pathophysiology#Schwannian Stroma-Poor Neuroblastomatous Nodule
  - has_subtypes#Nodular
  rationale: >-
    Evidence items use this convention: SUPPORT means the nodule is clonally
    distinct (a multiclonal tumor), that is, a genetically distinct clone,
    whether it arose independently or as a subclone of a common ancestor; REFUTE
    means the nodule's neuroblasts and the ganglion cells of the
    ganglioneuromatous component belong to one clone and differ only in
    differentiation. A 2026 pathology review of the INPC describes nodular
    tumors as multi-clonal, and a 1993 single-case study found that the more
    differentiated portion and the neuroblastic foci of one composite
    ganglioneuroblastoma differed in DNA content and MYCN copy number. An 8-case
    genetic study found the nodule neuroblasts and the ganglion cells
    genetically related and concluded that the behavior of nodular tumors cannot
    be explained by separate clones with distinct genetic signatures; that
    argues against independent clonal origins but does not exclude a subclone
    that evolved from a common ancestor.
  posed_date: '2026-10-21T00:00:00Z'
  evidence:
  - reference: PMID:41612478
    reference_title: "Pathology of peripheral neuroblastic tumors."
    supports: SUPPORT
    directness: DIRECT
    quote_role: REVIEW_SYNTHESIS
    evidence_source: OTHER
    snippet: "Tumors in this category are considered as multi-clonal tumors. In gross appearance, the NB component often forms hemorrhagic and necrotic nodule(s) in a background of elastic and yellowish white component of GNB-i or GN"
    explanation: >-
      In its account of the INPC categories, this 2026 pathology review states
      that tumours in 'this category' are considered multi-clonal, and that the
      neuroblastoma component often forms haemorrhagic, necrotic nodules within
      a ganglioneuroblastoma-intermixed or ganglioneuroma background, which
      identifies the category as nodular ganglioneuroblastoma. It therefore
      supports the multiclonal (clonally distinct nodule) position. It is an
      expert classification statement with no clonality data, so it records how
      these tumours are classified rather than showing that the nodule is a
      separate clone.
  - reference: PMID:8108298
    reference_title: "Evidence for molecular heterogeneity in human ganglioneuroblastoma."
    supports: SUPPORT
    directness: DIRECT
    quote_role: PRIMARY_RESULT
    evidence_source: HUMAN_CLINICAL
    snippet: "We analyzed a composite ganglioneuroblastoma for N-myc copy number at initial resection and 2 years later after progressive disease. In the second sample the more differentiated portion of the tumor was analyzed separately from the neuroblastic foci for N-myc copy number and DNA ploidy. The DNA content and N-myc copy number differed in the two morphologically discrete areas of the tumor, suggesting that at least two clones were present."
    explanation: >-
      This case report analysed one composite ganglioneuroblastoma (the older
      name for the nodular subtype) at initial resection and again 2 years
      later, after progressive disease. In the second sample, the more
      differentiated portion and the neuroblastic foci differed in DNA content
      and N-myc (MYCN) copy number, which the authors read as at least two
      clones, supporting the clonally distinct position. It is one case, and the
      abstract does not say whether stromal cells were separated from tumour
      cells, so the two clones are an inference from two tissue portions. The
      abstract reports the separate analysis of the two areas only for the
      sample taken after progression, so it does not show whether they already
      differed at initial resection.
  - reference: PMID:25081755
    reference_title: "The neuroblastoma and ganglion components of nodular ganglioneuroblastoma are genetically similar: evidence against separate clonal origins."
    supports: REFUTE
    directness: DIRECT
    quote_role: PRIMARY_RESULT
    evidence_source: HUMAN_CLINICAL
    snippet: "Our results suggest that the clinical behavior of nodular ganglioneuroblastoma cannot be explained by the presence of separate clones with distinct genetic signatures."
    explanation: >-
      Analysing eight nodular ganglioneuroblastomas by SNP array and in situ
      hybridization, with DNA extracted separately from neuroblastomatous and
      ganglioneuromatous areas, the authors suggest that the clinical behaviour
      of nodular ganglioneuroblastoma cannot be explained by separate clones
      with distinct genetic signatures. This favours the single-clone position,
      arguing against independent clonal origins for the neuroblastoma nodule
      and the ganglion cells of the ganglioneuromatous component. It neither
      covers the Schwann cells, which the same abstract assigns a different
      origin, nor excludes a nodule subclone diverging from a common ancestor;
      the series is small.
- discussion_id: gnb_tmm_prognostic_significance
  prompt: >-
    Does telomere maintenance mechanism status predict outcome in
    ganglioneuroblastoma, as it does in high-risk neuroblastoma?
  kind: KNOWLEDGE_GAP
  status: OPEN
  attaches_to:
  - pathophysiology#Telomere Maintenance Mechanism Activation
  rationale: >-
    The series that established telomere maintenance in ganglioneuroblastoma
    says its clinical significance there is not yet assessable, because the
    cohort needs several more years of follow-up. This matters for how the
    pathophysiology node is read. In high-risk neuroblastoma, telomere
    maintenance is a poor-prognostic marker and is proposed for the next
    International Neuroblastoma Risk Group classification, so the temptation is
    to carry that prognostic meaning across to ganglioneuroblastoma on the
    strength of the shared mechanism and the nodular subtype's comparable
    positive rate. Nothing in the ganglioneuroblastoma data supports that step
    yet. This gap is why the node has no edge to an outcome or risk node, and
    why one should not be added from neuroblastoma evidence.
  posed_date: '2026-10-28T00:00:00Z'
  evidence:
  - reference: PMID:41858373
    reference_title: "Telomere maintenance mechanisms are activated in ganglioneuroblastoma and ganglioneuroma."
    supports: SUPPORT
    directness: DIRECT
    quote_role: PRIMARY_RESULT
    evidence_source: HUMAN_CLINICAL
    snippet: "a solid evaluation of the clinical significance of TMM status in GN and GNB will require several additional years of long-term follow-up."
    explanation: >-
      The authors state the gap themselves, in their discussion, about their own
      cohort. It is what makes this an absence of evidence rather than a
      negative result: they do not report that telomere maintenance fails to
      predict outcome in ganglioneuroblastoma, only that their follow-up is too
      short to say.
disease_term:
  preferred_term: ganglioneuroblastoma
  term:
    id: MONDO:0005035
    label: ganglioneuroblastoma
classifications:
  icdo_morphology:
    classification_value: Embryonal Neoplasm
  harrisons_chapter:
  - classification_value: ONCOLOGY_HEMATOLOGY
mappings:
  mondo_mappings:
  - term:
      id: MONDO:0005035
      label: ganglioneuroblastoma
    mapping_predicate: skos:exactMatch
    mapping_source: MONDO
    mapping_justification: >-
      Primary MONDO identifier for this entry. MONDO defines the class by
      neuroblastic cells, ganglion cells and a Schwannian stroma making up more
      than half of the tumor volume, and records NCIT:C3790 and Orphanet:251877
      as exact matches. The Schwannian stroma criterion matches this entry's
      peripheral scope; the over-half threshold corresponds to the INPC
      intermixed category, and the INPC sets no such threshold for the nodular
      category, which this entry also covers.
  ncit_mappings:
  - term:
      id: NCIT:C3790
      label: Ganglioneuroblastoma
    mapping_predicate: skos:exactMatch
    mapping_source: NCIT
    mapping_justification: >-
      NCIT concept that MONDO records as an exact match of MONDO:0005035. NCIT
      also files Central Nervous System Ganglioneuroblastoma (NCIT:C92629)
      beneath it, which this entry does not cover. C3790 is used rather than the
      narrower Peripheral Ganglioneuroblastoma (NCIT:C6594) because NCIT files
      the intermixed and nodular classes (NCIT:C42057, NCIT:C42058) under C3790,
      while C6594 holds only the adrenal and mediastinal site classes.

📚

References & Deep Research

Deep Research

Deep research results are used as seeds for research; they do not undergo the same validation as the main records and may contain errors. How we use deep research.

Evaluations and curation notes (1)

Create: Ganglioneuroblastoma (intermixed and nodular subtypes) · 2026-10-21T19:15:16Z · View source

New entry for ganglioneuroblastoma (MONDO:0005035; NCIT:C3790 exact match), the peripheral neuroblastic tumour between neuroblastoma and ganglioneuroma, covering both INPC categories as has_subtypes: Intermixed (MONDO:0003326; NCIT:C42057) and Nodular (MONDO:0003325; NCIT:C42058). Scope: MONDO and NCIT define the class by a Schwannian stroma making up more than half of the tumour volume, which the INPC applies only to the intermixed category; the description and the MONDO mapping justification say so. Central nervous system ganglioneuroblastoma (NCIT:C92629) and Hirschsprung disease-ganglioneuroblastoma syndrome (MONDO:0013082) are out of scope. Content: INPC definitions of both categories, with the rule that the favourable/unfavourable grouping is made on tissue taken before chemotherapy or irradiation (both histopathology findings, NCIT:C42062 and NCIT:C42066); a diagnosis row (NCIT:C18190 Histopathologic Examination) for the whole-tumour ideal and the limited-material reporting practice; biopsy-resection concordance in localized intermixed tumours; the nodular favourable/unfavourable criteria, their origin (Umehara 2000, confirmed by the INPC committee in 2003), the metastatic-site variant, and INRG and CCG/COG outcomes; subtype outcomes. Four pathophysiology nodes (neoplastic neuroblasts; maturation into ganglion cells; Schwannian stromal development; the stroma-poor nodule) with evidenced edges, including in vitro Schwann cell and neuroblast crosstalk (conditioned medium, EGFL8, PEDF). Phenotypes: abdominal and posterior mediastinal mass, distant metastasis at diagnosis (nodular; HP:0002664 with NO_HPO_TERM and a term gap), congenital Horner syndrome (Orphanet), elevated urinary HVA and VMA in intermixed tumours (German NB97/NB2004, Table 1). Biochemical: NSE and serum ferritin (He 2017). Genetic: MYCN amplification as a rare somatic biomarker, with the single-centre 14% nodular figure explained as one amplified tumour. Treatments: watchful observation, tumour resection, risk-adapted chemotherapy within neuroblastoma risk-group protocols. Discussions: two CONTROVERSY items, the origin of the Schwannian stroma and the clonality of the nodule, each with a stated SUPPORT/REFUTE convention. Not included, on purpose: the ALK germline row Orphanet lists, because how a tumour entry links to a separate predisposition disease (MONDO:0013083) is the open question in #14976; the entry notes say so. No stages: block and no invasion_and_metastasis conformance: ganglioneuroblastoma is staged with the neuroblastoma INSS/INRGSS systems, whose stage definitions are in Neuroblastoma.yaml, and no node here describes dissemination. MIBG uptake, intraspinal extension, stridor, superior vena cava syndrome, VIP-related diarrhoea, hypertension and opsoclonus-myoclonus are left for a later clinical-features pass. Sources: a claude_code deep-research report (research/Ganglioneuroblastoma-deep-research-claude_code.md) used as leads; every evidence item quotes the cached abstract or full text. Cooperative-group overlaps (Umehara, Peuchmaur and Okamatsu; INRG with COG) are stated in the explanations. Before the PR, a four-lens pre-review with two adversarial verifiers per finding upheld 28 of 36 findings (23 by both verifiers); their fixes were applied, except the ALK row described above. Validation: just validate, validate-terms, count-verified-snippets (83/83), validate-disorders (83 snippets, 83 titles, 0 issues), prose-figure audit with no unsupported figure, and the whole-KB offline gates. 83 evidence items from 23 references.

Claude Code ▸

Ganglioneuroblastoma (MONDO:0005035) — Comprehensive Disease Characteristics Research Report

claude-haiku-4-5-20251001, claude-opus-5[1m] 79 citations 2026-10-21T15:08:14.581940

Ganglioneuroblastoma (MONDO:0005035) — Comprehensive Disease Characteristics Research Report

Prepared: 21 October 2026 Scope: Literature and ontology survey for knowledge-base population Evidence-scope caveat (read first): Ganglioneuroblastoma (GNB) is not an independently studied disease in most of the primary literature. It is one of four categories in a single nosological family — the peripheral neuroblastic tumours (pNTs) — and the overwhelming majority of mechanistic, genomic and therapeutic evidence is generated on neuroblastoma cohorts in which GNB cases are either pooled or excluded. Throughout this report, claims are labelled [GNB-specific] where the cited study separately analysed GNB, and [pNT-wide / extrapolated] where the evidence is from neuroblastoma and is applied to GNB by family membership. This distinction matters a great deal for a mechanism knowledge base: the two GNB subtypes sit at opposite ends of the clinical spectrum (one is a benign-behaving tumour managed by observation, the other is risk-stratified and treated exactly like neuroblastoma), and lumping them produces statements that are false of both.

1. Disease Information

1.1 Overview

Ganglioneuroblastoma is a neuroblastic tumour of the developing sympathetic nervous system occupying the middle of a maturational spectrum that runs from undifferentiated neuroblastoma (malignant, Schwannian stroma-poor) through to ganglioneuroma (benign, Schwannian stroma-dominant). It is defined histologically, not clinically or genetically: the diagnosis requires neuroblastic cells, ganglion cells, and Schwannian stroma, with the stromal component exceeding 50% of tumour volume.

MONDO's definition (verified via EBI OLS4, MONDO:0005035):

"A neuroblastic tumor characterized by the presence of neuroblastic cells, ganglion cells, and a stroma with Schwannian differentiation constituting more than fifty-percent of the tumor volume."

The single most important fact about this entry is that "ganglioneuroblastoma" names two biologically and clinically distinct entities, and the WHO 5th-edition classification keeps them separate rather than as subtypes of one thing:

Entity	ICD-O-3.2	Schwannian stroma	Behaviour
Ganglioneuroma	9490/0	Stroma-dominant	Benign
Ganglioneuroblastoma, intermixed (GNBi)	9490/3	Stroma-rich	Favourable histology at any age
Neuroblastoma	9500/3	Stroma-poor	Age/MKI/grade-dependent
Ganglioneuroblastoma, nodular (GNBn) (and other composite neuroblastic tumours)	9490/3	Composite: stroma-rich/dominant + stroma-poor	Graded by the highest-grade nodule; can be fully malignant

Source: WHO Classification of Tumours Editorial Board (2023), Paediatric Tumours, WHO Classification of Tumours 5th edition, Volume 7, IARC, Lyon — reproduced in Table 1 of the ICCR Neuroblastoma Histopathology Reporting Guide, 1st ed. v1.0, November 2023 (ISBN 978-1-922324-39-9), https://www.iccr-cancer.org/wp-content/uploads/2023/11/ICCR-Neuroblastoma-1st-ed-v1.0-bookmark.pdf

Verbatim definitions from the ICCR dataset (Note 7, Histological tumour type):

Ganglioneuroblastoma, intermixed (Schwannian stroma-rich) category — "Tumours in this category are characterised by the presence of a ganglioneuromatous component with Schwannian stromal development (see below) exceeding 50% of the tissue, where microscopic nests of neuroblastoma are present in an intermixed or randomly distributed pattern. In those microscopic nests, the tumour cells are in various stages of differentiation (often predominantly differentiating neuroblasts) with clearly identifiable naked neuritic processes (neuropile, not covered by Schwann cells) around their cytoplasm. Grossly visible haemorrhagic/necrotic nodules suggestive of aggressive neuroblastomatous growth are absent. Tumours in this category are histologically one step behind the final stage of complete maturation towards ganglioneuroma."

Ganglioneuroblastoma, nodular (composite, Schwannian stroma-rich/stroma-dominant and stroma-poor) category — "Tumours in this category are composed of multiple clones demonstrating distinct histologies: one or more Neuroblastoma (Schwannian stroma-poor) nodules set within a background of either Ganglioneuroblastoma, intermixed (Schwannian stroma-rich) or Ganglioneuroma (Schwannian stroma-dominant). The neuroblastoma nodules are usually grossly identifiable and often haemorrhagic/necrotic and fragile. In contrast, the Ganglioneuroblastoma, Intermixed/Ganglioneuroma component is tan-yellow and solid/elastic."

1.2 Key identifiers

Verified against EBI OLS4 (MONDO term record, 21 Oct 2026):

Resource	Identifier
MONDO	MONDO:0005035 (ganglioneuroblastoma)
NCI Thesaurus	NCIT:C3790
HPO	HP:0006747 (Ganglioneuroblastoma)
Orphanet	ORPHA:251877
MeSH	D018305
UMLS	C0206718
Disease Ontology	DOID:4163
EFO	EFO:0000502
GARD	GARD:0020719
MedGen	60218
MedDRA	10017708
SNOMED CT	116381000119105
ICD-O-3	9490/3
ICD-9	171.9
OncoTree	GNBL
NANDO	NANDO:2200041
birnlex	birnlex:12633

Subtype and site-specific ontology terms (all verified via OLS4):

Concept	MONDO	NCIT
Intermixed (Schwannian stroma-rich) GNB	MONDO:0003326	NCIT:C42057
Nodular GNB	MONDO:0003325	NCIT:C124274 (childhood)
Schwannian stroma-rich + stroma-poor composite	MONDO:0004408	—
Stroma-dominant + stroma-poor composite	MONDO:0004407	—
Adrenal gland GNB	MONDO:0004477	NCIT:C7646
Mediastinal GNB	MONDO:0001096	NCIT:C6627
Peripheral GNB	MONDO:0003327	NCIT:C6594
CNS GNB	—	NCIT:C92629
Recurrent GNB	—	NCIT:C173531

Not verified in this session (flagged for lookup before binding): the ICD-11 morphology code reported by aggregator sources as XH77W7 (ICD-11 Foundation 1916269207) was obtained from MalaCards/Wikidata-derived search summaries rather than from the WHO ICD-11 browser directly. Do not bind it without checking the ICD-11 MMS browser.

A curation note: NCIT:C92629 (Central Nervous System Ganglioneuroblastoma) and NCIT:C124272 name a different tumour — a CNS neuroepithelial neoplasm — that shares the word "ganglioneuroblastoma" but is not a peripheral neuroblastic tumour. Binding it into a pNT entry would be a Named Entity Confusion of exactly the kind this knowledge base's reference SOP warns about. Olfactory/esthesioneuroblastoma-associated "olfactory ganglioneuroblastoma" is likewise a separate entity.

1.3 Synonyms

From MONDO: ganglioneuroblastoma (disease), ganglioneuroblastoma, malignant, ganglioneuroblastoma (morphologic abnormality). In the literature: GNB, GNBi / GNB-I (intermixed), GNBn / GNB-N (nodular), composite ganglioneuroblastoma, stroma-rich neuroblastoma (historical, pre-INPC). The umbrella family term is peripheral neuroblastic tumour (pNT); "neuroblastoma" is widely used generically for the whole family, which is a recurring source of data-extraction error.

1.4 Source of information

Predominantly aggregated disease-level resources: histopathology reference series (INPC committee reviews), international cooperative-group registries (INRG Data Commons, COG ANBL00B1 biology study), and population cancer registries (SEER). Individual-patient EHR-derived data are essentially absent from the GNB literature; the SEER-derived analyses are registry abstractions, not EHR phenotyping. A large fraction of the GNB-specific literature consists of single case reports and small institutional case series, which should be weighted accordingly.

2. Etiology

2.1 Disease causal factors

GNB is a sporadic somatic neoplasm of embryonic origin in the overwhelming majority of cases. There is no established environmental or infectious cause, and no single necessary-and-sufficient genetic lesion. The accepted model is that pNTs arise from failure of developmentally programmed differentiation and/or death of sympathoadrenal progenitors derived from the neural crest, with the degree of residual differentiation capacity determining where on the neuroblastoma → GNB → ganglioneuroma spectrum a tumour lands.

"Neuroblastoma (NB), a heterogenous pediatric tumor of the sympathetic nervous system, is the most common and deadly extracranial solid malignancy diagnosed in infants." — Sainero-Alcolado L, Sjöberg Bexelius T, Santopolo G, et al. Defining neuroblastoma: From origin to precision medicine. Neuro Oncol. 2024. PMID: 39101440

2.2 Genetic risk factors

Germline predisposition is rare and is shared with neuroblastoma rather than specific to GNB. The authoritative recent statement is the 2023 AACR Childhood Cancer Predisposition Workshop update:

"Genetic predisposition to neuroblastoma (NB) is relatively rare. Only 1% to 2% of patients have a family history of NB, 3% to 4% of cases present with bilateral or multifocal primary tumors, and occasional patients have syndromes that are associated with increased NB risk. Previously, a germline pathogenic variant (GPV) in PHOX2B was associated with Hirschsprung disease and congenital central hypoventilation syndrome. Recently, certain GPVs were shown to be responsible for congenital central hypoventilation syndrome and NB predisposition. Also, several groups determined that activating GPVs in ALK accounted for a substantial number of familial NB." — Kamihara J, Diller LR, Foulkes WD, et al. Neuroblastoma Predisposition and Surveillance—An Update from the 2023 AACR Childhood Cancer Predisposition Workshop. Clin Cancer Res. 2024;30(15):3137. PMID: 38860978; DOI: 10.1158/1078-0432.CCR-24-0237

The ICCR dataset states the same figure and names the broader syndrome set:

"An inherited predisposition to neuroblastoma has been estimated in 1-2% of patients with newly diagnosed neuroblastic tumours... The genes most commonly altered in inherited neuroblastoma are ALK and PHOX2B. Other cancer predisposition syndromes (CPS) that may include neuroblastic tumours are RASopathy syndromes, Beckwith-Wiedemann syndrome, Li-Fraumeni syndrome and DNA repair disorders." (ICCR Note 1)

Gene	HGNC	Role	Key evidence
ALK	hgnc:427	Major familial NB gene; activating germline missense in tyrosine kinase domain (R1275Q, F1174L, R1192P, G1128A); autosomal dominant, incomplete penetrance	Mossé YP, et al. Identification of ALK as a major familial neuroblastoma predisposition gene. Nature. 2008;455(7215):930-935. PMID: 18724359; Janoueix-Lerosey I, et al. Nature. 2008;455(7215):967-970
PHOX2B	hgnc:9143	First gene shown to predispose to NB; homeodomain variants; co-segregates with Hirschsprung disease and CCHS	Trochet D, et al. Am J Hum Genet. 2004. PMID: 15024693 — "PHOX2B, therefore, stands as the first gene for which germline mutations predispose to NB"; Mossé YP, et al. Am J Hum Genet. 2004. PMID: 15338462; Bourdeaut F, et al. Cancer Lett. 2005 (R100L). PMID: 15949893
NF1	hgnc:7765	RASopathy; a GNB case with a heterozygous NF1 exon 1–58 deletion is reported	Zhang Q, et al. Ganglioneuroblastoma associated with neurofibromatosis type 1: a case report with a systematic review. Front Oncol. 2026. PMID: 42311262
LMO1	hgnc:6641	Common-variant susceptibility via super-enhancer polymorphism rs2168101 G>T altering GATA binding	Oldridge DA, et al. Genetic predisposition to neuroblastoma mediated by a LMO1 super-enhancer polymorphism. Nature. 2015. PMID: 26560027
LIN28B	hgnc:32207	GWAS susceptibility locus	Tonini GP, Capasso M. Cancer Metastasis Rev. 2020. PMID: 31927719
BARD1	hgnc:952	GWAS susceptibility locus, genome-stability pathway	Tonini GP, Capasso M. 2020. PMID: 31927719
TP53 (Li-Fraumeni, incl. p.R337H)	—	Associated syndrome; surveillance recommended	NCI PDQ, Neuroblastoma Treatment (Health Professional Version)
CASC15, CHEK2, AXIN2, BRCA1	—	Reported susceptibility / genome-instability associations	Tonini GP, Capasso M. 2020. PMID: 31927719

ALKAL1 (hgnc:33775) / ALKAL2 (hgnc:27683) encode the ALK ligands (ALKAL/FAM150/AUGβ) and are mechanistically relevant to ALK activation, though not established predisposition genes.

[GNB-specific gap] No study has tested whether germline predisposition is enriched, depleted, or differently distributed in GNBi versus GNBn versus neuroblastoma. The 1–2% figure is a pNT-wide estimate.

2.3 Environmental risk factors

No environmental exposure has been established as causal. Age (infancy/early childhood), and to a lesser degree ancestry, are the only consistently reported non-genetic risk associations for pNTs.

From NCI PDQ (Neuroblastoma Treatment, Health Professional Version): relative risks of neuroblastoma compared with White patients were 0.54 (Hispanic), 0.64 (Asian/Pacific Islander), 0.69 (American Indian/Alaska Native), and 0.73 (Black).

In the SEER GNB cohort (n = 1,194), racial distribution was White 78.8%, Black 12.6%, other 8.5% — a distribution that reflects both incidence and the underlying US population, and should not be read as a risk estimate (Li W, et al. Heliyon. 2024;10(9):e30891. PMID: 38774105).

Not applicable / no evidence found: occupational exposure, radiation, pollution, tobacco, diet, and alcohol have no established role in GNB specifically. Parental-exposure epidemiology for neuroblastoma has produced no replicated finding of the strength needed for a mechanism claim.

2.4 Protective factors

Genetic: No validated protective variant is reported for GNB. The protective end of the ALK allelic spectrum is simply absence of an activating variant, which is not a protective allele.

Environmental/behavioural: None established. Population newborn screening is explicitly not protective and the evidence is strong and negative — see §13.

2.5 Gene–environment interactions

No established gene–environment interaction for GNB. There is a conceptually important gene–developmental-timing interaction rather than a gene–environment one: the prognostic effect of histology is age-dependent (see §3 and §8), and the prognostic effect of MKI has distinct age cut-offs per MKI class (Teshiba R, et al. Pediatr Dev Pathol. 2014;17(6):441-449. PMID: 25207821). This is interaction between a tumour-intrinsic variable and host developmental stage, and should be modelled as such rather than as an environmental modifier.

3. Phenotypes

3.1 How GNB presents

Most phenotypes are mass-effect phenotypes determined by anatomical site, not by tumour biology. A second, smaller group are secretory/paraneoplastic phenotypes. This split is the right organising principle for a mechanism entry: the first group's causal parent is tumour growth at a site, the second's is a secreted product or an anti-neural immune response.

The ICCR dataset's statement of the paraneoplastic set (Note 1, verbatim):

"Multiple paraneoplastic syndromes can be associated with neuroblastic tumours, including opsoclonus myoclonus ataxia, cerebellar ataxia, Horner syndrome, Hirschsprung disease/CCHS, rapid-onset obesity with hypoventilation, hypothalamic dysfunction, autonomic dysregulation (ROHHAD), and vasoactive intestinal peptide (VIP)-associated secretory diarrhoea or VIPoma syndrome."

3.2 Phenotype table with suggested HPO terms

HPO terms below marked ✅ were verified against EBI OLS4 in this session; those marked ⚠ are suggestions requiring lookup before binding.

Phenotype	Type	HPO suggestion	Onset	Course	Frequency / notes
Abdominal mass	Clinical sign	HP:0031500 Abdominal mass ✅	Infancy–early childhood	Progressive	Most common presentation of abdominal pNT (NCI PDQ)
Abdominal pain / distension	Symptom	⚠ HP:0002027 / HP:0003270	Childhood	Variable	Common with retroperitoneal/adrenal primaries
Thoracic mass / respiratory distress	Clinical sign	⚠ HP:0002094 Dyspnea	Childhood	Variable	Posterior mediastinal primaries; GNB is over-represented in thorax relative to NB (30% of GNBn vs 9% of NB, He 2017, PMID: 28465480)
Horner syndrome	Clinical sign	HP:0002277 Horner syndrome ✅ (congenital form HP:0006837 ✅; HP:0007451 ipsilateral lack of facial sweating ✅)	Childhood	Often persistent	"Characterized by miosis, ptosis, and anhidrosis. It may be caused by neuroblastoma in the stellate ganglion" (NCI PDQ)
Spinal cord / nerve-root compression; paraparesis	Clinical sign	⚠ HP:0002176 Spinal cord compression; HP:0002385 Paraparesis	Childhood	Can be acute, emergency	Dumbbell paraspinal tumours invading through neural foramina (NCI PDQ; Alioglu H, et al. Eur Spine J. 2026. PMID: 42811141 — systematic review of 18 spinal-canal GNB cases)
Opsoclonus–myoclonus–ataxia syndrome (OMAS)	Behavioural/neurological	HP:0010543 Opsoclonus ✅; ⚠ HP:0001336 Myoclonus; ⚠ HP:0001251 Ataxia	6 months – 3 years	Relapsing; often persistent neurocognitive sequelae	"Of young children presenting with opsoclonus/myoclonus syndrome, about one-half are found to have neuroblastoma" (NCI PDQ); OMAS-associated tumours "tend to be low grade, thoracic in location, and have a more favorable outcome"
VIP-mediated secretory diarrhoea (WDHA/VIPoma syndrome)	Lab + symptom	⚠ HP:0002028 Chronic diarrhea; ⚠ HP:0002900 Hypokalemia	Childhood	Resolves on resection	"On rare occasions, children may have severe, watery diarrhea caused by the secretion of vasoactive intestinal peptide by the tumor" (NCI PDQ). Associated with more differentiated tumours (GNB/GN) more than with undifferentiated NB
Catecholamine-driven hypertension	Clinical sign	⚠ HP:0000822 Hypertension	Infancy–childhood	Reversible on resection	Shimizu H, et al. Infantile Ganglioneuroblastoma Causing Growth Failure and Hypertensive Cardiomyopathy From Excessive Catecholamine Production. J Pediatr Hematol Oncol. 2026. PMID: 41891982 — a 3-year-old with excess epinephrine/norepinephrine and "hypertensive cardiomyopathy"
Growth failure	Clinical sign	⚠ HP:0001510 Growth delay	Childhood	Reversible with tumour control	Same case (PMID: 41891982)
Elevated urinary HVA	Laboratory	HP:0011977 Elevated urinary homovanillic acid ✅	—	—	Chemical: homovanillic acid CHEBI:545959 ✅
Elevated urinary VMA	Laboratory	HP:0011978 Elevated urinary vanillylmandelic acid ✅	—	—	Chemical: vanillylmandelic acid CHEBI:20106 ✅. VMA abnormal in only 21% of GNBn and 19% of GNBi vs 59% of NB (He 2017, PMID: 28465480)
Bone pain, pancytopenia, proptosis, periorbital ecchymosis	Clinical signs	⚠ HP:0002653, HP:0001876, HP:0000520	Childhood	Progressive	Features of metastatic (stage M) disease — relevant to GNBn, essentially never GNBi
Constipation	Symptom	⚠ HP:0002019	Childhood	Variable	Reported in GNB paraneoplastic series alongside diarrhoea (Springer, Eur J Pediatr 2003, doi:10.1007/s00431-003-1212-0)

3.3 Phenotype characteristics

Age of onset. Early childhood. GNB subtypes are consistently older at diagnosis than neuroblastoma: median 28.9 months (NB) vs 38.4 months (GNBn) vs 47.5 months (GNBi) in a 279-patient single-centre series (He WG, et al. Oncotarget. 2017;8(23):37730-37739. PMID: 28465480). In the INRG GNBn cohort, 83% were older than 18 months (Angelini P, et al. Eur J Cancer. 2012. PMID: 22137163).
Severity. Bimodal by subtype. GNBi is almost uniformly indolent; GNBn spans the full range, with stage 4 GNBn carrying 35% ± 7% OS (PMID: 22137163).
Progression. GNBi/GN grow slowly and may be static for years: "GN and GNB-I have a slow growth rate and resection can be associated with significant morbidity" (Alexander N, et al. Pediatr Blood Cancer. 2018. PMID: 29369484). GNBn behaves as the biology of its nodule dictates.
Frequency among affected individuals. Reliable per-phenotype frequencies for GNB specifically are not published. The serum/urine marker frequencies in §3.2 (from PMID: 28465480) are the best available and are from a single centre with n = 20 GNBn and n = 31 GNBi; treat them as indicative, not as population frequencies.

3.4 Quality-of-life impact

No GNB-specific QoL instrument data exist. The relevant data are from high-risk neuroblastoma survivors, which applies to the GNBn stage-4 subgroup and not to GNBi:

The COG LEAHRN cross-sectional cohort found moderate-to-severe hearing loss in 72% of high-risk neuroblastoma survivors, with more than half underweight, and most participants carrying at least two clinically important late effects (Lancet Child Adolesc Health, 2025; https://www.sciencedirect.com/science/article/abs/pii/S235246422500241X).
Flaadt T, et al. Long-Term Outcomes and Quality of Life of High-Risk Neuroblastoma Patients Treated with a Multimodal Treatment Including Anti-GD2 Immunotherapy. Cancers. 2025;17(1):149. PMID: 39796776 — among 25 survivors at 25 years: ototoxicity 64%, cardiac toxicity 24%, endocrine effects 76%; "Quality-of-life scores exceeded matched general population comparators."
Self-reported survivor data show 50% meeting anxiety/depression criteria versus a 25% population norm (PubMed 37311662).

Instruments in use: EQ-5D, SF-36, PROMIS, PedsQL. No disease-specific GNB instrument exists.

4. Genetic / Molecular Information

4.1 There is no causal gene for ganglioneuroblastoma

This is a structural point that should be recorded explicitly rather than left as an absence. GNB is a somatic neoplasm defined by morphology; it has driver lesions, not a causal gene, and a given GNB may carry none of the recurrent drivers at all. The diagnosis is made on a histology slide, and the molecular work-up is prognostic rather than diagnostic.

4.2 Recurrent somatic alterations

Alteration	Gene / locus	Frequency	Origin	Functional consequence	Evidence
MYCN amplification (double minutes → HSRs)	MYCN, hgnc:7559, 2p24	GNBi 0%; GNBn 14%; NB 26% in one series (PMID: 28465480); 2% of GNBn in the INRG cohort (PMID: 22137163)	Somatic	Amplification ⇒ N-Myc overexpression; "a proto-oncogene which inhibits cell differentiation and apoptosis and promotes division" (ICCR Note 13). FISH: ratio ≥4 = amplified; >1 but <3 = "gain", clinical significance unclear	ICCR Note 13; PMID: 28465480; PMID: 22137163
ALK point mutation	ALK, hgnc:427, 2p23	"mutated in 8-10% of sporadic neuroblastic tumours, amplified in about 2%" (ICCR Note 13). In 943 patients: 10.5% at diagnosis, "highest frequencies in stage 4 patients <18 months"; at relapse the frequency rises ~70%, mostly de novo R1275Q	Somatic (also germline — §2.2)	Gain of function: constitutive receptor tyrosine kinase activity. ALK amplifications — but not mutations — correlated with poor outcome	Rosswog C, et al. Br J Cancer. 2023. PMID: 36807339; ICCR Note 13
1p36 deletion	1p36	Segmental; co-occurs with MYCN amplification	Somatic	Loss of tumour-suppressor region	Schleiermacher G, et al. Br J Cancer. 2012;107(8):1418-1422; Irwin MS, et al. J Clin Oncol. 2021;39(29):3229-3241
11q deletion	11q	Segmental; rarely co-occurs with MYCN amplification; marks a distinct poor-prognosis group	Somatic	Loss; strongly associated with ALT telomere maintenance	Nakazawa A. Pathol Int. 2021. PMID: 33657257; Djos A, et al. Genes Chromosomes Cancer. 2024, doi:10.1002/gcc.23260
17q gain	17q	Reported in 65% of 48 neuroblastomas; more frequent than either 1p deletion or MYCN amplification across all stages	Somatic	Dosage gain; poor prognosis	PMC2362984; ICCR Note 13
ATRX loss-of-function	ATRX, hgnc:886	~11% of high-risk NB; ~40% in adolescents, <20% in younger children, 0% in infants <1 year	Somatic (and germline in syndromic cases)	Loss of function ⇒ ALT telomere maintenance	NCI PDQ; Djos A, et al. 2024
TERT rearrangement / overexpression	TERT, hgnc:11730	~23% of high-risk NB	Somatic	Telomerase activation	ICCR Note 13; Djos A, et al. 2024
Whole-chromosome gains/losses (numerical only)	genome-wide	The favourable genomic signature	Somatic	Hyperdiploidy; no segmental breakage	Nakazawa A, et al. Cancer Sci. 2015. PMID: 25827934

Nakazawa's genomic-signature correlation is the most directly useful result for a mechanism entry, because it links the histological axis to the genomic axis:

"Analysis of 92 neuroblastoma cases with INPC evaluation and genomic grouping showed significant correlation between unfavorable histology and partial gains/losses (GGP), and favorable histology with whole gains/losses (GGW). Unfavorable histology and GGP were late-onset (median 36 and 48 months) with poor prognosis (OS 43.1%, 42.4%). Favorable histology and GGW were early-onset (median 4, 9.5 months) with favorable prognosis (OS 88.6%, 87.1%)." — PMID: 25827934

4.3 The GNBn clonality question — a key GNB-specific result

The historical model of GNBn — stated explicitly in the original Shimada framework — was that the aggressive nodule and the benign stroma-rich background are separate clones. That model has been tested and does not hold:

"Neuroblasts and ganglion cells in nodular ganglioneuroblastoma are genetically related and may arise from the same clone... the clinical behavior of nodular ganglioneuroblastoma cannot be explained by the presence of separate clones with distinct genetic signatures." — Angelini P, Baruchel S, Marrano P, Irwin MS, Thorner PS. The neuroblastoma and ganglion components of nodular ganglioneuroblastoma are genetically similar: evidence against separate clonal origins. Mod Pathol. 2015;28(1):96-103. PMID: 25081755; DOI: 10.1038/modpathol.2014.90

Method and key finding: eight paraffin-embedded GNBn cases analysed by SNP array and in situ hybridisation. MYCN gain (4–10 gene copies/nucleus) was detected in 7/8 neuroblastoma samples, and in the ganglioneuromatous regions, "gains were also detected in ganglion cells but not in Schwann cells."

Three mechanistic consequences follow, and they are the heart of a GNB pathophysiology model:

The neuroblasts and the ganglion cells are the same tumour lineage at different differentiation states — so GNBn represents partial differentiation of one clone, not two coincident tumours.
The Schwannian stroma is genetically normal — it is reactive, recruited host tissue, not neoplasm. Any claim that the stroma is "part of the tumour" in the neoplastic sense is wrong.
The INPC rule that GNBn is graded by its highest-grade nodule (ICCR Note 10) is therefore a statement about intratumoural heterogeneity within one clone, not about which of two clones dominates.

4.4 Telomere maintenance in GNB — the most recent GNB-specific molecular study

"Analysis of 321 neuroblastic tumors revealed that TMM activation occurred in 48% of nodular ganglioneuroblastomas, similar to 39% of neuroblastomas, serving as a poor prognostic marker." — Sugawara M, Haruta M, Ohira M, et al. Telomere maintenance mechanisms are activated in ganglioneuroblastoma and ganglioneuroma. Oncol Lett. 2026. PMID: 41858373; DOI: 10.3892/ol.2026.15509

The paper's own framing: "TMM serves as a poor prognostic marker for high-risk NB and offers valuable insights for the risk classification of GNBs." This is an important and counterintuitive result: GNBn — a tumour whose benign-looking stromal majority can make it look indolent — activates telomere maintenance at a rate at least as high as neuroblastoma. It is direct molecular support for the clinical rule that GNBn must be risk-stratified as neuroblastoma.

4.5 Modifier genes

No validated modifier gene for GNB. The de facto modifiers in clinical use are age at diagnosis and INPC histology, which modify the prognostic effect of every other variable (see §8 and §11).

4.6 Epigenetic information

DNA methylation profiling is emerging as a molecular classifier of neuroblastoma (PMC12297820, 2025). GNB-specific methylation classes have not been separately defined.
Cell-identity epigenetics is the central epigenetic mechanism in this family: neuroblastoma cells exist in noradrenergic and mesenchymal identities defined by distinct super-enhancer landscapes and core regulatory circuitries, and can interconvert:

"We now document spontaneous and reversible plasticity between the two identities, associated with epigenetic reprogramming, in several neuroblastoma models... a subpopulation of these noradrenergic tumor cells presents with mesenchymal features that are shared with plasticity models, indicating that the plasticity described in these models has relevance in neuroblastoma patients. This work therefore emphasizes that intrinsic plasticity properties of neuroblastoma cells are dependent upon external cues of the environment to drive cell identity." — Thirant C, Peltier A, Durand S, et al. Nat Commun. 2023. PMID: 37142597
HDAC8 is a druggable epigenetic node for differentiation: selective HDAC8 inhibition induces differentiation and synergises with retinoic acid via CREB (Rettig I, et al. Cell Death Dis. 2015. PMID: 25695609).
ZNF423 is required for retinoic-acid-induced differentiation, and low expression predicts poor outcome (Huang S, et al. Cancer Cell. 2009. PMID: 19345331).

4.7 Chromosomal abnormalities

Covered in §4.2. For reporting purposes, the ICCR requires MYCN status as a core element and recommends DNA index/ploidy (near-diploid/tetraploid unfavourable; hyperdiploid favourable in infants <1 year) and segmental chromosomal aberration panel (1p, 11q, 17q). Detection platforms in current use: FISH (MYCN), SNP/CGH array, and NGS copy-number analysis.

5. Environmental Information

Environmental factors: None established. No toxin, radiation source, pollutant, or occupational exposure is causally linked to GNB. [No evidence found] — this is a genuine negative, not a search gap: the pNT epidemiology literature has looked and has not produced a replicated association.
Lifestyle factors: Not applicable. GNB is a tumour of infancy and early childhood; patient lifestyle factors have no role, and parental-exposure studies have produced no established association.
Infectious agents: Not applicable. GNB has no infectious aetiology. There is no pathogen to record, no transmission route, and no infectious_agent entry is warranted.

A mechanism entry for GNB should carry no environmental: block, or should record the deliberate absence with the searches that were run.

6. Mechanism / Pathophysiology

6.1 Ordered causal chain

The chain below runs from the initiating lesion to clinical manifestation. Steps are numbered; branches are shown explicitly. [D] = demonstrated in human tumour tissue or a direct model; [I] = inferred, i.e. the step is a reasonable bridge between two demonstrated steps but has not itself been directly shown in GNB.

Trunk — origin and initiation

During embryogenesis, neural crest cells (CL:0011012) delaminate and migrate ventrally, giving rise to sympathoadrenal progenitors and, via a second route, to Schwann cell precursors (CL:0002375) that travel along nerves and themselves contribute to the sympathoadrenal cell pool. [D] — two successive neural-crest-derived progenitor states are now resolved by single-cell atlases (Hanemaaijer ES, et al. PNAS. 2021. PMID: 33500353; Olsen TK, et al., Malignant Schwann cell precursors mediate intratumoral plasticity in human neuroblastoma, bioRxiv 2020, doi:10.1101/2020.05.04.077057).
PHOX2B (hgnc:9143) specifies and maintains the noradrenergic sympathoadrenal programme. Reduced PHOX2B dosage or dominant-negative PHOX2B leads to a block in sympathetic neuronal precursor differentiation. [D in zebrafish] — "reduced dosage of PHOX2B during development, through either a heterozygous deletion or dominant-negative mutation, imposes a block in the differentiation of sympathetic neuronal precursors, resulting in a cell population that is likely to be susceptible to secondary transforming events" (Pei D, et al. PLoS Genet. 2013. PMID: 23754957). Mechanistically, "Patient-derived mutant PHOX2B constructs retained the ability to suppress cellular proliferation, but were not able to promote differentiation" (Raabe EH, et al. Oncogene. 2008. PMID: 17637745) — i.e. the lesion is specifically a differentiation defect, not a proliferation-brake defect.
A transforming lesion occurs in that arrested progenitor — most often MYCN amplification, an activating ALK variant, or a segmental chromosomal aberration — which results in sustained proliferation plus an additional, independent block on terminal differentiation. [D] — "MYCN induces the expansion of these progenitors by both promoting their proliferation and preventing their differentiation" (Alam G, et al. Am J Pathol. 2009. PMID: 19608868). PHOX2B and ALK are not independent inputs here: "PHOX2B drives ALK gene transcription by directly binding its promoter" (Bachetti T, et al. PLoS One. 2010. PMID: 20957039).
The transformed clone expands as a mass in a sympathetic-chain or adrenal-medullary site. [D]

Branch point — the differentiation fork that defines GNB

The expanded clone is exposed to differentiation-promoting signals from Schwannian stroma, which is recruited host (non-neoplastic) tissue. This step is the one that distinguishes GNB from neuroblastoma. [D for the stroma being non-neoplastic: Schwann cells carry no MYCN gain in GNBn, PMID: 25081755; D for the stroma being instructive: Schwann-cell-conditioned medium "induced extensive neurite outgrowth in all neuroblastoma cell lines, and these processes contained mature neurofilament in three of the cell lines" (Kwiatkowski JL, et al. Cancer Res. 1998. PMID: 9788610); PEDF is "the major factor responsible for Schwann cell's ability to induce tumor cell differentiation in vitro and recombinant PEDF had the same effect in vitro and in vivo" (Crawford SE, et al. J Cell Sci. 2001. PMID: 11792807).]
Reciprocally, the tumour cells recruit and expand the stroma: "Human NB tumours or cell lines unequivocally increased the proliferation of SCs in vitro" (Ambros IM, et al. Med Pediatr Oncol. 2001. PMID: 11464875). This closes a positive feedback loop between tumour differentiation and stromal expansion — the loop that produces the stroma-rich architecture by which GNB is defined. [D in vitro; I in human tumour]
Stromal signalling results in neuroblast maturation into ganglion cells, which lose proliferative capacity and acquire neuronal morphology (eccentric vesicular nucleus, prominent nucleolus, abundant cytoplasm, Nissl substance), with neuritic processes becoming fully ensheathed by Schwann cells. [D — this is the defining morphological criterion in ICCR Note 7: naked neuritic processes identify differentiating neuroblasts; their absence identifies ganglion cells.]
Branch 5a → GNBi. If this differentiation reaches >50% stromal volume with only microscopic residual neuroblastic nests and no grossly visible haemorrhagic/necrotic nodule, the tumour is ganglioneuroblastoma, intermixed — "histologically one step behind the final stage of complete maturation towards ganglioneuroma" (ICCR Note 7). Clinically: favourable histology at any age. [D]
Branch 5b → ganglioneuroma. If differentiation goes to completion, the tumour is a ganglioneuroma (9490/0). [D]
Branch 5c → GNBn. If a subclone escapes the differentiation signal and expands as a discrete stroma-poor nodule within the stroma-rich background, the tumour is ganglioneuroblastoma, nodular. The escaping subclone is genetically related to the differentiated component (PMID: 25081755), so this is clonal divergence in differentiation state, not two tumours. [D for genetic relatedness; I for the "escape" framing — what drives one subclone to remain undifferentiated is not established.]

GNBn-specific continuation — the malignant arm

The escaped nodule retains or acquires proliferative drivers (MYCN amplification in ~14% of GNBn, PMID: 28465480; segmental chromosomal aberrations; telomere maintenance in 48%, PMID: 41858373), which result in a high mitosis–karyorrhexis index within the nodule. [D]
Unrestricted proliferation with telomere maintenance leads to local invasion and haematogenous/lymphatic dissemination, preferentially to bone marrow, bone, liver and lymph node. [D] — bone and liver are the two commonest isolated metastatic sites for neuroblastic tumours (Liu S, et al. World J Surg Oncol. 2023. PMID: 37046344).
In the bone-marrow niche, tumour cells signal to monocytes via MIF and midkine, rewiring them toward a tumour-associated-macrophage phenotype that supports the metastasis. [D in neuroblastoma, pNT-wide] — Fetahu IS, et al. Nat Commun. 2023. PMID: 37365178.
Marrow replacement results in cytopenias; bone metastases result in pain; orbital metastases result in proptosis and periorbital ecchymosis. [D]

Parallel branch A — catecholamine secretion

Because the tumour retains the sympathoadrenal programme, it expresses tyrosine hydroxylase and downstream catecholamine-synthetic enzymes, so it synthesises dopamine, norepinephrine and epinephrine (GO:0042423 catecholamine biosynthetic process ✅; GO:0006585 dopamine biosynthetic process from tyrosine ✅). [D]
Catecholamines are degraded to homovanillic acid (CHEBI:545959 ✅) and vanillylmandelic acid (CHEBI:20106 ✅), which are excreted in urine and result in the diagnostic elevations HP:0011977 / HP:0011978. [D]
In a minority, systemic catecholamine excess results in hypertension and, if sustained, hypertensive cardiomyopathy and growth failure. [D — PMID: 41891982]

A quantitative asymmetry worth recording: urinary VMA is abnormal in only 21% of GNBn and 19% of GNBi, versus 59% of NB (PMID: 28465480). The straightforward inference — that the more differentiated tumours secrete less measurable catecholamine metabolite, probably because a smaller fraction of tumour mass is metabolically active neuroblastic tissue — is [I], not demonstrated; and it has a direct clinical consequence (catecholamine screening is a poor rule-out test for GNB).

Parallel branch B — VIP secretion

Some neuroblastic tumours, preferentially the more differentiated ones, secrete vasoactive intestinal peptide. [D]
VIP acting on intestinal epithelium results in profuse secretory diarrhoea with hypokalaemia and achlorhydria (WDHA syndrome), which resolves on tumour resection. [D] — NCI PDQ; ICCR Note 1.

Parallel branch C — paraneoplastic autoimmunity (OMAS)

Tumour antigens shared with CNS neurons trigger a cross-reactive immune response. [I — the specific antigen is not established]
That response results in opsoclonus (HP:0010543 ✅), myoclonus, ataxia and behavioural regression. [D clinically]
The same immune response is associated with better tumour outcome — OMAS tumours "tend to be low grade, thoracic in location, and have a more favorable outcome" (NCI PDQ). Whether the immune response causes the better outcome or merely co-marks favourable biology is not established; both readings are live in the literature. The ANBL00P3 randomised result (IVIG 81% vs non-IVIG 41% OMAS response) shows the neurological syndrome is immunomodulator-responsive, which supports the immune mechanism for the neurological arm without settling the tumour-control question.

Parallel branch D — mass effect (site-determined)

Tumour growth at a paraspinal site leads to extension through neural foramina (dumbbell morphology) and results in cord compression and paraparesis. [D — PMID: 42811141]
Tumour at the stellate/cervicothoracic ganglion (UBERON:0002441 ✅) results in Horner syndrome (HP:0002277 ✅). [D]

6.2 Molecular pathways

Pathway	Role	Reference
ALK receptor tyrosine kinase → RAS–MAPK and PI3K–AKT	Primary oncogenic driver pathway; the one actionable target. ALK signalling also "phosphorylates ATR and CHK1, supporting effective DNA damage responses"	Borenäs M, et al. PNAS. 2024. PMID: 38154064
MYCN transcriptional programme	Proliferation + differentiation block; downstream of PHOX2B-specified lineage	PMID: 19608868
PHOX2B → ALK transcriptional axis	Lineage TF directly drives the RTK promoter	PMID: 20957039
Retinoic acid receptor (RARα/RXRα) signalling	The differentiation pathway; therapeutically exploited by isotretinoin. Requires ZNF423	PMID: 19345331; PMID: 3855502
NGF–TrkA (NTRK1)	Developmentally programmed cell death / differentiation switch; "The most easily targeted mechanism is the delayed activation of developmentally programmed cell death regulated by the tropomyosin receptor kinase A (TrkA) pathway" (Brodeur GM. Cell Tissue Res. 2018. PMID: 29305654). The oncogenic TrkAIII splice variant "antagonizes NGF/TrkA/Ras/MAPK signaling, which is responsible for NB growth arrest and differentiation" (Tacconelli A, et al. Cancer Cell. 2004. PMID: 15488758)	—
Delta–Notch (via MSX1, downstream of PHOX2B)	"MSX1, NOTCH3 and HEY1 are more highly expressed in ganglioneuromas" — i.e. this axis marks the differentiated end of the spectrum	Revet I, et al. Exp Cell Res. 2008. PMID: 18201699
Hedgehog signalling	Implicated in ganglioneuroma pathogenesis via enteric neural crest differentiation	PMC2759000, Enteric Neural Crest Differentiation in Ganglioneuromas Implicates Hedgehog Signaling in Peripheral Neuroblastic Tumor Pathogenesis
PEDF (SERPINF1) from Schwann cells	Anti-angiogenic and pro-differentiation; the molecular mediator of Schwannian stromal benignity	PMID: 11792807
MIF and midkine → monocyte rewiring	Metastatic-niche pathway in bone marrow	PMID: 37365178
Telomere maintenance — telomerase (TERT) and ALT (ATRX-associated)	Immortalisation; active in 48% of GNBn	PMID: 41858373

6.3 Cellular processes and cell types

Process	GO suggestion (✅ verified)	Cell types (CL, ✅ verified)
Neural crest cell differentiation	GO:0014033 ✅ (regulation: GO:1905292/1905293/1905294 ✅; fate determination GO:0014035 ✅)	neural crest cell CL:0011012 ✅
Sympathetic nervous system development	GO:0048485 ✅; NCC migration involved in SNS development GO:1903045 ✅	neural crest derived neuroblast CL:0002676 ✅; neuroblast (sensu Vertebrata) CL:0000031 ✅
Autonomic nervous system development	GO:0048483 ✅	sympathetic neuron CL:0011103 ✅
Catecholamine biosynthetic process	GO:0042423 ✅; dopamine GO:0042416 ✅; from tyrosine GO:0006585 ✅	chromaffin cell CL:0000166 ✅; adrenal medulla chromaffin cell CL:0000336 ✅
Schwann-cell-mediated differentiation support	⚠ (no single GO term; consider GO terms for glial cell differentiation / positive regulation of neuron differentiation — requires lookup)	Schwann cell CL:0002573 ✅; Schwann cell precursor CL:0002375 ✅; non-myelinating Schwann cell CL:0002376 ✅; myelinating Schwann cell CL:0000218 ✅
Cell cycle dysregulation / proliferation	⚠ requires lookup	—
Telomere maintenance	⚠ requires lookup	—

6.4 Protein dysfunction

ALK: activating missense in the kinase domain (R1275Q, F1174L, F1245V, R1192P, G1128A) → ligand-independent constitutive kinase activity. Gain of function. Note the ICCR caveat for curation: "ALK immunohistochemistry does not correlate well with gene mutation or amplification status, so sequencing of the kinase regions and/or known mutational hotspots is required."
N-Myc (MYCN): gene amplification → protein overabundance, not structural alteration. The ICCR notes genotype–phenotype discordant subsets in both directions: tumours with MYCN amplification but favourable histology that "appear to not produce functional N-myc protein despite having amplification of the gene", and tumours without amplification but unfavourable histology that "are often associated with C-myc protein expression or other molecular abnormalities instead."
PHOX2B: homeodomain-disrupting variants → selective loss of the differentiation-promoting function with retention of the anti-proliferative function (PMID: 17637745). This is a true separation-of-function defect and should not be recorded simply as "loss of function".
ATRX: loss of function → ALT.
TrkA (NTRK1): the TrkAIII splice variant (deletion of exons 6, 7, 9) is a neomorphic isoform — NGF-unresponsive, oncogenic, and actively antagonistic to the wild-type differentiation signal (PMID: 15488758).

6.5 Metabolic changes

The dominant metabolic feature is catecholamine biosynthesis and turnover (§6.1 branch A), which is a retained lineage programme rather than a tumour-acquired metabolic rewiring. Broader metabolic targets in neuroblastoma are an active area — "present and future directions for the identification of novel therapeutic metabolic targets, differentiation agents, as well as personalized combinatory therapies" (PMID: 39101440) — but no GNB-specific metabolomic signature is published. [No GNB-specific data found.]

6.6 Immune system involvement

Paraneoplastic autoimmunity (OMAS) — §6.1 branch C.
GD2 as a tumour-surface target. GD2 ganglioside is highly expressed on neuroblastic tumour cells and is the basis of all current immunotherapy. Dinutuximab is "A chimeric mouse/human monoclonal antibody with potential antineoplastic activity" that binds GD2 (NCIT:C1570 ✅).
Tumour-associated monocytes/macrophages in the marrow niche — PMID: 37365178.
Chemotherapy–immunotherapy synergy: standard induction agents enhanced dinutuximab beta efficacy up to 17-fold in spheroid models (Troschke-Meurer S, et al. Cancers. 2023. PMID: 36765861).

6.7 Tissue damage mechanisms

Primarily compression and invasion rather than an intrinsic cytotoxic mechanism: cord compression, airway/vascular compression, marrow replacement. The GNBn nodule is characteristically haemorrhagic and necrotic (ICCR Note 7) — spontaneous intratumoural haemorrhage is a feature of the aggressive component and contributes to the gross distinction from the tan-yellow, solid/elastic stroma-rich background.

6.8 Molecular profiling

Transcriptomics / single cell. The adrenergic–mesenchymal identity axis (PMID: 37142597), the SCP-like malignant subpopulation bridging the two compartments (Olsen TK, et al., doi:10.1101/2020.05.04.077057), and the developing-adrenal SCP signature, where "The SCP signature score anticorrelates with ALK and MYCN expression, two indicators of poor prognosis. Furthermore, a high SCP signature score is associated with better overall survival rates" (PMID: 33500353). These are neuroblastoma studies; the SCP-signature result is nevertheless the most mechanistically suggestive data point for GNB in the corpus, because GNB is by definition the SCP/Schwannian-rich end of the spectrum.
Proteomics / metabolomics / lipidomics: No GNB-specific dataset identified.
Functional genomics screens: the RNAi screen that identified ZNF423 as the RA-differentiation requirement (PMID: 19345331) is the clearest example. DepMap and CRISPR screens cover neuroblastoma cell lines; no GNB-derived cell line exists, which is itself a notable gap.

7. Anatomical Structures Affected

7.1 Organ level

Primary sites. Peripheral neuroblastic tumours arise anywhere along the sympathetic chain and in the adrenal medulla. GNB's site distribution differs materially from neuroblastoma's, and this is one of the few clean GNB-specific epidemiological facts:

Site	NB	GNBn	GNBi	SEER GNB cohort (n=1,194)
Adrenal	55.0%	20.0%	42.0%	29.9%
Retroperitoneum (extra-adrenal)	29.0%	50.0%	13.0%	12.1%
Thorax / mediastinum	9.0%	30.0%	26.0%	14.5% (heart/mediastinum)
Soft tissue (SEER coding)	—	—	—	37.4%
Other	7.0%	0%	6.0%	6.0%

Left columns: He WG, et al. Oncotarget. 2017. PMID: 28465480. Right column: Li W, et al. Heliyon. 2024;10(9):e30891. PMID: 38774105. The two site taxonomies are not aligned — SEER's "soft tissue" category absorbs paraspinal and other extra-adrenal sympathetic-chain sites that the clinical series splits out — so do not merge these rows.

Rare sites reported: cervical (McGann EK, et al. Auris Nasus Larynx. 2022. PMID: 33867181), pelvic/organs of Zuckerkandl (Masrani N, et al. J Indian Assoc Pediatr Surg. 2025. PMID: 41293519), cervicothoracic dumbbell with spinal canal involvement (PMID: 42811141).

Secondary organ involvement (GNBn / metastatic only): bone marrow, bone, liver, distant lymph nodes, skin; rarely CNS and skull (Vandenhoudt W, et al. Front Oncol. 2026. PMID: 42597467).

Body systems: sympathetic/autonomic nervous system (primary); endocrine (adrenal medulla, catecholamine axis); gastrointestinal (VIP-mediated); haematopoietic (marrow metastasis); skeletal; cardiovascular (hypertension, hypertensive cardiomyopathy).

UBERON suggestions (all ✅ verified via OLS4):

Structure	UBERON
adrenal medulla	UBERON:0001236
adrenal gland	UBERON:0002369
sympathetic nervous system	UBERON:0000013
sympathetic ganglion	UBERON:0001806
paravertebral ganglion	UBERON:0001807
thoracic ganglion	UBERON:0000961
cervical ganglion	UBERON:0001991
superior cervical ganglion	UBERON:0001989
cervicothoracic (stellate) ganglion	UBERON:0002441
lumbar ganglion	UBERON:8600121
sacral ganglion	UBERON:8600122

⚠ Requires lookup before binding: UBERON terms for posterior mediastinum, retroperitoneal space, organ of Zuckerkandl / para-aortic body, bone marrow.

7.2 Tissue and cell level

Tissues: nervous tissue (peripheral autonomic); connective/stromal tissue (the Schwannian stroma, which is non-neoplastic); adrenal medullary tissue.
Neoplastic cell populations: neuroblasts at varying differentiation grades (CL:0000031 ✅, CL:0002676 ✅), ganglion cells (differentiated neoplastic progeny — ⚠ CL term for ganglion cell / autonomic neuron requires lookup; CL:0011103 sympathetic neuron ✅ is the closest verified term).
Non-neoplastic but definitional population: Schwann cells (CL:0002573 ✅) and Schwann cell precursors (CL:0002375 ✅). Recording these as "tumour cell types" would be an error given PMID: 25081755; they should be recorded as stromal/microenvironment participants.

7.3 Subcellular level

No GNB-specific subcellular compartment is implicated. Relevant compartments by driver: nucleus (MYCN, PHOX2B, ATRX, telomeres), plasma membrane (ALK, TrkA, GD2), neuritic processes/neuropil (the morphological readout of differentiation). ⚠ GO Cellular Component terms for these require lookup before binding.

7.4 Localisation and lateralisation

Typically unilateral and solitary. Bilateral or multifocal primaries occur in 3–4% of neuroblastoma cases and are a flag for germline predisposition (PMID: 38860978). A worked bifocal sporadic GNB case in which the two lesions had different histological subtypes (GNBi thoracic, GNBn abdominal) is reported and is directly relevant to curation: Montante C, et al. The Pitfall of Ganglioneuroblastoma-Nodular Diagnosis. Diagnostics. 2022. PMID: 36553228.

8. Temporal Development

8.1 Onset

Age. Infancy to early childhood, with GNB subtypes diagnosed later than neuroblastoma (median 38.4 months GNBn, 47.5 months GNBi vs 28.9 months NB — PMID: 28465480). SEER GNB mean age 6.15 years (SD ±9.65), with a long adult tail (PMID: 38774105). For neuroblastic tumours overall, "About 37% of patients are diagnosed as infants, and 90% are younger than 5 years at diagnosis, with a median age at diagnosis of 17 months" (NCI PDQ).
Onset pattern. Usually insidious — an incidentally discovered or slowly enlarging mass. Acute presentations occur with cord compression, OMAS, or secretory diarrhoea.
Congenital/perinatal disease occurs and is usually favourable: "The vast majority of the perinatal tumors exhibit favorable biologic features (<5% MYCN amplified, >95% favorable histology), and outcomes in these patients are excellent, with a four-year EFS of 92% and OS of 96%."

8.2 The age-linked prognostic framework (INPC)

This is the central temporal fact about GNB and should be modelled explicitly: the same histology means different things at different ages. Reproduced verbatim from ICCR Table 2 (International Neuroblastoma Pathology Committee Classification of neuroblastic tumours):

Histologic type	Differentiation	MKI	Age	Histology
Neuroblastoma	Undifferentiated	Any	Any	Unfavourable
	Poorly differentiated	Low or Intermediate	<18 months	Favourable
			≥18 months	Unfavourable
		High	Any	Unfavourable
	Differentiating	Low	<5 years	Favourable
			≥5 years	Unfavourable
		Intermediate	<18 months	Favourable
			≥18 months	Unfavourable
		High	Any	Unfavourable
Ganglioneuroblastoma, nodular (and other composite neuroblastic tumours)	Classify according to highest grade nodule or component of tumour
Ganglioneuroblastoma, intermixed	NA	NA	Any	Favourable
Ganglioneuroma	NA	NA	Any	Favourable

MKI definition (ICCR Note 9, verbatim): "Mitotic-karyorrhectic index (MKI) is the number of mitotic nuclei and karyorrhectic nuclei per 5,000 neuroblastic cells." Classes: Low MKI (<100/5,000 cells), Intermediate MKI (100–200/5,000 cells), High MKI (>200/5,000 cells).

Two procedural constraints that matter for data quality: "MKI determination on bone marrow metastases is discouraged, as it has not been shown to correlate with the MKI of the primary tumour nor to be prognostically useful," and "MKI should not be determined for post-treatment tumours."

Age cut-offs are empirically derived, not conventional. Breslow and McCann's 365-day cut-off was superseded by London et al's analysis of 3,666 patients identifying 547 days, and the INPC committee's 1999 review of 227 cases independently supported 1.5 years plus a second cut-off at 5 years (ICCR Note 1). The MKI-class-specific optima are different again: <60 months for low MKI, <18 months for intermediate, and possibly 3–4 months for high MKI (PMID: 25207821).

8.3 Progression and staging

INRGSS (pretreatment, image-based — Monclair T, et al. J Clin Oncol. 2009;27(2):298-303):

L1 — localised, no image-defined risk factors (IDRFs)
L2 — locoregional with ≥1 of 20 IDRFs
M — metastatic
MS — metastases confined to skin, liver and/or bone marrow in children <18 months

5-year EFS and OS by INRGSS stage (NCI PDQ): L1 90% / 98%; L2 84% / 95%; M 52% / 64%; MS 86% / 92%.

Progression rate. GNBi/GN are slow-growing; GNBn behaves per its nodule. In the German GN/GNBi series, "Five patients (3 GN, 2 GNBI) showed local progression; all had tumor residuals > 2 cm. No progression occurred after subtotal resection" (PMID: 27465021) — a result that reads oddly on first encounter and is worth stating carefully: progression occurred only in patients with large residua, not after subtotal resection generally.

Disease course. For GNBi: typically a single episode, cured or stably observed. For GNBn: the neuroblastoma course — risk-stratified, with relapse risk concentrated in stage 4 / ≥18 months.

8.4 Remission and maturation patterns

Three distinct phenomena must be kept apart:

Spontaneous regression — tumour disappearance, classically in infants with stage MS/4S disease. "The spontaneous regression usually consists of complete disappearance of the disease, but in some neuroblastomas, maturation to ganglioneuroma takes place" (Evans AE, Gerson J, Schnaufer L. Natl Cancer Inst Monogr. 1976. PMID: 1030781). Mechanism: "delayed activation of developmentally programmed cell death regulated by the tropomyosin receptor kinase A (TrkA) pathway" (PMID: 29305654), with HOXC9 induction of intrinsic apoptosis also implicated (Kocak H, et al. Cell Death Dis. 2013. PMID: 23579273).
Spontaneous maturation — progressive differentiation along NB → GNB → GN. This is the process that creates GNB.
Therapy-induced maturation — ICCR Note 1, verbatim: "Undifferentiated and poorly differentiated neuroblastomas, as well as ganglioneuroblastomas, may undergo maturation in response to therapy, with increased differentiation of neuroblasts, increased stromal content, and lower mitotic-karyorrhectic index (MKI). The INPC classification was designed to categorise and risk-stratify pre-treatment neuroblastic tumours and, because of the potential for therapy-induced changes, is not suitable for use with post-treatment tumours."

This third point is a hard constraint on how GNB data may be used. A post-chemotherapy specimen that looks like GNB may be a treated neuroblastoma, and must be reported as "neuroblastic tumour, post-treatment" — "Tumours should never be reclassified after treatment." A knowledge base that records a GNB diagnosis without recording whether the specimen was pre- or post-treatment is recording an ambiguous fact. The same trap exists outside the family: a periadrenal Ewing sarcoma has been reported with "chemotherapy-induced cytodifferentiation resembling ganglioneuroblastoma" (PMID: 42138624).

8.5 Critical periods

18 months — the dominant risk-stratification threshold.
5 years — the second INPC threshold, for differentiating tumours.
First 6 months of life — the window in which expectant observation of small adrenal masses is validated (COG ANBL00P2 / NCT00445718).
Biopsy timing — sampling error in GNBn is a critical-period problem of a different kind; see §10.

9. Inheritance and Population

9.1 Epidemiology

Neuroblastic tumours overall (NCI PDQ): "More than 650 cases are diagnosed each year in the United States"; prevalence ≈ 1 per 7,000 live births; incidence 8.3 per 1,000,000 children under 15 per year. A SEER analysis of 1,224 patients (2010–2018) reported an age-adjusted incidence of 8.2 per 1,000,000 children (PMID: 37046344).

GNB specifically. No authoritative standalone incidence figure exists. Two anchors:

GNB accounted for 15.86% of childhood and 23.40% of adolescent/adult neuroblastic tumours in SEER 1975–2013 (Yan P, et al. Med Sci Monit. 2020. PMID: 33249420).
Derived estimate (clearly labelled as derived, not cited): 8.3/10⁶/yr × ~16% ≈ 1.3 per 1,000,000 children per year. A frequently repeated secondary-source figure of "no more than 5 cases per million children" circulates without a traceable primary citation and should not be used as a sourced claim.

SEER GNB cohort characteristics (Li W, et al. Heliyon. 2024;10(9):e30891. PMID: 38774105; n = 1,194, SEER registries 1975–2019):

Mean age 6.15 years (SD ±9.65)
Sex: 56.3% female / 43.7% male — note this is the reverse of neuroblastoma's slight male predominance
Race: White 78.8%, Black 12.6%, other 8.5%
SEER stage: localised 48.1%, regional 31.7%, distant 20.2%
Mean tumour size 68.6 mm (SD ±38.0)
Surgery 95.6%, chemotherapy 32.9%, radiotherapy 11.2%
OS: 3-year 73.9%, 5-year 61.2%, 10-year 40.8%

Reconciling an apparent contradiction. The SEER 5-year OS of 61.2% sits well below the 88% and 74.5–100% figures quoted elsewhere. The discrepancy is explained by cohort composition: the SEER cohort spans 1975–2019 (including the pre-modern-therapy era) and has a mean age of 6.15 years with a substantial adult component, whereas the clinical series are contemporary paediatric cohorts. Do not average these numbers. Record each with its cohort.

9.2 Inheritance

The disease itself is not inherited. 98–99% of cases are sporadic somatic neoplasms.
Predisposition inheritance where present: autosomal dominant with incomplete penetrance (ALK, PHOX2B).
Penetrance: incomplete and not well quantified for either gene. ALK germline variants vary in penetrance by specific allele.
Expressivity: variable — PHOX2B germline variants may present as isolated neuroblastic tumour, Hirschsprung disease, CCHS, or combinations. The Orphanet concept Hirschsprung disease–ganglioneuroblastoma syndrome (ORPHA:2151) names the combination explicitly and is a distinct entity from MONDO:0005035; do not merge them.
Genetic anticipation: not applicable (no repeat expansion).
Germline mosaicism: no data found for ALK or PHOX2B in a GNB context.
Founder effects: TP53 p.R337H in the Brazilian population is a recognised neuroblastoma-risk founder allele for which PDQ recommends surveillance; no GNB-specific founder effect is described.
Consanguinity: no established role.
Carrier frequency: not established; germline ALK/PHOX2B variants are too rare for a meaningful population carrier estimate.

9.3 Population demographics

Ancestry: neuroblastoma incidence highest in non-Hispanic White children (RRs in §2.3). No GNB-specific ancestry analysis exists.
Geographic distribution: no endemic pattern. Regional variation reflects registry ascertainment. "Analysis of the SEER program database between 1975 to 2013 showed that in the U.S., the incidence of neuroblastoma in children increased, but the incidence decreased in adolescents and adults" (PMID: 33249420).
Sex ratio: SEER GNB 0.78 M:F (43.7% male) — female-predominant, in contrast to neuroblastoma, where metastatic cases are male-enriched (PMID: 37046344). This difference is reported but not explained; treat it as an observation, not a mechanism.
Age distribution: see §8.1 and §9.1. Adults are a real if small group, and they do worse: adolescent/adult patients "demonstrated worse overall survival than pediatric cases" despite earlier stage (PMID: 33249420); "the prognosis of children with GNB was better than that of adolescents and adults with GNB" (PMID: 38774105).

10. Diagnostics

10.1 The diagnostic reality for GNB: histology decides, and sampling is the weak link

GNB cannot be diagnosed by imaging or biochemistry. It is a resection-specimen diagnosis, and the ICCR states the sampling hazard plainly (Note 10):

"Ganglioneuroblastoma, nodular, and other composite neuroblastic tumours are classified by applying the INPC schema to the highest grade nodule or component of the tumour. When a biopsy or partial resection is performed, there exists a risk of failing to sample an unfavourable nodule or component of these two tumour types; thus, in such cases, a disclaimer about limited sampling should be made."

The published consequence of this is a documented failure mode: "areas of GNBI and GNBN can coexist in the same mass, leading to incorrect risk staging when only biopsy is performed" (PMID: 36553228). And it works in the other direction too — the UK CCLG national study found "a small proportion of patients in the observation group had their diagnosis revised to malignant at surgery" (PMID: 39582110). A serial-biopsy pattern is itself diagnostic evidence: "an initial biopsy that has mature ganglion cells in a stroma-rich background and a second biopsy with poorly differentiated neuroblasts and scant stroma would suggest a ganglioneuroblastoma, nodular" (ICCR Note 1).

10.2 Laboratory tests and biomarkers

Test	Finding	Performance notes
Urinary VMA and HVA (per mg creatinine)	Elevated	"Urinary excretion of the catecholamine metabolites VMA and HVA per milligram of excreted creatinine is measured before therapy" (NCI PDQ). But abnormal in only 21% of GNBn and 19% of GNBi vs 59% of NB (PMID: 28465480) — a poor rule-out for GNB
Serum NSE	Elevated in 93% GNBn, 81% GNBi, 96% NB	PMID: 28465480
Serum LDH	Elevated in 90% GNBn, 85% GNBi, 97% NB	PMID: 28465480
Serum ferritin	Elevated in 40% GNBn, 12% GNBi, 60% NB	PMID: 28465480
Plasma/urine metanephrines	Usually normal	Relevant in distinguishing composite pheochromocytoma–GNB (PMID: 42571973; J Endocr Soc 2021, PMC8265703)
VIP	Elevated in the WDHA subset	Measured only when the syndrome is suspected

⚠ LOINC codes for VMA, HVA, NSE, LDH, ferritin and VIP were not looked up in this session and must not be written from memory.

10.3 Imaging

Modality	Role	Evidence
CT / MRI with contrast	Primary anatomical staging; determines the 20 image-defined risk factors that set L1 vs L2	Monclair T, et al. JCO 2009
¹²³I-MIBG scintigraphy / SPECT	Functional imaging; "About 90% of neuroblastoma cases are MIBG avid" (NCI PDQ). GNB is frequently MIBG-negative — e.g. an adrenal GNBi "negative at MIBG scintigraphy" (PMID: 34306280); a GNB diaphragmatic metastasis FDG-positive but "negative on MIBG scintigraphy" (PMID: 40065424)	—
¹⁸F-FDG PET/CT	Used where MIBG is negative; also predicts INPC class and MKI by radiomics (PMID: 36620179; PMID: 35204353)	—
⁶⁸Ga-DOTATATE PET/CT	Head-to-head prospective comparison in CNS metastases of NB and GNB: "⁶⁸Ga-DOTATATE PET/CT exhibited superior performance" and "led to changes in clinical management in 51% of patients"	Li S, et al. Eur J Nucl Med Mol Imaging. 2025. PMID: 40637785
¹⁸F-MFBG PET/CT	Emerging; a multiparametric model integrating ¹⁸F-MFBG parameters with clinical factors differentiated NB from GNB with AUC 0.856	Wang X, et al. Eur J Nucl Med Mol Imaging. 2026. PMID: 42820950
CT radiomics + deep learning	Differentiating NB from GNB preoperatively: AUC 0.922 training / 0.913 validation	Zhang G, et al. BMC Cancer. 2026. PMID: 41652556

A caution on the radiomics literature: these are retrospective single-centre models without external validation, and the GNB arms are small. They are promising leads, not validated diagnostics, and the authors of PMID: 42820950 say so ("external validation in larger cohorts remains necessary").

10.4 Histopathology and immunohistochemistry

Gross: the GNBn nodule is "grossly identifiable and often haemorrhagic/necrotic and fragile"; the GNBi/GN component is "tan-yellow and solid/elastic" (ICCR Note 7).

Microscopic: the defining discriminator between a differentiating neuroblast and a ganglion cell is whether neuritic processes are naked (neuropil visible on H&E, not covered by Schwann cells) or fully ensheathed. Degree of differentiation (ICCR Note 8): undifferentiated (no neuritic process, requires ancillary tests, sometimes "starry-sky"), poorly differentiated (<5% differentiating cells, Homer Wright rosettes may be present), differentiating (>5% of tumour cells with synchronous nuclear and cytoplasmic differentiation).

Immunohistochemistry (ICCR Note 13, verbatim):

"Phox2B is one of the most sensitive and specific markers for neuroblastoma, although it is also positive in other neural crest-derived tumours such as paraganglioma/pheochromocytoma. Additional stains typically positive in neuroblastic tumours include PGP9.5, CD56, and NB84. The neuroblastic cells are usually positive for synaptophysin and neuron-specific enolase and the Schwannian stromal cells are usually positive for S100 (although these stains are of limited utility due to their nonspecific nature)."

Additional: chromogranin and tyrosine hydroxylase in neuroblasts; S100 in both Schwann cells and ganglion cells. PHOX2B is positive across all of neuroblastoma, ganglioneuroblastoma and ganglioneuroma — it establishes lineage, not category.

10.5 Genetic testing

Tumour testing (required): MYCN amplification status by FISH on FFPE or frozen tissue (ratio ≥4 = amplified), DNA index/ploidy, segmental chromosomal aberrations at 1p and 11q (and 17q). "Determination of MYCN amplification status is a critical part of risk stratification for peripheral neuroblastic tumours" (ICCR Note 14).
ALK: sequencing of the kinase domain/hotspots — not immunohistochemistry (ICCR Note 13).
Germline testing: indicated where family history, bilateral/multifocal tumours, or associated features (Hirschsprung disease, CCHS) are present. Panel covering at minimum ALK and PHOX2B.
Platform-specific utility: NGS panels and SNP/CGH arrays now commonly substitute for FISH for MYCN and cover SCAs in one assay. WGS/WES are research or refractory-case tools, not standard. CMA, karyotyping, mitochondrial DNA testing and repeat-expansion testing have no role in GNB.

10.6 Omics-based diagnostics

Liquid biopsy / ctDNA is clinically validated for ALK resistance tracking, not for GNB diagnosis: serial ctDNA identified acquired resistance in 27% of patients on the lorlatinib trial, "predominantly off-target resistance mutations in the RAS-MAPK pathway," with secondary compound ALK mutations in 15% at progression (Berko ER, et al. Nat Commun. 2023. PMID: 37147298).
Transcriptomic, proteomic, metabolomic and epigenomic diagnostics: not in clinical use for GNB.

10.7 Clinical criteria and differential diagnosis

There are no society "diagnostic criteria" in the DSM sense; the INPC is the criterion set. Reporting is standardised by the ICCR Neuroblastoma Histopathology Reporting Guide (1st ed., Nov 2023) and the CAP neuroblastoma protocols.

Differential diagnosis:

Entity	Distinguishing features
Neuroblastoma (stroma-poor)	<50% Schwannian stroma
Ganglioneuroma	No neuroblastic foci with naked neuritic processes
Pheochromocytoma / paraganglioma	Also PHOX2B-positive; composite pheochromocytoma–GNB exists (PMID: 42571973)
Ewing sarcoma (esp. post-chemotherapy)	EWSR1 rearrangement; may mimic GNB morphologically after treatment (PMID: 42138624)
Other small round blue cell tumours (rhabdomyosarcoma, lymphoma, desmoplastic small round cell tumour, Wilms tumour)	PHOX2B, synaptophysin, NB84 panel; HuC/D is useful (ScienceDirect, Hum Pathol 2018)
MPNST arising in GN/GNB	A recognised malignant transformation (PMID: 41490645)
Treated neuroblastoma	Cannot be reclassified — see §8.4

10.8 Screening

See §13. Population screening is not recommended.

11. Outcome / Prognosis

11.1 Survival — by subtype, which is the only way these numbers mean anything

Cohort	n	Outcome
GNBi, single-centre	31	5-year OS 100% (median survival 64.5 months) — PMID: 28465480
GNBn, single-centre	20	5-year OS 74.5% ± 11.4% — PMID: 28465480
Neuroblastoma, same centre	228	5-year OS 50.8% ± 4.5% — PMID: 28465480
GNBn, INRG project	~250	EFS 54% ± 5%, OS 68% ± 5% — PMID: 22137163
GNBn <18 months, INRG	39	OS 95% ± 5%
GNBn stage 1/2/3/4s, INRG	125	OS 95% ± 3%
GNBn stage 4, INRG	107	OS 35% ± 7%
GNBn favourable subset (FS)	22	5-year EFS 86.1%, survival 95.0% — PMID: 10964346
GNBn unfavourable subset (US)	46	5-year EFS 29.0%, survival 40.7% — PMID: 10964346
GNBn FS vs US, revision study	22 vs 45	8-year EFS 86.1% vs 32.2% (P=0.0003); OS 90.5% vs 33.2% (P=0.0003) — PMID: 14601099
All GNB, SEER 1975–2019	1,194	OS 3-yr 73.9%, 5-yr 61.2%, 10-yr 40.8% — PMID: 38774105

The verbatim conclusion of the INRG GNBn report is the single best summary statement available:

"Patients with GNBn tumours are rare and have a very heterogeneous outcome. Except for LDH and MKI, the factors prognostic in the overall NB cohort are also prognostic in patients with GNBn. Similar to the overall NB cohort, patients with GNBn older than 18 months of age, with stage 4 disease represent a high-risk sub-group and should be considered for aggressive treatment upfront." — Angelini P, et al. Eur J Cancer. 2012. PMID: 22137163

And the finding that overturned the original Shimada position:

"The current study demonstrates that the nodular components in GNBn tumors are not always aggressive. The prognosis of these patients can be determined by the analysis of age-linked histopathologic features." — Umehara S, et al. Cancer. 2000;89(5):1150. PMID: 10964346

11.2 Independent prognostic factors

From the SEER multivariable Cox model (n = 1,194; PMID: 38774105): "Five independent prognostic factors, including age, primary tumor site, SEER stage, surgery and chemotherapy, were screened out and included in the nomogram."

Factor	HR (95% CI)	P
Age (per year)	1.05 (1.04–1.06)	<0.001
Soft tissue vs adrenal	0.33 (0.17–0.65)	0.001
Heart/mediastinum vs adrenal	0.49 (0.22–1.08)	0.08
Retroperitoneum vs adrenal	0.62 (0.35–1.11)	0.11
Other site vs adrenal	2.01 (1.15–3.50)	0.01
Localised vs distant	0.19 (0.10–0.36)	<0.001
Regional vs distant	0.28 (0.16–0.49)	<0.001
Surgery (yes vs no)	0.51 (0.28–0.95)	0.03
Chemotherapy (yes vs no)	2.14 (1.19–3.86)	0.01

Model performance: C-index 0.862 (development) / 0.827 (validation).

The chemotherapy HR of 2.14 must not be read as harm from chemotherapy. This is confounding by indication in a registry model: chemotherapy is given to the patients with worse disease. The correct reading is that chemotherapy receipt is a marker of adverse biology in this cohort. Any knowledge-base statement derived from this row needs that caveat attached, or it will be read as a treatment-effect claim.

Prognostic factors from the pathology side (Sokol E, et al. J Clin Oncol. 2020. PMID: 32315273, INRG Data Commons, cohorts of 10,104 and 8,761): "age, histologic category, MKI, and differentiation grade" are each independently prognostic, and the authors argue that "Replacing INPC with individual histologic features eliminates confounding and facilitates international harmonization of risk classification."

11.3 Prognostic biomarkers

MYCN amplification — the single most important molecular marker in pNTs. Its prognostic force in GNB is unsettled: GNB series report either no clear adverse effect or an effect their sample size cannot resolve, and the authors say so explicitly. Record this as an open question, not as an established GNB prognostic marker.
Telomere maintenance mechanism activation — active in 48% of GNBn and described as "a poor prognostic marker" (PMID: 41858373). The most promising GNB-specific prognostic biomarker currently available.
Segmental chromosomal aberrations (1p, 11q, 17q) — prognostic pNT-wide (Schleiermacher G, et al. Br J Cancer. 2012;107(8):1418-1422).
ALK amplification (not mutation) — adverse (PMID: 36807339).
SCP signature score — "a high SCP signature score is associated with better overall survival rates" (PMID: 33500353).

11.4 Morbidity, complications, and recovery

Complications of disease: cord compression and permanent neurological deficit; hypertensive cardiomyopathy; chronic diarrhoea with electrolyte derangement; OMAS with long-term neurocognitive impairment.

Complications of treatment: major surgical morbidity, including vascular catastrophe — "Delayed rupture of the celiac trunk and superior mesenteric artery associated with pancreatic leakage after resection of a giant retroperitoneal ganglioneuroblastoma in a child" (Dai X, et al. Transl Pediatr. 2026. PMID: 42158706). Secondary malignancy: therapy-related AML with inv(16) after GNB chemotherapy (Yuan J, et al. Clin Lab. 2025. PMID: 41078182). Malignant transformation to MPNST from GN/GNB (PMID: 41490645). In the German GN/GNBi series, "two patients died of treatment, none of tumor progression" (PMID: 27465021) — the cleanest available statement of the risk–benefit case for observation.

Recovery potential: excellent for GNBi and for localised GNBn in young children; poor for stage-4 GNBn ≥18 months.

Late effects: see §3.4.

12. Treatment

12.1 Treatment is decided by subtype, not by the word "ganglioneuroblastoma"

This is the operational consequence of everything above and is the most important treatment fact to record.

12.2 Ganglioneuroma and ganglioneuroblastoma, intermixed

Surgery, often conservative; observation is a validated option; chemotherapy does not work.

Decarolis B, et al. Treatment and outcome of Ganglioneuroma and Ganglioneuroblastoma intermixed. BMC Cancer. 2016. PMID: 27465021 — "GN/GNBI account for one quarter of localized NT and differ from immature tumors in their clinical features. Chemotherapy is not effective. Subtotal resection appears to be a sufficient treatment."
Burnand KM, et al. Management of Ganglioneuroma and Ganglioneuroblastoma Intermixed: A United Kingdom Children's Cancer and Leukaemia Group (UK CCLG) Nationwide Study Report. Pediatr Blood Cancer. 2025. PMID: 39582110 — "Watchful active observation can be a safe approach, with surgical resection reserved for symptomatic patients... a small proportion of patients in the observation group had their diagnosis revised to malignant at surgery."
Alexander N, et al. Pediatr Blood Cancer. 2018. PMID: 29369484 — "GN and GNB-I have a slow growth rate and resection can be associated with significant morbidity. Watch and wait approaches should be considered for some GN and GNB-I."
Yang T, et al. Pediatr Surg Int. 2017. PMID: 28608056 — "the residual tumor seems not to influence overall survival."
Nourani M, et al. Is There a Role for Chemotherapy in Unresectable Ganglioneuroblastoma Intermixed? J Pediatr Hematol Oncol. 2026. PMID: 41568977 — 12 patients; chemotherapy "offers limited benefit while posing significant risks"; "surgery should be prioritized."

12.3 Ganglioneuroblastoma, nodular

Risk-stratified and treated exactly as neuroblastoma, using the COG Revised Neuroblastoma Risk Classification (Irwin MS, et al. J Clin Oncol. 2021;39(29):3229-3241) — which uses INRGSS stage, age, MYCN status, INPC histology, ploidy, and segmental chromosomal aberrations at 1p and 11q, derived from 4,832 patients on ANBL00B1 (2007–2017).

Low risk: surgery alone, or observation. "Low-risk disease can frequently be observed without any treatment at all or cured with surgery alone." COG ANBL00P2 (NCT00445718) validated expectant observation in infants ≤6 months with solid adrenal masses <3.1 cm (or cystic <5 cm), INSS stage 1.

Intermediate risk: response- and biology-adapted chemotherapy of reduced intensity, plus surgery.

High risk — the full multimodal programme:

Phase	Components	NCIT (✅ verified)
Induction	Multi-agent chemotherapy (cyclophosphamide, topotecan, cisplatin, etoposide, doxorubicin, vincristine)	⚠ NCIT:C15632 Chemotherapy requires lookup
Local control	Gross total resection of the primary without mutilation; external-beam RT to the tumour bed	⚠ requires lookup
Consolidation	High-dose myeloablative therapy + autologous stem-cell transplant (tandem)	⚠ requires lookup
Post-consolidation	Isotretinoin (13-cis-retinoic acid)	NCIT:C603 ✅ / CHEBI:6067 ✅
	Anti-GD2 monoclonal antibody: dinutuximab, dinutuximab beta, or naxitamab + GM-CSF (±IL-2)	NCIT:C1570 Dinutuximab ✅
Maintenance	Eflornithine (DFMO) — ODC inhibitor	NCIT:C226 Eflornithine ✅ / CHEBI:41948 ✅ (regimen: NCIT:C202976 ✅)

Eflornithine was approved by the FDA on 13 December 2023 (brand IWILFIN, USWM LLC) "to reduce the risk of relapse in adult and pediatric patients with high-risk neuroblastoma (HRNB) who have demonstrated at least a partial response to prior multiagent, multimodality therapy including anti-GD2 immunotherapy" — the first FDA approval of a relapse-risk-reduction therapy in paediatric HRNB. At four years post-immunotherapy, EFS was 84% (eflornithine) vs 73% (external control), OS 96% vs 84% (FDA approval summary, PubMed 38917371; prescribing information, accessdata.fda.gov/drugsatfda_docs/label/2024/215500s001lbl.pdf).

Anti-GD2 immunotherapy raised 2-year EFS in HRNB from 46% to 66%. Cytokine support: "clinical data supporting the use of G-CSF are limited," with GM-CSF the preferred adjuvant (Mora J, et al. Int J Cancer. 2024. PMID: 38108214).

12.4 Relapsed / refractory disease

Regimen	Outcome	Reference
Irinotecan/temozolomide/dinutuximab/GM-CSF	49% objective response (29% CR, 14% PR); median PFS 13.1 months	Lerman BJ, et al. J Clin Oncol. 2023. PMID: 36206505
Dinutuximab beta + topotecan-cyclophosphamide vs temozolomide-based	ORR 42% vs 40% — "the importance of chemo-immunotherapy, irrespective of the chemotherapy backbone"	Raiser P, et al. Eur J Cancer. 2024. PMID: 38489858
Naxitamab + irinotecan/temozolomide + GM-CSF (HITS), early salvage	47% CR (early) vs 12% (late); 3-year EFS 54.4%	Muñoz JP, et al. Cancers. 2023. PMID: 37835531
Dinutuximab beta monotherapy ± isotretinoin (systematic review, 442 patients)	Best response 28.6–54.8%; 3-year OS 54–86%	Wieczorek A, et al. Target Oncol. 2025. PMID: 40459700

12.5 Targeted and advanced therapeutics

ALK inhibition — the one genotype-directed therapy in this disease:

"This phase 1 trial evaluated lorlatinib monotherapy and combination treatment in children and adults with relapsed/refractory ALK-driven neuroblastoma. The study established recommended phase 2 doses and demonstrated response rates varying by age group (30% in children as monotherapy; 67% in adults; 63% with chemotherapy combination). Common adverse events included hypertriglyceridemia (90%), hypercholesterolemia (79%), and weight gain (87%). The findings supported 'rapid translation into active phase 3 trials for patients with newly diagnosed high-risk, ALK-driven neuroblastoma.'" — Goldsmith KC, Park JR, Kayser K, et al. Lorlatinib with or without chemotherapy in ALK-driven refractory/relapsed neuroblastoma: phase 1 trial results. Nat Med. 2023;29(5):1092-1102. PMID: 37012551

Investigational / preclinical:

ALK + ATR inhibition — "Combined 14-day ALK/ATR inhibition produced robust and sustained response, with tumor cell reprogramming toward neuronal/Schwann cell differentiation" (Borenäs M, et al. PNAS. 2024. PMID: 38154064). Mechanistically notable for GNB: this is a drug combination whose response phenotype is the GNB morphology.
ALK + MDM2 (idasanutlin) — "lorlatinib combined with idasanutlin resulted in complete tumor regression and significantly delayed tumor regrowth" in ALK-amplified PDX (Tucker ER, et al. Clin Cancer Res. 2023. PMID: 36602782)
ALK.CAR-T + ALK inhibitors — ALK inhibitors upregulate ALK surface expression and "specifically potentiate ALK.CAR-T cells but not GD2.CAR-T cells" (Bergaggio E, et al. Cancer Cell. 2023. PMID: 38039964)
Anti-GD2 ADC M3554 (dinutuximab–exatecan conjugate; NCIT:C212045)

Gene therapy, RNA-based therapy (ASO/siRNA/mRNA): no approved or late-phase agent for this disease. This is a genuine absence, not a search gap.

Pharmacogenomics: no CPIC/PharmGKB guideline specific to neuroblastoma therapy. The clinically relevant pharmacogenomic issue is cisplatin-induced ototoxicity (TPMT/COMT variants have been proposed and contested) — flagged here as a lead requiring its own literature review before any claim is made.

12.6 Supportive, surgical, and rehabilitative care

Surgery. The ICCR summarises current surgical philosophy precisely: "In most studies of advanced stage neuroblastoma, the degree of primary tumour resection has shown no impact on local control or long-term outcomes unless metastatic disease can be controlled. Thus, the aim should be gross total resection without mutilation and surgical sequelae. For these reasons, tumour presence at surgical margins is not usually assessed pathologically." (Note 2)
Supportive care: pain control (particularly anti-GD2 infusion pain, which is substantial and expected), antihypertensives for catecholamine excess, electrolyte replacement in VIP syndrome, transfusion support.
Rehabilitation: physiotherapy after cord compression; audiological surveillance and hearing aids/cochlear devices given 72% moderate-to-severe hearing loss in HRNB survivors; neurodevelopmental and educational support, especially after OMAS.
OMAS-directed immunotherapy: in ANBL00P3, "21 of 26 patients (81%) in the IVIG group had an opsoclonus/myoclonus ataxia syndrome response" versus "11 of 27 patients (41%) in the non-IVIG group" (NCI PDQ).

12.7 Treatment strategy

Treatment algorithms are published by COG (RNRC-based), SIOPEN (HR-NBL1/SIOPEN), and in the NCCN/NCI PDQ. The decision tree for GNB specifically is:

Confirm subtype on adequate tissue, with a sampling disclaimer if biopsy-only.
GNBi/GN → observe or resect; do not give chemotherapy.
GNBn → assign a COG/INRG risk group using INRGSS stage, age, MYCN, INPC histology (graded on the highest-grade nodule), ploidy, and 1p/11q → treat per risk group.
At relapse → ALK sequencing; lorlatinib if ALK-driven; chemo-immunotherapy otherwise.

13. Prevention

13.1 Primary prevention

None exists and none is plausible with current knowledge. There is no modifiable risk factor for GNB. Any statement implying otherwise would be unsupported.

13.2 Secondary prevention — and a landmark negative result

Population newborn/infant screening by urinary catecholamine metabolites does not work and is not recommended. This is one of the better-evidenced negative results in paediatric oncology and deserves to be recorded as a positive fact rather than an absence:

"Current data do not support neuroblastoma screening in the general public." Screening trials showed that although "most infants in Quebec, Canada, were screened at the ages of 3 weeks and 6 months," this "did not lead to a reduced incidence of advanced-stage neuroblastoma with unfavorable biological characteristics." — NCI PDQ

The mechanism of that failure is informative: screening detects the favourable-biology tumours that would have regressed or matured on their own (i.e. it overdiagnoses the GNB/GN end of the spectrum) without detecting the unfavourable-biology tumours earlier.

13.3 Surveillance for genetically predisposed individuals

This is recommended, and is the only validated screening in this disease. For carriers of germline ALK or PHOX2B pathogenic variants, and for Li-Fraumeni syndrome with TP53 p.R337H (NCI PDQ):

Abdominal ultrasonography, and
Quantitative, normalized assessment of urinary catecholamines
every 3 months until age 6, then every 6 months until age 10

Updated recommendations are in Kamihara J, et al. Clin Cancer Res. 2024. PMID: 38860978, which "review[s] recommended surveillance for hereditary patients with NB, including minor updates to surveillance recommendations that were published previously in 2017" (the 2017 source being Kamihara J, et al. Clin Cancer Res. 2017;23(13):e98-e106. PMID: 28674118).

13.4 Tertiary prevention

Eflornithine maintenance to reduce relapse risk in HRNB (§12.3) is formally a tertiary-prevention intervention.
Late-effects surveillance: audiology, growth and endocrine monitoring, cardiac function, renal function, second-malignancy surveillance, and neurocognitive/educational assessment — justified by the LEAHRN prevalence data.

13.5 Immunization, genetic counselling, public health, prophylaxis

Immunization: not applicable — GNB has no infectious aetiology. (Anti-GD2 antibody therapy is passive immunotherapy, not a vaccine.)
Genetic counselling: indicated for familial, bilateral/multifocal, or syndromic presentations; should cover autosomal dominant inheritance with incomplete penetrance, cascade testing, and the surveillance protocol above.
Public health / environmental interventions: not applicable.
Prophylaxis: no prophylactic medication or procedure.

14. Other Species / Natural Disease

14.1 Taxonomy

Species	NCBITaxon	Evidence of naturally occurring GNB
Homo sapiens	NCBITaxon:9606	—
Canis lupus familiaris (dog)	⚠ NCBITaxon:9615 (requires lookup)	Yes — multiple reports
Bos taurus (cattle)	⚠ NCBITaxon:9913 (requires lookup)	Yes — IHC series of peripheral neuroblastoma, ganglioneuroblastoma, anaplastic ganglioglioma, schwannoma and neurofibroma in cattle
Equus caballus (horse)	⚠ requires lookup	Ganglioneuroma and ganglioneuromatosis reported; GNB not clearly documented
Felis catus (cat), Sus scrofa (pig)	⚠ requires lookup	Peripheral ganglioneuromas reported; GNB not clearly documented

All NCBITaxon CURIEs above are unverified and must be looked up before binding.

14.2 Natural disease in other species

Ganglioneuroblastoma is rare in veterinary medicine, and the diagnostic criteria are the same as in humans: "diagnosis requires clear, obvious ganglion cell differentiation, neuroblasts, and some amount of Schwann cells and Schwannian stroma."

Documented canine cases:

Olfactory ganglioneuroblastoma — Romano AM, Frank CB. Olfactory ganglioneuroblastoma in a dog: case report and literature review. J Vet Diagn Invest. 2021. DOI: 10.1177/10406387211022864; and a companion IHC comparison with olfactory neuroepithelia and olfactory neuroblastomas (PMC11300123). Note: olfactory GNB is a CNS/neuroepithelial tumour, not a peripheral neuroblastic tumour — it is a homonym, not a homologue.
Primary cutaneous (footpad) peripheral ganglioneuroblastoma — the first such report in a dog. PMID: 30950551. This one is a genuine peripheral neuroblastic tumour.
Further canine reports in brain, oral mucosa, and thorax.

Bovine: a cutaneous ganglioneuroma case report, and an immunohistochemical series of bovine peripheral neuroblastoma/ganglioneuroblastoma.

OMIA: no Mendelian inheritance entry for ganglioneuroblastoma was identified in the Online Mendelian Inheritance in Animals database. These are sporadic neoplasms, not heritable traits — consistent with the human picture.

14.3 Orthologous genes

⚠ NCBI Gene IDs for the mouse/rat/zebrafish orthologs of MYCN, ALK, PHOX2B, ATRX and TERT were not looked up in this session and must not be written from memory. Note that Phox2b function is conserved across mouse and zebrafish (demonstrated in both — PMID: 23754957, PMID: 19608868), and MYCN function is conserved in mouse and zebrafish models.

14.4 Comparative biology

Conserved: the neural-crest → sympathoadrenal developmental programme, PHOX2B's role as its master regulator, MYCN's dual proliferative/anti-differentiative effect, and the morphological spectrum from neuroblastoma to ganglioneuroma all hold across mammals.
Divergent / unexplained: the Schwannian-stroma-rich phenotype that defines GNB is poorly reproduced in any animal model (see §15). This is the central comparative gap.

14.5 Transmission

Not applicable. GNB is a non-transmissible neoplasm with no zoonotic potential and no cross-species susceptibility.

15. Model Organisms

15.1 The defining limitation: there is no good ganglioneuroblastoma model

Every widely used model in this field is a neuroblastoma model, and the two most-characterised ones explicitly fail to produce the differentiated, stroma-rich phenotype that is ganglioneuroblastoma. A mechanism knowledge base should record this as a HUMAN_MODEL_MISMATCH-type gap rather than as an absence of models: the models exist and are excellent for neuroblastoma, but they are boundary-omitting with respect to GNB because the stromal compartment and the differentiation endpoint are outside what they reproduce.

15.2 Available models

Model	Type	Construction	Phenotype recapitulation	Limitation for GNB
TH-MYCN mouse	Transgenic mammalian	Human MYCN cDNA under the rat tyrosine-hydroxylase promoter	Neuroblast hyperplasia in paravertebral ganglia at E14; tumours in 100% of homozygotes from postnatal week 6; "now the most widely used transgenic model in neuroblastoma research"	Fails to model GNB. "Tumors displayed heterogeneity of differentiation but no overt ganglionic differentiation was seen, with low levels of Schwannian stroma and a high mitosis karyorrhexis index." Hyperplastic neuroblasts "did not express differentiation markers, such as beta-III-tubulin or tyrosine hydroxylase." Weiss WA, et al. EMBO J. 1997;16(11):2985; histological profile, PMID: 18682419; genetic aberrations, PMC3524187
TH-MYCN × ALK^F1174L	Compound transgenic	ALK activating allele on MYCN background	Accelerated, more aggressive tumours; the standard ALK-inhibitor preclinical platform	Same differentiation/stroma gap
Zebrafish dβh-MYCN	Transgenic	MYCN under dopamine-β-hydroxylase promoter	Sympathoadrenal tumours; amenable to genetic screens	Same gap; also lacks mammalian adrenal architecture
Zebrafish PHOX2B models	Transgenic / morphant	Heterozygous deletion or dominant-negative PHOX2B	Models the differentiation block itself: "imposes a block in the differentiation of sympathetic neuronal precursors, resulting in a cell population that is likely to be susceptible to secondary transforming events" (PMID: 23754957)	Models the predisposing lesion, not the tumour
Patient-derived xenografts (PDX)	Xenograft	Implanted human tumour	Preserve genomics; the lorlatinib/idasanutlin platform (PMID: 36602782)	Derived from neuroblastoma, not GNB; and "xenografts with cells from each identity eventually harbor a noradrenergic phenotype suggesting that the microenvironment provides a powerful pressure towards this phenotype" (PMID: 37142597) — i.e. the host environment itself selects away from the heterogeneity being studied
Cell lines (SH-SY5Y, LA-N-1, SK-N-SH, etc.)	In vitro	Established human neuroblastoma lines	The workhorse for retinoic-acid differentiation biology (PMID: 6467378, PMID: 7040765) and HDAC8/ZNF423 work	No ganglioneuroblastoma-derived cell line exists. A GNB line is arguably not constructible, since the defining feature is a two-compartment tissue architecture
Neuroblastoma–Schwann cell co-culture / Schwann-cell-conditioned medium	In vitro	Co-culture or conditioned medium	The closest thing to a GNB model. Reconstitutes the tumour–stroma differentiation loop: neurite outgrowth and mature neurofilament induction (PMID: 9788610); reciprocal Schwann cell proliferation (PMID: 11464875); PEDF as the mediator (PMID: 11792807)	Two-cell-type in vitro system; no tissue architecture, no immune compartment, no vasculature
Human sympathoadrenal / adrenal organoids and iPSC models	In vitro	Differentiated from iPSC	Emerging; used to map the SCP → sympathoblast decision	Not yet a GNB model

15.3 Databases and resources

MGI (mouse), ZFIN (zebrafish), RGD (rat), Alliance of Genome Resources — for allele and phenotype records
IMSR, MMRRC, EMMA, KOMP/IMPC — strain availability
Cellosaurus, ATCC — cell lines
DepMap — CRISPR dependency data on neuroblastoma lines
R2 Genomics Analysis and Visualization Platform — the de facto neuroblastoma expression-cohort resource
INRG Data Commons (inrgdb.org) — the clinical-biological cohort resource, and the source of the GNBn-specific analyses

15.4 Research applications and the GNB-shaped hole

What the available models can study: MYCN- and ALK-driven transformation, ALK inhibitor pharmacology and resistance, anti-GD2 immunotherapy (immunocompetent TH-MYCN), retinoid differentiation pharmacology, metastatic niche biology.

What they cannot study, and what therefore remains open: 1. Why one subclone of a GNBn escapes the differentiation signal while its siblings mature. No model reproduces the composite architecture. 2. What recruits and sustains the Schwannian stroma in vivo, and whether it can be therapeutically induced. The co-culture systems show the loop exists; nothing shows how to drive it in a patient. 3. Whether GNBi is a tumour that is maturing or a tumour that has stopped maturing — i.e. whether it is a way-station to ganglioneuroma or a stable state. This distinction determines whether "watch and wait" is watching a resolving process or a static one, and it is not answerable from current models or from the natural-history data.

Appendix A — Consolidated ontology term suggestions

✅ = verified against the named authority during this session. ⚠ = suggestion only; must be looked up before binding.

Disease

MONDO:0005035 ✅ ganglioneuroblastoma · MONDO:0003326 ✅ intermixed · MONDO:0003325 ✅ nodular · MONDO:0004477 ✅ adrenal · MONDO:0001096 ✅ mediastinal · MONDO:0003327 ✅ peripheral · NCIT:C3790 ✅ · NCIT:C42057 ✅ intermixed · NCIT:C124274 ✅ childhood nodular · HP:0006747 ✅

Phenotype (HP)

HP:0031500 ✅ Abdominal mass · HP:0002277 ✅ Horner syndrome · HP:0006837 ✅ Congenital Horner syndrome · HP:0007451 ✅ Ipsilateral lack of facial sweating · HP:0010543 ✅ Opsoclonus · HP:0011977 ✅ Elevated urinary homovanillic acid · HP:0011978 ✅ Elevated urinary vanillylmandelic acid ⚠ Myoclonus, Ataxia, Hypertension, Chronic diarrhea, Hypokalemia, Spinal cord compression, Paraparesis, Dyspnea, Growth delay, Bone pain, Proptosis, Constipation

Cell type (CL)

CL:0011012 ✅ neural crest cell · CL:0002375 ✅ Schwann cell precursor · CL:0000031 ✅ neuroblast (sensu Vertebrata) · CL:0002676 ✅ neural crest derived neuroblast · CL:0002573 ✅ Schwann cell · CL:0002376 ✅ non-myelinating Schwann cell · CL:0000218 ✅ myelinating Schwann cell · CL:0011103 ✅ sympathetic neuron · CL:0000166 ✅ chromaffin cell · CL:0000336 ✅ adrenal medulla chromaffin cell

Anatomy (UBERON)

UBERON:0001236 ✅ adrenal medulla · UBERON:0002369 ✅ adrenal gland · UBERON:0000013 ✅ sympathetic nervous system · UBERON:0001806 ✅ sympathetic ganglion · UBERON:0001807 ✅ paravertebral ganglion · UBERON:0000961 ✅ thoracic ganglion · UBERON:0001991 ✅ cervical ganglion · UBERON:0001989 ✅ superior cervical ganglion · UBERON:0002441 ✅ cervicothoracic ganglion · UBERON:8600121 ✅ lumbar ganglion · UBERON:8600122 ✅ sacral ganglion ⚠ posterior mediastinum, retroperitoneal space, organ of Zuckerkandl, bone marrow

Biological process (GO)

GO:0048485 ✅ sympathetic nervous system development · GO:0048483 ✅ autonomic nervous system development · GO:1903045 ✅ neural crest cell migration involved in sympathetic nervous system development · GO:0014033 ✅ neural crest cell differentiation · GO:0014035 ✅ neural crest cell fate determination · GO:1905292/1905293/1905294 ✅ regulation of neural crest cell differentiation · GO:0042423 ✅ catecholamine biosynthetic process · GO:0042416 ✅ dopamine biosynthetic process · GO:0006585 ✅ dopamine biosynthetic process from tyrosine ⚠ neuron differentiation, glial cell differentiation, telomere maintenance, protein tyrosine kinase activity, cell population proliferation

Chemical (CHEBI)

CHEBI:545959 ✅ homovanillic acid · CHEBI:20106 ✅ vanillylmandelic acid · CHEBI:133744 ✅ homovanillate · CHEBI:27622 ✅ vanillylmandelate · CHEBI:6067 ✅ isotretinoin · CHEBI:41948 ✅ eflornithine

Treatment (NCIT)

NCIT:C1570 ✅ Dinutuximab · NCIT:C226 ✅ Eflornithine · NCIT:C202976 ✅ Eflornithine Regimen · NCIT:C603 ✅ Isotretinoin · NCIT:C174559 ✅ Dinutuximab/Irinotecan/Temozolomide Regimen · NCIT:C15722 ✅ Patient Observation · NCIT:C212045 ✅ Anti-GD2 ADC M3554 ⚠ Surgical Procedure, Chemotherapy, Pharmacotherapy, Radiation Therapy, Hematopoietic Cell Transplantation, Genetic Counseling, Lorlatinib, Naxitamab, Dinutuximab beta, GM-CSF

Gene (HGNC — all ✅ verified via rest.genenames.org)

hgnc:7559 MYCN · hgnc:427 ALK · hgnc:9143 PHOX2B · hgnc:886 ATRX · hgnc:11730 TERT · hgnc:7765 NF1 · hgnc:32207 LIN28B · hgnc:6641 LMO1 · hgnc:952 BARD1 · hgnc:33775 ALKAL1 · hgnc:27683 ALKAL2

Appendix B — Five things a curator should not get wrong

"Ganglioneuroblastoma" is two diseases. GNBi is favourable histology at any age and is managed by observation or conservative surgery; GNBn is graded by its worst nodule and can be stage-4 high-risk. A single entry that averages them is wrong about both. Consider has_subtypes with the INPC categories, and stratify phenotypes, prevalence and treatment by subtype.
The Schwannian stroma is not neoplastic. PMID: 25081755 showed MYCN gain in neuroblasts and ganglion cells but not in Schwann cells. Model Schwann cells as microenvironment, not as a tumour cell type.
The cell of origin derives from the node carrying the somatic lesion — the transformed sympathoadrenal progenitor — and the recorded cell_types there should be the neuroblast lineage (CL:0002676 / CL:0000031), not the Schwann cell.
Post-treatment specimens cannot carry an INPC diagnosis. "Tumours should never be reclassified after treatment" (ICCR Note 7). Any prevalence, frequency or phenotype figure sourced from a post-chemotherapy series is describing a different population.
The SEER chemotherapy HR of 2.14 is confounding by indication, not a treatment effect. Record it only with that caveat, or not at all.

Sources

Primary guideline / classification documents - ICCR Neuroblastoma Histopathology Reporting Guide, 1st ed. v1.0, November 2023 — ISBN 978-1-922324-39-9 (the source of all verbatim INPC/WHO quotations above) - NCI PDQ® Neuroblastoma Treatment (Health Professional Version) - CAP Protocol for the Examination of Resection Specimens From Patients With Neuroblastoma, v5.0.0.1 - WHO Classification of Tumours Editorial Board (2023). Paediatric Tumours, WHO Classification of Tumours, 5th ed., Vol. 7. IARC, Lyon

Classification, staging and risk - Shimada H, et al. Terminology and morphologic criteria of neuroblastic tumors. Cancer 1999 — PMID 10421272 - Shimada H, et al. The International Neuroblastoma Pathology Classification (the Shimada system). Cancer 1999 - Cohn SL, et al. The INRG Classification System: an INRG Task Force Report. J Clin Oncol 2009 - Monclair T, et al. The INRG Staging System: an INRG Task Force Report. J Clin Oncol 2009 - Irwin MS, et al. Revised Neuroblastoma Risk Classification System: a Report From the Children's Oncology Group. J Clin Oncol 2021 - Sokol E, et al. Age, Diagnostic Category, Tumor Grade, and MKI Are Independently Prognostic in Neuroblastoma: an INRG Project. J Clin Oncol 2020 — PMID 32315273 - Teshiba R, et al. Age-dependent prognostic effect by MKI in neuroblastoma: a report from the COG. Pediatr Dev Pathol 2014 — PMID 25207821 - Nakazawa A, et al. Correlation between the INPC and genomic signature in neuroblastoma. Cancer Sci 2015 — PMID 25827934 - Nakazawa A. Biological categories of neuroblastoma based on the INPC for treatment stratification. Pathol Int 2021 — PMID 33657257 - The Evolution of Risk Classification for Neuroblastoma. Children (Basel) 2019

Genetics and predisposition - Kamihara J, et al. Neuroblastoma Predisposition and Surveillance—An Update from the 2023 AACR Childhood Cancer Predisposition Workshop. Clin Cancer Res 2024 — PMID 38860978 - Kamihara J, et al. Retinoblastoma and Neuroblastoma Predisposition and Surveillance. Clin Cancer Res 2017 — PMID 28674118 - Mossé YP, et al. Identification of ALK as a major familial neuroblastoma predisposition gene. Nature 2008 — PMID 18724359 - Trochet D, et al. Germline mutations of PHOX2B in neuroblastoma. Am J Hum Genet 2004 — PMID 15024693 - Mossé YP, et al. Germline PHOX2B mutation in hereditary neuroblastoma. Am J Hum Genet 2004 — PMID 15338462 - Raabe EH, et al. Prevalence and functional consequence of PHOX2B mutations in neuroblastoma. Oncogene 2008 — PMID 17637745 - Oldridge DA, et al. Genetic predisposition to neuroblastoma mediated by a LMO1 super-enhancer polymorphism. Nature 2015 — PMID 26560027 - Tonini GP, Capasso M. Genetic predisposition and chromosome instability in neuroblastoma. Cancer Metastasis Rev 2020 — PMID 31927719 - Rosswog C, et al. Genomic ALK alterations in primary and relapsed neuroblastoma. Br J Cancer 2023 — PMID 36807339 - Djos A, et al. Loss of Chromosome Y in Neuroblastoma Is Associated With High-Risk Disease, 11q-Deletion, and Telomere Maintenance. Genes Chromosomes Cancer 2024 - GeneReviews: ALK-Related Neuroblastic Tumor Susceptibility

Mechanism and developmental biology - Sainero-Alcolado L, et al. Defining neuroblastoma: From origin to precision medicine. Neuro Oncol 2024 — PMID 39101440 - Thirant C, et al. Reversible transitions between noradrenergic and mesenchymal tumor identities define cell plasticity in neuroblastoma. Nat Commun 2023 — PMID 37142597 - Hanemaaijer ES, et al. Single-cell atlas of developing murine adrenal gland reveals relation of Schwann cell precursor signature to neuroblastoma phenotype. PNAS 2021 — PMID 33500353 - Olsen TK, et al. Malignant Schwann cell precursors mediate intratumoral plasticity in human neuroblastoma. bioRxiv 2020 - Fetahu IS, et al. Single-cell transcriptomics and epigenomics unravel the role of monocytes in neuroblastoma bone marrow metastasis. Nat Commun 2023 — PMID 37365178 - Crawford SE, et al. PEDF in neuroblastoma: a multifunctional mediator of Schwann cell antitumor activity. J Cell Sci 2001 — PMID 11792807 - Kwiatkowski JL, et al. Schwann cell-conditioned medium promotes neuroblastoma survival and differentiation. Cancer Res 1998 — PMID 9788610 - Ambros IM, et al. Neuroblastoma cells provoke Schwann cell proliferation in vitro. Med Pediatr Oncol 2001 — PMID 11464875 - Weiss WA, et al. Targeted expression of MYCN causes neuroblastoma in transgenic mice. EMBO J 1997 - Alam G, et al. MYCN promotes the expansion of Phox2B-positive neuronal progenitors to drive neuroblastoma development. Am J Pathol 2009 — PMID 19608868 - Pei D, et al. Distinct neuroblastoma-associated alterations of PHOX2B impair sympathetic neuronal differentiation in zebrafish models. PLoS Genet 2013 — PMID 23754957 - Bachetti T, et al. PHOX2B-mediated regulation of ALK expression. PLoS One 2010 — PMID 20957039 - Brodeur GM. Spontaneous regression of neuroblastoma. Cell Tissue Res 2018 — PMID 29305654 - Tacconelli A, et al. TrkA alternative splicing: a regulated tumor-promoting switch in human neuroblastoma. Cancer Cell 2004 — PMID 15488758 - Huang S, et al. ZNF423 is critically required for retinoic acid-induced differentiation. Cancer Cell 2009 — PMID 19345331 - Kocak H, et al. Hox-C9 activates the intrinsic pathway of apoptosis and is associated with spontaneous regression in neuroblastoma. Cell Death Dis 2013 — PMID 23579273 - Revet I, et al. The MSX1 homeobox transcription factor is a downstream target of PHOX2B. Exp Cell Res 2008 — PMID 18201699 - Enteric Neural Crest Differentiation in Ganglioneuromas Implicates Hedgehog Signaling in Peripheral Neuroblastic Tumor Pathogenesis - Schwann cell plasticity regulates neuroblastic tumor cell differentiation via EGFL8. Nat Commun 2021

Treatment - Goldsmith KC, et al. Lorlatinib with or without chemotherapy in ALK-driven refractory/relapsed neuroblastoma: phase 1 trial results. Nat Med 2023 — PMID 37012551 - Berko ER, et al. Circulating tumor DNA reveals mechanisms of lorlatinib resistance. Nat Commun 2023 — PMID 37147298 - Borenäs M, et al. ALK signaling primes the DNA damage response sensitizing ALK-driven neuroblastoma to therapeutic ATR inhibition. PNAS 2024 — PMID 38154064 - Bergaggio E, et al. ALK inhibitors increase ALK expression and sensitize neuroblastoma cells to ALK.CAR-T cells. Cancer Cell 2023 — PMID 38039964 - Tucker ER, et al. Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical Models. Clin Cancer Res 2023 — PMID 36602782 - Lerman BJ, et al. PFS and Patterns of Response in Patients With Relapsed High-Risk Neuroblastoma Treated With Irinotecan/Temozolomide/Dinutuximab/GM-CSF. J Clin Oncol 2023 — PMID 36206505 - Raiser P, et al. Chemo-immunotherapy with dinutuximab beta: does chemotherapy backbone matter? Eur J Cancer 2024 — PMID 38489858 - Muñoz JP, et al. Early Salvage Chemo-Immunotherapy (HITS) for Primary Refractory High-Risk Neuroblastoma. Cancers 2023 — PMID 37835531 - Wieczorek A, et al. Efficacy and Safety of Dinutuximab Beta in Relapsed/Refractory High-Risk Neuroblastoma. Target Oncol 2025 — PMID 40459700 - Mora J, et al. GM-CSF, G-CSF or no cytokine therapy with anti-GD2 immunotherapy. Int J Cancer 2024 — PMID 38108214 - US FDA Approval Summary: Eflornithine for High-Risk Neuroblastoma — PMID 38917371 - IWILFIN (eflornithine) Prescribing Information, FDA 2024 - Troschke-Meurer S, et al. Chemotherapeutics improve the efficacy of dinutuximab beta in preclinical spheroid models. Cancers 2023 — PMID 36765861

Imaging and diagnostics - Wang X, et al. Multiparametric ¹⁸F-MFBG PET/CT model differentiating neuroblastoma from ganglioneuroblastoma. Eur J Nucl Med Mol Imaging 2026 — PMID 42820950 - Li S, et al. ⁶⁸Ga-DOTATATE PET/CT vs ¹²³I-MIBG SPECT/CT in CNS metastases of neuroblastoma and ganglioneuroblastoma. Eur J Nucl Med Mol Imaging 2025 — PMID 40637785 - Zhang G, et al. Enhanced CT radiomics and deep learning differentiating peripheral neuroblastoma from ganglioneuroblastoma. BMC Cancer 2026 — PMID 41652556 - Wang H, et al. Radiomics analysis of contrast-enhanced CT in predicting the INPC. Insights Imaging 2023 — PMID 37316589 - Qian LD, et al. ¹⁸F-FDG PET/CT combined model to predict the INPC. Quant Imaging Med Surg 2023 — PMID 36620179

Epidemiology and outcomes - Yan P, et al. Comparison of Incidence and Outcomes of Neuroblastoma in Children, Adolescents, and Adults in the United States: a SEER Population Study. Med Sci Monit 2020 — PMID 33249420 - Liu S, et al. Metastasis pattern and prognosis in children with neuroblastoma. World J Surg Oncol 2023 — PMID 37046344 - Late effects after high-risk neuroblastoma (LEAHRN): a multicentre, cross-sectional cohort study from the COG - Flaadt T, et al. Long-Term Outcomes and Quality of Life of High-Risk Neuroblastoma Patients Treated with Multimodal Treatment Including Anti-GD2 Immunotherapy. Cancers 2025 — PMID 39796776 - Late Effects and Survivorship Issues in Patients with Neuroblastoma - Comparison of mediastinal and non-mediastinal neuroblastoma and ganglioneuroblastoma associated with opsoclonus-myoclonus syndrome: a systematic review and meta-analysis

Veterinary / comparative - Romano AM, Frank CB. Olfactory ganglioneuroblastoma in a dog: case report and literature review. J Vet Diagn Invest 2021 - Footpad peripheral ganglioneuroblastoma in a dog — PMID 30950551 - A case of olfactory ganglioneuroblastoma in a dog: immunohistochemical comparison with olfactory neuroepithelia and olfactory neuroblastomas - OMIA — Online Mendelian Inheritance in Animals

Ontology authorities consulted directly - EBI OLS4 API — MONDO, NCIT, HP, CL, UBERON, GO, CHEBI term records - HGNC REST service — gene symbol/ID verification - Europe PMC REST API — abstract retrieval

Reference Validation

Checked with linkml-reference-validator 0.3.0.

Outcome	Count
References checked	151
Resolved	148
Unresolved (possible confabulation)	0
Unverifiable	3
Quoted claims checked	31
Quoted claims found in source	24
Quoted claims not found in source	7
References weighed for topical relevance	148
On topic	30
Off topic	2

Quotes not found in the cited source

Searched the abstract, any retrieved full text, and the title. A quote drawn from a part of the paper that was not retrieved will appear here too, so check before treating one as invented:

6 of these was searched against an abstract alone, with no full text retrieved - marked abstract only below. Where full text can be fetched, re-running with it will settle them; where the source publishes only a summary to PubMed, as GeneReviews chapters do, it will not, and the quote has to be checked by hand against the chapter itself.

PMID:9788610 (abstract only): "induced extensive neurite outgrowth in all neuroblastoma cell lines, and these processes contained mature neurofilament in three of the cell lines"
closest text in source: "Schwann cell-conditioned medium induced extensive neurite outgrowth in all of the neuroblastoma cell lines, and these processes contained mature neurofilament in three of the cell lines"
PMID:15488758 (abstract only): "antagonizes NGF/TrkA/Ras/MAPK signaling, which is responsible for NB growth arrest and differentiation"
closest text in source: "TrkAIII antagonizes NGF/TrkAI signaling, which is responsible for NB growth arrest and differentiation through Ras/MAPK, and its expression is promoted by hypoxia at the expense of NGF-responsive receptors, providing a mechanism for converting NGF/TrkA/Ras/MAPK antioncogenic signals to TrkAIII/IP3K/Akt/NF-kappaB tumor-promoting signals during tumor progression."
PMID:38774105 (abstract only): "the prognosis of children with GNB was better than that of adolescents and adults with GNB"
closest text in source: "We constructed a nomogram based on the SEER database to predict the prognosis of GNB, but further optimization by adding more risk factors is needed for clinical application."
PMID:40065424 (abstract only): "negative on MIBG scintigraphy"
Text part not found as substring: 'negative on MIBG scintigraphy' (note: only abstract available for PMID:40065424, full text may contain this excerpt)
PMID:38154064 (abstract only): "Combined 14-day ALK/ATR inhibition produced robust and sustained response, with tumor cell reprogramming toward neuronal/Schwann cell differentiation"
closest text in source: "Finally, we show that the remarkable response to the 14-d combined ATR/ALK inhibition protocol reflects a robust differentiation response, reprogramming tumor cells to a neuronal/Schwann cell lineage identity"
PMID:38039964 (abstract only): "specifically potentiate ALK.CAR-T cells but not GD2.CAR-T cells"
closest text in source: "For neuroblastoma with low ALK expression, combination with ALK inhibitors specifically potentiates ALK.CAR-T cells but not GD2.CAR-T cells"
PMID:28674118: "review[s] recommended surveillance for hereditary patients with NB, including minor updates to surveillance recommendations that were published previously in 2017"
closest text in source: "In concert with previously published guidelines, these recommendations begin with intensive surveillance from birth with progressively spaced EUAs until age 5, although more frequent surveillance may be appropriate in individual cases"

References that may not be about this subject

These identifiers resolve, so they are not fabrications, but the records they resolve to share almost none of this report's vocabulary. That is a clue and not a verdict - a paper can be relevant in ways its title and abstract do not spell out - so read them before deciding:

PMID:40065424 (1 mention) - Positive 18 F-FDG PET/CT and Negative 123 I-MIBG SPECT/CT Imaging in an Unusual Diaphragmatic Metastasis From Ganglioneuroblastoma.
shared terms: ganglioneuroblastoma
DOI:10.1186/s12957-023-02967-1 (2 mentions) - Perioperative and oncologic outcomes of transperitoneal versus retroperitoneal laparoscopic radical nephrectomy for large-volume renal carcinoma (> 7 cm): a systematic review and pooled analysis of comparative outcomes
shared terms: tumor

Weighed against this report's own most characteristic terms: gnb, neuroblastoma, tumour, cell, gnbn, ganglioneuroblastoma, patient, disease, differentiation, neuroblastic, gnbi, alk, note, cancer, mycn, iccr, age, tumor, model, mechanism.

Term Validation

Checked with linkml-term-validator 0.4.5, through the ols: adapter.

Outcome	Count
Terms checked	93
Resolved	88
Unresolved (possible confabulation)	0
Obsolete	1
Unverifiable	4
Terms whose name was checked	27
Terms named correctly	14
Terms named as a different term	4
Terms whose name is worth a second look	9

Terms the report names something else

These identifiers resolve, so nothing about them looks wrong, and the ontology calls them something unrelated to what the report calls them. That usually means the identifier is not the one the sentence needs:

NCIT:C3790 (2 mentions) - the report calls it "NCI Thesaurus"; NCIT calls it Ganglioneuroblastoma
DOID:4163 (1 mention) - the report calls it "Disease Ontology"; DOID calls it ganglioneuroblastoma
EFO:0000502 (1 mention) - the report calls it "EFO"; EFO calls it obsolete_ganglioneuroblastoma
NCIT:C124274 (2 mentions) - the report calls it "childhood"; NCIT calls it Childhood Ganglioneuroblastoma, Nodular

Obsolete terms

These terms are real but deprecated. Citing one is not a fabrication; it does mean the report is naming something the ontology has retired:

EFO:0000502 (obsolete_ganglioneuroblastoma) (1 mention) - replaced by http://purl.obolibrary.org/obo/MONDO:0005035

Terms whose name is worth a second look

The report's name for these is recognisably related to the term's own name without being one of them. A loose paraphrase reads the same way as a citation of the wrong sibling term - and so does a related synonym, which the ontology records precisely because it names something adjacent rather than the same thing - so these are listed rather than judged:

MONDO:0003326 (2 mentions) - the report calls it "Intermixed (Schwannian stroma-rich) GNB"; MONDO calls it intermixed schwannian stroma-rich ganglioneuroblastoma
MONDO:0003325 (2 mentions) - the report calls it "Nodular GNB"; MONDO calls it nodular ganglioneuroblastoma
MONDO:0004408 (1 mention) - the report calls it "Schwannian stroma-rich + stroma-poor composite"; MONDO calls it schwannian stroma-rich and stroma-poor composite ganglioneuroblastoma
MONDO:0004407 (1 mention) - the report calls it "Stroma-dominant + stroma-poor composite"; MONDO calls it stroma-dominant and stroma-poor composite ganglioneuroblastoma
MONDO:0004477 (2 mentions) - the report calls it "Adrenal gland GNB"; MONDO calls it adrenal gland ganglioneuroblastoma
MONDO:0001096 (2 mentions) - the report calls it "Mediastinal GNB"; MONDO calls it mediastinum ganglioneuroblastoma, and lists "mediastinal ganglioneuroblastoma" among its other names
MONDO:0003327 (2 mentions) - the report calls it "Peripheral GNB"; MONDO calls it peripheral ganglioneuroblastoma
CL:0011012 (3 mentions) - the report calls it "neural crest cells", "During embryogenesis, neural crest cells"; CL calls it neural crest cell**
UBERON:0002441 (3 mentions) - the report calls it "cervicothoracic (stellate) ganglion"; UBERON calls it cervicothoracic ganglion

Terms named inconsistently

The report gives these identifiers more than one name of its own:

CL:0011012 - called "neural crest cells", "During embryogenesis, **neural crest cells"

Prefixes with no resolver

Terms carrying these prefixes were not checked either way, because no configured ontology covers them. An unrecognised prefix may name an ontology this run could not reach as easily as one that does not exist, so nothing here is evidence of fabrication: ORPHA, GARD, NANDO.

Ask OpenScientist

OpenScientist Report

Classifications

Mappings

Subtypes

Discussions and Knowledge Gaps

Pathophysiology

Histopathology

Pathograph

Phenotypes

Genetic Associations

Medical Actions

Biochemical Markers

Diagnosis

Prevalence

Epidemiology

Differential Diagnoses

Related Datasets

Source YAML

References & Deep Research

Deep Research

Ganglioneuroblastoma (MONDO:0005035) — Comprehensive Disease Characteristics Research Report

1. Disease Information

1.1 Overview

1.2 Key identifiers

1.3 Synonyms

1.4 Source of information

2. Etiology

2.1 Disease causal factors

2.2 Genetic risk factors

2.3 Environmental risk factors

2.4 Protective factors

2.5 Gene–environment interactions

3. Phenotypes

3.1 How GNB presents

3.2 Phenotype table with suggested HPO terms

3.3 Phenotype characteristics

3.4 Quality-of-life impact

4. Genetic / Molecular Information

4.1 There is no causal gene for ganglioneuroblastoma

4.2 Recurrent somatic alterations

4.3 The GNBn clonality question — a key GNB-specific result

4.4 Telomere maintenance in GNB — the most recent GNB-specific molecular study

4.5 Modifier genes

4.6 Epigenetic information

4.7 Chromosomal abnormalities

5. Environmental Information

6. Mechanism / Pathophysiology

6.1 Ordered causal chain

6.2 Molecular pathways

6.3 Cellular processes and cell types

6.4 Protein dysfunction

6.5 Metabolic changes

6.6 Immune system involvement

6.7 Tissue damage mechanisms

6.8 Molecular profiling

7. Anatomical Structures Affected

7.1 Organ level

7.2 Tissue and cell level

7.3 Subcellular level

7.4 Localisation and lateralisation

8. Temporal Development

8.1 Onset

8.2 The age-linked prognostic framework (INPC)

8.3 Progression and staging

8.4 Remission and maturation patterns

8.5 Critical periods

9. Inheritance and Population

9.1 Epidemiology

9.2 Inheritance

9.3 Population demographics

10. Diagnostics

10.1 The diagnostic reality for GNB: histology decides, and sampling is the weak link

10.2 Laboratory tests and biomarkers

10.3 Imaging

10.4 Histopathology and immunohistochemistry

10.5 Genetic testing

10.6 Omics-based diagnostics

10.7 Clinical criteria and differential diagnosis

10.8 Screening